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ABSTRACT
SEX-BASED DIFFERENCES IN MICROBIOTA COMPOSITION AND
METABOLOMIC PROFILES ASSOCIATED WITH ALTERED MACROPHAGE
FUNCTION AND PROTECTION FROM LUPUS IN BWF1 MICE
James W. Harder
January 14, 2021
Systemic lupus erythematosus (SLE) is a complex and an insidious disease that is
still not completely understood, and has very few treatment options. Those that are
available are ineffective and/or have serious side effects. Both genetic and environmental
factors contribute to the susceptibility and resistance to SLE, and understanding the
environmental factors underlying this disease could lead to more effective prevention
and/or treatment strategies. Like most autoimmune diseases, SLE is much more prevalent
in females than males. While there are numerous factors that contribute to this lupus
susceptibility, there is increasing evidence that the microbiota can strongly influence
lupus progression, and that sex-based differences in microbiota composition and function
may play a role in the sex bias (i.e., susceptibility in females and resistance in males) of
disease. The NZBxNZW F1 (BWF1) mouse model of lupus has many of the same
disease features seen in humans including the sex bias, making it an ideal model for
studying sex-based differences in microbiota and how they affect lupus progression.
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Previous findings from our laboratory have shown that not only do female and male
BWF1 microbiota profiles differ significantly, but male BWF1 microbiota can suppress
lupus when cecal contents are transferred into female BWF1 recipients. The overall goal
of this dissertation was to identify the players involved and begin to understand the
potential mechanisms underlying the suppressive effect of the male microbiota on
disease. Three aims were designed to address these issues. The goal of aim 1 was to
identify the bacterial populations in the microbiota of female and male BWF1 mice that
may either cause or suppress disease. The goal of aim 2 was to analyze the function of
female and male microbiota by identifying metabolites that may be involved in the
suppression of disease. In aims 1 and 2, we also investigated the impact of androgens on
bacterial populations and metabolite profiles, respectively, by comparing intact and
castrated male mice. In aim 3, the goal was to investigate the potential immune
mechanisms that could underlie the suppression of disease mediated by male microbiota.
The results of the first aim indicate that changes in the abundances of Bacteroides,
Clostridium, and Alistipes strongly correlated with the ability of transferred male BWF1
microbiota to suppress disease in female BWF1 recipients. We took advantage of a
change in animal facility that had a significant impact on our mouse colony and its
microbiota populations, and gave us an opportunity to analyze and compare bacterial
populations during periods of time when microbiota transfers had varying results.
Specifically, we found that Bacteroides (primarily the Bacteroides acidifaciens species)
abundance was high, Clostridium (primarily the Clostridium leptum species) abundance
was low, and Alistipes was present during the periods when transfer of male microbiota
was effective at suppressing disease in female BWF1 mice. Conversely, Bacteroides

vi

abundance was low, Clostridium abundance was high, and Alistipes was absent when
male microbiota lost that capability. We concluded from our thorough microbiota
analyses that a high Bacteroides/Clostridium ratio in the male microbiota may be a
reliable predictor of disease-suppressing capability, since it correlated strongly with
disease suppression in female recipients of male microbiota. The second aim of the
project used analysis of metabolomic profiles to investigate functional differences in
female and male BWF1 microbiota. Differential production of immunomodulatory
metabolites is a major mechanism by which the gut microbiota influences the immune
system. By measuring the fecal metabolite profiles, we identified phytol as a potential
mediator of lupus suppression by male microbiota. Phytol is produced by the microbiota
and converted into phytanic acid by host enzymes. Both phytol and phytanic acid were
significantly more abundant in intact male than either female or castrated male BWF1
mice. Both phytol and phytanic acid have potent RXR and PPARγ agonist properties, all
of which can directly influence many different immune functions. The third aim of this
project investigated the differences in female and male macrophage efferocytosis (i.e.,
phagocytosis of apoptotic cells) efficacy and how phytol and/or phytanic acid could
affect this immune function. Deficiencies in efferocytosis, particularly by macrophages,
are a major risk factor for SLE because they result in the accumulation of debris that
stimulates autoantibody production. We found male BWF1 splenic macrophages were
more efficient at efferocytosis than female splenic macrophages, and treatment with
phytanic acid in vitro or in vivo could enhance female splenic macrophage efferocytosis.
Overall, we found that higher Bacteroides and lower Clostridium abundances
correlated with lupus suppression in female BWF1 recipients of male microbiota, and
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speculate that this protection could be due, at least in part, to higher levels of phytol and
phytanic acid production in males. Furthermore, phytol and phytanic acid produced by
males may suppress disease, again at least in part, via enhancement of macrophage
efferocytosis. Taken together, these data may provide the basis for a mechanistic
understanding of the impact that the microbiota can have on autoimmune diseases such as
lupus, and for the development of novel therapies.
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INTRODUCTION
Sex bias in systemic lupus erythematosus (SLE)
The core characteristic of mammalian immune systems is the ability to
differentiate between self and non-self-antigens. This self-tolerance is mediated by both
central and peripheral mechanisms. Central mechanisms involve removal of autoreactive
T and B cells before they fully mature, while peripheral mechanisms involve inducing
tolerance to self-antigens to suppress immune responses against non-foreign cells and
tissues. When these mechanisms fail and self-tolerance is lost, the result is autoimmunity.
Most autoimmune diseases have a significant sex bias. Women comprise over
80% of autoimmune disease patients in Western countries. For the multi-organ
autoimmune disease, systemic lupus erythematosus, also called SLE or lupus, this sex
difference is even more pronounced as about 9 in every 10 people affected by SLE are
women [1,2]. SLE is characterized by the loss of tolerance to nuclear self-antigens such
as double-stranded DNA (dsDNA), single-stranded DNA (ssDNA, dsRNA), singlestranded RNA (ssRNA), histones, small nuclear ribonucleoproteins (snRNPs), and
ribosomes. This results in the production of anti-nuclear antibodies, which bind nuclear
antigens and form antigen-antibody complexes that are deposited in the joints,
vasculature, skin lungs, kidneys, and other organs. These immune complex deposits
cause inflammation and immune cell infiltration. Over time this leads to increasing levels
of tissue damage that can result in organ failure if untreated. This can manifest as lupus

1

nephritis, vasculitis, pulmonary hypertension, or stroke, and over 50% of lupus patients
develop one or more of these complications [3]. These complications are even more
common in male SLE patients, who tend to have more severe and rapid disease
progression despite being less likely to develop the disease [4-8]. However, despite lupus
nephritis being more common in male SLE patients, the incidence of progression to endstage renal disease is not different between male and female SLE patients [5,9-13].
Musculoskeletal involvement, on the other hand, seems to be more common in women
[14].
There are many mouse models of lupus, and many of them share the same sex
bias as the human disease. The models can be divided into two major categories:
spontaneous and induced [15]. The most well-established spontaneous mouse model of
lupus is the NZBxNZW F1 (BWF1) model. Female BWF1 mice spontaneously develop
anti-dsDNA autoantibodies, lymphadenopathy, splenomegaly, and glomerulonephritis in
a manner that resembles the progression of disease in humans. Male BWF1 mice rarely
develop the disease, and the disease is much milder in them if they do [16]. Androgen
depletion of males by castration results in severe disease at a much younger age,
indicating that androgens are as critical for the sex bias in BWF1 mice as they are in
humans [17]. Backcrossing the BWF1 strain with the NZW strain has given rise to two
additional strains that are used as lupus models, NZM2410 and NZM2328 [15].
NZM2410 mice develop lupus-like disease similar to BWF1, however, the pronounced
sex bias seen in BWF1 mice is not present in the NZM2410 strain [18,19]. NZM2328, on
the other hand, does display a sex bias closer BWF1 mice, with females developing a

2

more severe form of lupus-like disease at an earlier age, though the penetrance of disease
is lower in female NZM2328 mice than in female BWF1 mice [15,20].
The SWRxNZB F1 (SNF1) mouse model of lupus shares the NZB parental strain
with the BWF1 model. It spontaneously develops lupus-like disease in a manner very
similar to BWF1, producing anti-nuclear autoantibodies that lead to glomerulonephritis
[21-23]. Also, like the BWF1 model, the SNF1 has a distinct sex bias. Female SNF1 mice
develop disease more often, more severely, and more quickly than male SNF1 mice
[21,24,25]. Although interestingly, unlike the BWF1 model where castration causes
severe disease and mortality in male mice, a recent study of SNF1 mice found that
castration of male mice caused only a slight increase in disease that was not a statistically
significant change [26].
Another mouse model of lupus is the MRL/lpr model, which lacks a functional
Fas gene. This results in the accumulation of double negative CD4-CD8- T cells and
levels of lymphadenopathy that is not seen in human SLE patients. However, it does
develop autoantibodies and glomerulonephritis at a younger age than other lupus mouse
models. This occurs in both male and female mice, with no sex bias in incidence [27],
though female MRL/lpr mice do develop severe nephritis and organ failure a few weeks
earlier than male MRL/lpr mice [28]. This contrasts with another mouse model, the
BXSB/Yaa (BXSB) model. The X chromosomes of this strain have a translocated Y
chromosome genetic locus that includes the gene for TLR7. Male BXSB mice thus have
2 copies of the locus and consequently develop lymphadenopathy, anti-nuclear
autoantibodies, and glomerulonephritis. Female BXSB mice do not develop disease [29].
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There are also mouse models of lupus that require specific treatment to develop
disease. Pristane-induced lupus models of mice use intraperitoneal injections of the
pristane, a naturally occurring hydrocarbon oil that induces chronic inflammation in the
peritoneal cavity. This leads to the production of anti-nuclear autoantibodies and
glomerulonephritis [30]. The exact responses depend on the strain of mice, and in some
strains, such as the SJL strain, the induced disease is more severe in female mice [31,32]
Another class of induced-lupus models uses chronic graft-versus-host disease
(cGVHD) to mimic lupus. These models rely on transferring donor lymphocytes into
MHC mismatched recipients. Disease is stimulated by the alloreactive donor CD4+ T
cells reacting with the MHC class II expressing host B cells resulting in polyclonal
activation and the development of autoantibody-producing B cells [15,33]. There are
several variations of the cGVHD model based on what strains are used for donors and
recipients. Two of the most common are the DBA/2 donor into (C57BL/6 X DBA/2) F1
recipient model (DBA->BDF1) and the C57BL/6.bm12 donor into C57BL/6 recipient
model (bm12->B6). While both models result in lupus-like disease, with anti-nuclear
autoantibody production and glomerulonephritis, the DBA->BDF1 model exhibits a sex
bias where female to female transfer recipients develop more severe renal disease than
male to male transfer recipients, but the bm12->B6 model has no sex bias [33-35]. This is
due to the fact that the bm12->B6 model only has an MHC II mismatch while the DBA>BDF1 has an MHC I and MHC II mismatch. While the MHC II mismatch drives
disease as described above, the MHC I mismatch results in a graft vs host reaction where
the donor CD8+ cytotoxic lymphocytes (CTL) recognize the host autoantibody-producing
B cells as foreign and eliminate them. This graft vs host CD8+ T cell CTL response is
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much stronger when the donor cells are from male mice. This stronger CD8+ T cell CTL
has two significant outcomes. First, the reduction of numbers of host B cells results in
lower autoantibody production and lower disease. Second, the strong response of the
male donor CD8+ T cells results in subsequent contraction of the male donor CD8+ T cell
population and lower engraftment of male donor CD8+ T cells. After the initial CTL
response is over and the donor CD8+ T cells engraft, they promote disease via an IFN-γ
production. Thus, the lower engraftment of CD8+ T cells in male mice leads to lower
IFN-γ production and contributes to the milder disease seen in males. Conversely, the
lower initial CD8+ T cell CTL responses and subsequent higher engraftment and IFN-γ
production in female results in a more severe disease [33,35].
Deficient CD8 CTL activity is also present in other mouse models, including
BWF1 mice [36-38], MRL/lpr mice [39,40], and BXSB-Yaa mice [41,42]. Humans prone
to SLE also exhibit dysfunctional CD8 T cells and lower cytolytic activity [43-49].
However, how this connects to the sex bias in humans is unclear. While studies have
found males have higher CD8 T cell frequencies, some studies have also found PBMCs
from women to have higher levels of CD8 cytotoxic activity [50-55]. These seemingly
contradictory results may be due to differences in estrogen levels in the women who
participated in the studies. Estrogen levels rise and fall during the menstrual cycle, and
estrogen has repeatedly been shown to suppress CD8+ T cell CTL activity [56-58].
Further complicating comparisons between male and female patients is the fact that sex
differences in levels of CD8 cells change with age [59]. This is interesting, as hormone
levels also change with age, and the changes in these levels have been shown to have a
significant impact on the incidence and progression of SLE. [60]. Together, these suggest
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the possibility that age-related differences in hormone levels could cause age-related
differences in CD8+ T cell activity. Since deficiencies in CD8+ T cells have been linked
to SLE [43-49], it suggests that the differences in SLE susceptibility at different ages may
be mediated by age-dependent hormonal suppression of CD8+ T-cells.

Influence of genetics on the sex bias of SLE
The wide variety of mouse models have benefitted lupus research because SLE is
an extremely heterogeneous disease influenced by many genetic, hormonal, and
environmental factors. Genome-wide association studies have identified many genetic
polymorphisms in genes like ITGAM, CD40, and IRF5 that are linked to susceptibility to
SLE [61-67]. However, twin studies have found concordance to be 24-35% in
monozygotic twins and 2-4% in dizygotic twins [60,68,69], showing that while SLE has a
strong genetic component, genetics alone is insufficient to account for disease
development. Similarly, the mechanisms behind the sex bias of SLE are not completely
understood, but differences in both sex-linked genes and sex hormones are believed to
play major roles.
The mammalian X chromosome contains many genes important for normal
immune function [2,70]. Males, who carry only one copy of each X-linked gene, are
much more susceptible to genetic immunodeficiencies [71]. In addition, the female’s
heterozygosity for the X-linked genes allows for a more robust and diverse immune
system [72]. Following viral exposure, peripheral mononuclear cells from women
produce greater levels of pro-inflammatory factors such as interferon-γ (IFNγ),
interferon- and tumor necrosis factor α (TNFα) [59,73]. In healthy controls, macrophages
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and neutrophils from female rats and mice have higher phagocytic activity than those
from male rats. [74,75]. Studies have found that circulating T-cells from women have a
more robust proliferative response after stimulation and higher cytotoxic T-cell activity
[76]. Parasitic infections provoke higher levels of T helper 1 (Th1) cytokine production in
adult female mice, which may explain their greater resistance to parasites like
Leishmania major [77]. Females also exhibit higher levels of basal immunoglobulin
levels and larger antibody responses [2,78-80]. All of this likely contributes to women’s
superior survival rates and outcomes after injury due to reduced susceptibility to sepsis
and infections [81,82].
However, this hyperreactive immune system does come with a downside, as
increased copies of the X chromosome also result in higher incidence of autoimmune
diseases in general, and lupus in particular. Men with Klinefelter’s syndrome (XXY)
have 14-fold higher rates of SLE than XY males [83], and females with XXX karyotypes
are 2.5 times more likely to develop the disease than XX females [84]. Conversely,
females with Turner syndrome (XO) have a lower prevalence of SLE than XX females
[85].
Women and men with Klinefelter’s syndrome have a compensatory mechanism to
equalize the gene dosage and limit overexpression of X-linked genes. One of the X
chromosomes is randomly silenced during female embryogenesis [2]. This process, called
X chromosome inactivation, was at first believed to be largely complete and stable, with
only a small number of genes not fully suppressed. However, studies since then have
shown that 20-30% of X-linked genes are incompletely inactivated and that the level of
inactivation varies widely between tissue and cell types [86-89]. This discovery has
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opened a whole new avenue for understanding the differences in lupus between males
and females.
To investigate the link between incomplete X inactivation and overexpression of
lupus-promoting genes, multiple studies have examined T cells from female lupus
patients. Studies have found considerable overlap between genes that are incompletely
silenced and genes that are upregulated T cells from lupus patients, including CD40L,
CXCR3, OGT, miR-98, let-7f-2, miR-188-3p, miR-421 and miR-503 [90-92]. Since XY
males, having only one X-chromosome, are not susceptible to increased lupus-promoting
X-linked gene expression due to incomplete X-inactivation, incomplete silencing of Xlinked genes may contribute to the sex bias of lupus. This phenomenon is not limited to T
cells, as a recent study found that in plasmacytoid dendritic cells (pDCs), B cells, and
monocytes from healthy women and men with Klinefelter syndrome (XXY), both copies
of the X-linked gene encoding Toll-like receptor 7 (TLR7) gene were transcribed
resulting in higher expression than in cells from XY men. TLR7 is important for
detecting viral RNA and promoting IFNα production, which drives antibody responses to
viral infections [93]. However, TLR7 signaling can also be activated by RNA-containing
immune complexes associated with advanced SLE [94]. Numerous studies of mouse
models of lupus have identified TLR7 as essential for the development of spontaneous
germinal centers and the production of autoantibodies [95-97]. This effect of TLR7 has
been found to be gene-dosage dependent, with increased TLR expression promoting the
development of lupus-like disease [98-100]. Incomplete inactivation of TLR7 has clear
implications for the development of SLE. However, a recent study of female BWF1 mice
found that TLR7 did not escape X inactivation in B cells and that, while the B cells did
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express higher levels of autoimmunity-associated genes, none of them were on the X
chromosome. This finding suggests that incomplete X inactivation may not be a major
cause of the sex bias in the BWF1 mouse model [101]

Contribution of sex hormones in the sex bias of SLE
The other major mechanism by which sex is thought to affect SLE is via the
production of sex hormones. The connection between sex hormones and immune
responses is long established. Estrogens generally promote immune responses, while
androgens typically suppress them [58,102,103]. There is ample evidence that higher
levels of estrogens increase lupus severity.
While estrogens are known to promote immune activation in general, at higher
doses they can suppress certain immune responses [102,104,105]. However, importantly
for SLE, both low and high concentrations of estrogen stimulate B cells to increase
production of immunoglobulins in mice and humans [58,104,106,107]. Consequently,
while high estrogen levels can suppress some aspects of disease that are more dependent
on T cells, its overall effect is to increase SLE severity and progression [58,108]. Even in
mice not prone to autoimmunity, high doses of estrogen increased the numbers of
antibody producing B cells, including cells that produced autoantibodies [109]. Estrogen
promotes B cell survival and activation, leading to the increased numbers of autoreactive
B cells escaping negative selection [106,110]. Estrogen can also inhibit B cell tolerance
and induce lupus-like phenotypes in mice [111]. Knocking out the estrogen receptor gene
in B cells has an impact on autoantibody production in BWF1 mice [112,113].
Additionally, treating peripheral blood mononuclear cells taken from SLE patients with

9

estrogen enhanced their production of autoantibodies [114]. Female mice with graftversus-host induced glomerulonephritis had higher levels of autoantibodies against
dsDNA and other nuclear antigens after treatment with 17-β-estradiol (E2), a form of
estrogen [71,115].
Estrogen’s effects are not limited to B cells. E2 causes dendritic cells (DCs) to
upregulate CD40, a costimulatory molecule that is critical for the induction of humoral
immunity [116]. A recent study found that proteinuria decreased in BWF1 lupus-prone
mice after treatment with a CD40 antagonist antibody [117]. There are several CD40blocking therapies undergoing clinical trials for SLE and other autoimmune diseases
[118]. Another type of dendritic cell, plasmacytoid DCs (pDCs), is a key producer of
interferon-α (IFNα) which activates B cells and drives autoantibody production. Lupus
immune complexes can activate pDCs via TLR7 and TLR9 and stimulate them to
produce IFNα. Studies have found that treating human or mouse pDCs with E2 increases
their IFNα production in response to TLR7 and TLR9 signaling [119,120]. Additionally,
there is a positive regulatory feedback loop between interferon and estrogen signaling
[121].
Androgens, especially testosterone, are strongly immunosuppressive and antiinflammatory [103]. Men who have androgen deficiencies have higher serum antibody
titers, CD4/CD8 T cell ratios, and higher levels of inflammatory cytokines including IL1β, IL-2, and TNFα [122-125]. Consequently, androgen levels have a significant effect
on autoimmune disease. Castration has been found to stimulate or exacerbate
autoimmune symptoms in several mouse models of autoimmune diseases, including
Experimental Autoimmune Encephalomyelitis (EAE), non-obese diabetic (NOD), and
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rheumatoid arthritis [126-128]. In those same mouse models, treatment with androgens
ameliorated disease symptoms [103,128-130]. In male rheumatoid arthritis patients,
lower levels of testosterone have been found to correlate with disease severity. Also,
testosterone supplementation reduces disease severity in postmenopausal men and
women with rheumatoid arthritis [131].
Studies with mouse models have repeatedly found that androgens play a
protective role in SLE. In a graft-versus-host induced glomerulonephritis mouse model,
testosterone treatments decreased proteinuria [132]. In the BWF1 mouse model of lupus,
treating disease-prone females with androgens delays disease onset and reduces serum
anti-dsDNA titers and other markers of disease [133]. When BWF1 mice were treated
with the androgen receptor-blocking drug flutamide, it accelerated mortality in both male
and female mice [134]. Similarly, male BWF1 mice that undergo androgen depletion by
castration develop more severe disease at an earlier age. Some studies have shown that
these male BWF1 mice have a testosterone-dependent splenic Gr1+CD11b+F4/80neutrophil population that inhibits autoantibody-producing germinal center reactions
[135,136]. However, while depleting Gr1+ neutrophils in male BWF1 mice increased
autoantibody levels, it did not have any impact on kidney disease progression [135]. This
finding and the findings of a more recent study that showed neutrophil depletion
accelerated both autoantibody production and kidney damage in female BWF1 mice, cast
doubt on the Gr1+ neutrophils as a significant source of male BWF1 disease resistance
[137].
Androgens are protective in humans as well as in mice. Women with active SLE
had decreased levels of androgens, including testosterone, androstenedione, and
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dehydroepiandrosterone [115,138]. Interestingly, the same has been found for female
SLE patients without active disease, suggesting that the low levels are not caused by
active disease activity [139,140]. Androgen levels are also lower in male SLE patients
[141-144], and a subset of them exhibit hypogonadism [143,145]. Both males and
females with SLE have been found to exhibit excessive estradiol hydroxylation, which
depletes testosterone and produces estrogens [144]. Similarly, men with Klinefelter
syndrome, who naturally have lower androgen levels and higher estrogen levels than XY
males, have a higher risk for SLE [146,147]. Since disease in men and women correlates
with higher estrogens, female SLE patients were treated with tamoxifen, a drug which
competes with estrogens for the estrogen receptor, but the treatment failed to alleviate
disease severity [148]. On the other hand, multiple studies have found that treatment with
androgens can ameliorate disease activity and lower anti-dsDNA antibody production
[149-152]. Clearly, androgens can have a major impact on lupus progression.

Efficacy of current androgen-based treatments and other therapeutics
While androgens are known to inhibit lupus progression, translating these
successes in the laboratory into effective clinical treatments has been challenging.
Treatment with the testosterone-like anabolic steroid, nandrolone resulted in some
patients improving but others saw no benefits [153-155]. Similarly,
dehydroepiandrosterone, a weak androgenic steroid, has been shown to have mild
benefits in premenopausal patients with non-severe disease, but it has been less beneficial
in postmenopausal patients [149,156-162]. While these androgens can alleviate some
symptoms of disease, the lack of consistency in benefits and the masculinizing side
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effects make these androgens non-viable as frontline treatments [163]. Nevertheless,
while directly treating with weak androgens has had little success, understanding
androgen’s mechanisms of action for immunosuppression may lead to the discovery of
targets for treating SLE [164].
In the past few years, therapies that deplete specific cell lineages or block certain
cell-cell interactions have been developed. One such therapeutic, Anifrolumab, blocks the
IFN-α cell signaling that can drive lupus progression. It has been found to benefit some
patients if used early in the course of the disease before active renal involvement, but
over half the patients tested did not respond to the treatment [165,166]. Another,
Rituximab, is an anti-CD20 antibody that depleted mature B cells, but it was not found to
be more effective than standard treatment [167,168]. Belimumab is an antibody that binds
the cytokine B-cell activating factor (BAFF) and prevents it from binding to B cells and
promoting their maturation. It has been found to be beneficial for patients with severe
disease that is not responding to standard treatments, but not for patients with mild to
moderate disease [169-171]. Atacicept, a recombinant protein that binds two B-cell
maturation-promoting cytokines, B-lymphocyte stimulator (BLyS) and A proliferationinducing ligand (APRIL), has recently been developed and clinical trials testing its ability
to treat SLE are underway. Initial results are promising, as it has been shown to decrease
lupus flares [172]. However, atacicept was only effective in a subset of lupus patients, as
40% of patients treated showed no benefit [173,174].
SLE has proved a challenging disease to treat. Between the 1950s and 1990s, the
10-year survival rate for adults increased dramatically from 50% up to 90% [175-177]. In
recent decades, though, progress has plateaued. Both survival rates [177,178] and the risk
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of end-stage renal disease resulting from lupus nephritis [179] are little different now
than they were in the 1990s. The current standard treatments are limited by high rates of
failure and toxicity. Corticosteroid therapy, a current first-line treatment, may actually
contribute to kidney damage over the long term [178]. Clearly, recent advances in
treatment have not succeeded in improving the condition of SLE patients, and there is a
dire need for new paradigms of SLE management.

Autoimmunity and the gut microbiota
In recent years, a new paradigm has emerged as we have learned more about the
interactions between the microbiota and the immune system. The immune system is
designed to detect and respond to foreign entities. The presence of a few thousand
bacteria in the blood or peripheral tissues would result in recognition by innate immune
cells followed by a strongly inflammatory immune response that would drive a
subsequent adaptive immune response [180]. In dramatic contrast, the trillions of bacteria
normally present in a healthy human intestine rarely trigger spontaneous pathological
inflammatory immune responses or systemic immune responses [181-183]. These
commensal bacteria are collectively termed the gut microbiota, and a complex system of
interactions with the host immune system is needed to maintain a state of mutualism and
homeostasis [181-184]. The past two decades have seen a dramatic increase in our
understanding of the importance of the microbiota in health and disease, including how
interactions between the host immune system and the gut microbiome are essential for
proper immune system development and function [184-187].
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Because colonization by commensal organisms begins after birth [188], it is
possible to use cesarean sections in a germ-free environment to derive mice that lack any
commensal bacteria [189,190]. Experiments comparing these germ-free (GF) mice to
genetically identical mice born with a microbiota (“conventional” mice) have greatly
enhanced our understanding of how the microbiome affects the host [186]. These studies
with germ-free animals have long shown that the absence of gut microbiota leads to
serious defects in the development of the spleen, thymus, lymph nodes, and other
lymphoid tissue [191,192]. Structures of gut-associated lymphoid tissue (GALTs) are
most affected. GF mice have lower frequencies of isolated lymphoid follicles as well as
smaller Peyer’s patches and mesenteric lymph nodes (mLN) [193-195]. In addition to
deficient lymphoid tissue structures, the lack of microbiota in GF mice also causes
significant and detrimental changes to immune cell populations. The numbers of αβ and
γδ intra-epithelial lymphocytes are considerably lower in GF mice than conventionally
colonized animals [196]. The balance between Th1 and Th2 T cells is also affected by the
lack of a microbiota [197]. The small intestine lamina propria normally contains a
considerable number of IL-17 producing T helper cells. These cells are critical for
defense against bacterial and fungal pathogens but are absent in GF mice [198,199].
Similarly, the microbiota also influences the development and V(D)J recombination of
lamina propria B cells [200]. These differences in B cell development may contribute to
the lower production of IgA antibodies, the primary antibody in protective mucosal
immunity, in GF mice [201].
Germ-free pups that have never been directly exposed to bacteria are still
affected by the microbiota of their mother. A recent study showed that germ-free pups
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whose mothers had been transiently colonized by E. coli during pregnancy had increased
intestinal group 3 innate lymphoid cells and F4/80+CD11c+ monocytes as well as higher
production of epithelial antibacterial peptides. This effect was dependent on maternal
antibodies, and the study found that maternal IgG facilitated transfer of microbiotaderived compounds to the fetus. It further showed that these changes had functional
consequences, as the pups whose mothers were transiently colonized had improved
intestinal barrier integrity that was better able to block bacterial translocation [202].
It is important to note that while many immune deficiencies of GF mice can be
corrected by colonization with commensals at a later age [197,199,201,203], some
defects are the result of the absence of microbiota during a crucial period of development
in early life [184,186]. This was demonstrated in a study that compared the intestinal
transcriptome profiles of mice born with a microbiota and mice that were born germ-free
but colonized with commensals as adults. The transcriptional profiles of jejunal and
colonic epithelial cells were significantly different between these two groups, with
dramatic differences in genes related to inflammatory responses, immune cell trafficking,
and other biological processes [204]. A more recent study identified an age-dependent
immune response to bacteria that affects the composition of the microbiota into
adulthood. It found that the neonatal mouse gut epithelium expresses the flagellin-sensing
Toll-like receptor 5 (TLR5). This expression is age-dependent and transitory. While it is
expressed, TLR5-mediated signaling drives a Reg3g c-type lectin-dependent immune
response that selects against flagellated bacteria. This resulted in a long-term reduction of
the presence of flagellated bacteria. Experiments with GF mice showed that the potential
for an anti-flagellated bacteria immune response was only present for a short period after
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birth, demonstrating that early life represents a crucial time for the establishment of the
microbiota and development of the immune system [205].
Multiple studies have shown that changes in the immune system brought about
by early-life exposure to microbes have considerable health ramifications. GF mice
accumulate higher numbers of invariant natural killer T (iNKT) cells in the lung and
colon. This made the mice more vulnerable to oxazolone-induced colitis and ovalbumindriven allergic asthma. These vulnerabilities could be eliminated if the GF mice were
colonized with a conventional microbiota as neonates, but colonization of adult GF mice
failed to protect them against disease [206]. GF mice also have abnormally high serum
levels of IgE [207]. This makes them more susceptible to severe allergic reactions and
systemic anaphylaxis. Colonizing GF mice with a conventional microbiota up to a week
after weaning prevents the development of high IgE and protects against allergic
reactions, but colonizing adult GF mice does not have the same therapeutic effect [208].
These effects can be seen even in mice that are not completely germ-free. Treating mice
with vancomycin, a widely-used antibiotic, can decrease microbiota diversity and cause
significant shifts in microbial populations. However, the effect of these changes on health
depends on the timing of the treatment. Mice that are treated with vancomycin as
neonates and as adults are more susceptible to experimental allergic asthma than mice
that only received the antibiotic as adults [209].
These findings in mice parallel findings in humans, as there is a plethora of
evidence that immune system interactions with the microbiota at an early age affect the
chances of developing immune-mediated diseases later in life. As an infant grows, the
diversity of the microbiota increases gradually, but the composition can shift abruptly in
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response to health or dietary changes [210,211]. One of the things that can cause a drastic
shift is if the child is treated with antibiotics. While the development of antibiotics has
been an incredible boon to the fight against infectious diseases, increasing evidence
suggests that their use during childhood increases the risk of developing asthma and other
autoimmune diseases [184]. Multiple studies have found children that are treated with
antibiotics during the first year of life are considerably more likely to develop asthma
[212-214]. Another study found that treating pre-school children with macrolide
antibiotics resulted in a long-lasting shift in the microbiota, with lower levels of
Actinobacteria and higher levels of Bacteroidetes and Proteobacteria. These changes
correlated with increased risk of asthma and antibiotic-associated weight gain [215]
Similarly, children receiving antibiotic treatment before one year of age are 5 times more
likely to develop inflammatory bowel disease [216,217]. Clearly, the long-term adverse
effects of antibiotics on the microbiota can increase the chances of immune-mediated
diseases. Understanding the mechanisms by which the microbiota affects the immune
system will be key to mitigating the long-term side effects of these crucial medicines.
By inhibiting the growth of bacteria, antibiotics cause a change in the bacterial
composition of the microbiome. This can potentially lead to an imbalance and/or a loss of
diversity that results in the microbiota promoting disease. Bacteria that promote health
may be lost or suppressed, and bacteria that promote inflammatory and harmful effects
may be gained or expand. A microbiome in this state is said to be in dysbiosis. While
childhood treatment with antibiotics offers a dramatic view of the effects of dysbiosis,
adults can develop a dysbiotic microbiota as well [184,218,219]. Also, while antibiotics
are a common cause of dysbiosis, it can also result from other environmental factors such
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as the side effects of other medications, dietary deficiencies, and infectious diseases.
Since the 1950s, there has been a significant increase in the prevalence of autoimmune
diseases and allergies, and there is considerable evidence this is partly due to changes in
microbial exposure [220-222]. Increases in antibiotic treatments, reductions in the
frequency of infections, and other environmental changes have led to alterations in the
microbiota which in turn have affected the functions of the immune system [222].
Consistent with this hypothesis, dysbiosis has been linked to multiple autoimmune
diseases [184,218,219]. Considerable effort has been put into understanding how
dysbiosis and autoimmune disease are linked [184]. Understanding the mechanisms that
connect dysbiotic microbiota and autoimmune disease could potentially lead to therapies
that treat or prevent autoimmune disease by altering the microbiota into a more beneficial
state.
One disease with considerable evidence linking it to the microbiota is
inflammatory bowel disease (IBD) [223,224]. IBD, which includes Crohn’s disease and
ulcerative colitis, is characterized by chronic and relapsing immune-mediated intestinal
inflammation that causes abdominal pain, diarrhea and bloody stools [223,224]. The
correlation between IBD and dysbiosis is well established [225-235], and treatment with
antibiotics can alleviate disease symptoms, indicating that the bacteria do play a causative
role in the disease [236-240]. While all of these studies found dysbiosis in IBD patients,
the specific alterations in bacterial taxa varied widely [223,225-235]. The most
consistently found alteration was an increase in Enterobacteriaceae in IBD patient stools
relative to healthy individuals, but even this finding was not universal [223,241-245].
Adherent-invasive strains of the Enterobacteriaceae member, E. coli have been found in
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the ileal mucosa of Crohn’s patients, but no clear cause-and-effect relationship has been
established [246]. Multiple studies found lower levels of the Firmicutes member
Faecalibacterium prausnitzii in the stools of IBD patients [230-235], though studies of
mucosal biopsies from IBD patients have not consistently replicated that finding
[247,248]. This lack of consistency is likely due to the heterogeneous nature of both the
disease and the human microbiota [223,224]. Differences in environment and genetics
result in the human microbiota varying widely from person to person and from region to
region [223,224]. The more controlled settings of mouse models have shed light on the
mechanisms of microbiota-immune system interactions that can drive or suppress IBD.
Some bacterial species, including Bacteroides fragilis, and assorted Clostridia strains,
can suppress disease in mice by promoting the development of immunosuppressive
regulatory T cells (Tregs) in the intestine. Other bacterial species have been shown to
promote disease. Some IBD models induce disease by injecting mice with exogenous
inflammatory Th17 cells, which drive inflammation and tissue damage in an interferon
gamma (IFNγ) dependent manner [249]. However, these cells will not cause disease in
the absence of a microbiota [250,251]. Helicobacter muridarum, Helicobacter
hepaticus, and segmented filamentous bacteria have been identified as being able to
stimulate colitis-promoting activities in adoptively transferred Th17 cells [250-252].
These studies show that differences in microbiota composition can affect autoimmune
disease progression.
Just as interactions with the microbiota shape the immune system, the actions of
the immune system affect the composition of the microbiota. The immune system can
produce pathogen specific IgA antibodies to coat and neutralize problematic bacteria in
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the intestine. Studies have found that known colitis-promoting pathobionts such as
Prevotellaceae, Helicobacter, and SFB are more likely to be coated in IgA. Transferring
IgA-coated bacteria from IBD patients into mice rendered the recipient mice significantly
more susceptible to severe DSS-induced colitis [253-255]. Additionally, IgA deficiency
is associated with increased risk for ulcerative colitis and Crohn’s disease [253] This
highlights the complexity of the interactions between the microbiota and the immune
system, as a deficiency in the immune system can alter the composition of the microbiota,
which in turn can affect the immune system and promote responses that result in disease.
Consequently, attempting to determine whether dysbiosis or inflammation was the initial
cause of the disease is not an easy task.
The microbiota can also affect the development of autoimmune diseases in tissues
outside the intestine. Rheumatoid arthritis (RA) has also been linked to dysbiosis. RA is a
chronic autoimmune disease characterized by the production of autoantibodies against
collagen and mediate synovial inflammation resulting in destruction of bone cartilage in
affected joints. In addition to genetic and environmental factors, the microbiome is
believed to influence the pathogenesis of RA [184,256,257]. This systemic disease is
associated with periodontitis, a severe infection of the gums, and treatment of
periodontitis ameliorates RA disease activity [258-260]. Studies investigating this link
have shown that infection with one of the major periodontal pathogens, Porphyromonas
gingivalis, can drive RA progression. One of the characteristics of RA is the production
of antibodies against cyclic citrullinated proteins (CCP), self-antigens present in cartilage.
Infection with P. gingivalis correlates with increased production of anti-CCP antibodies,
because P. gingivalis produces an enzyme that citrullinates proteins. Antibodies against
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these proteins also bind the self-antigen CCP and thus the immune response against P.
gingivalis promotes the autoimmune response that causes RA [261-264]. In addition to
promoting autoantibody production via molecular mimicry, P. gingivalis infection also
induces a Th17 response via TLR2 stimulation that further drives RA disease activity
[265]. Recently, other periodontitis-causing bacteria, including Anaerglobus geminatus
and Aggregatibacter actinomycetemcomitans, have also been found to promote RA
progression via an anti-CCP antibody-dependent mechanism [266,267]. In addition to the
oral microbiome, the intestinal microbiome has also been implicated in the pathogenesis
of RA. Both individuals at high risk for RA [268] and new-onset RA patients who have
not begun treatment [269,270] have increased abundance of intestinal Prevotella copri. A
recent study used the SKG mouse model of RA to investigate whether P. copri could play
a causative role. The SKG mouse model of RA contains a point mutation in ZAP-70 that
decreases T cell receptor (TCR) signaling, allowing auto-reactive T cells to escape
negative selection. This renders SKG mice susceptible to arthritis induction by activation
of innate immunity. When treated with innate-immune activating compounds such as the
fungal-derived zymosan, SKG mice develop arthritis similar to human RA. However,
because disease induction depends on innate immunity, it is affected by the microbiota,
and arthritis cannot be induced in germ-free mice that contain no commensals [271,272].
To test whether the presence of P. copri would affect the course of disease, microbiota
from high-Prevotella-abundance RA patients or from healthy controls was transferred
into germ-free SKG mice and the mice were treated with Zymosan to induce arthritis.
The mice that received the high-Prevotella microbiota developed significantly more
severe arthritis with higher IL-17 responses [270]. A recent study found T cells activated
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by Prevotella epitopes cross-reacted with the self-antigens GNS and FLNA, suggesting
that P. copri could potentially drive RA progression by activating autoreactive T cells
[273]. However, a study of gut commensal compositions of people from Africa and
tropical Asia found that healthy people had a large abundance of Prevotella species,
including P. copri, in their intestines [274]. Similarly, another recent study found
Prevotella histicola isolated from the intestine of healthy humans decreased disease
severity in a collagen-induced mouse model of RA [275]. These seeming contradictions
emphasize the challenges of identifying what bacterial species in the human microbiota
can promote disease. The context of the microbiota and the other species that it contains
will affect the effect of a given species, and even in very similar contexts, closely related
species can have opposite effects.
Like rheumatoid arthritis, systemic lupus erythematosus (SLE) is a systemic
disease characterized by autoantibody production, and SLE patients also exhibit
dysbiosis. Numerous recent studies have found the microbiota of SLE patients differ
significantly from those of healthy controls [276-283]. However, while all of these
studies found dysbiosis, the differences in specific taxa were significantly less consistent.
The only finding that was replicated across multiple studies was an increase in the
Bacteroidetes phylum and a decrease in Firmicutes phylum in SLE patients [277280,284]. Another recent study confirmed the lower ratio of Firmicutes/Bacteroidetes in
SLE patients and found that treatment with glucocorticoids increased the
Firmicutes/Bacteroidetes ratio and correlated with lower serum levels of inflammatory
cytokines [285]. Overall richness, as measured by α-diversity is generally decreased in
SLE patients in comparison to healthy controls [276,280,282]. Despite this lack of
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consistency, investigations of the microbiota in SLE patients as well as in mouse models
of lupus yielded several interesting discoveries that have increased our understanding of
how the gut microbiota can affect disease progression.
One study identified Ruminococcus gnavus as a potential pathobiont that could
contribute to lupus progression. SLE patients have 5-fold greater abundance of R. gnavus,
and many had antibodies against one or more strains of R. gnavus. The level of anti R.
gnavus antibodies correlated positively with overall autoantibody levels and active
nephritis, which could suggest that immune responses against R. gnavus may increase
disease severity [276].
Another study found that the pathobiont Enterococcus gallinarum might drive
lupus both in human SLE patients, and the NZWxBXSB F1 (NxB F1) mouse model of
lupus. NxB F1 male mice develop lupus due to having a duplicate TLR7 gene, and the
study found male mice with disease had E. gallinarum in their livers. Liver biopsies from
patients with SLE or other autoimmune diseases were more likely to contain E.
gallinarum than biopsies from healthy patients. This could be due to impaired gut barrier
function, which is common in SLE patients and mouse models of lupus. Germ-free B6
mice monocolonized with E. gallinarum developed impaired barrier function, E.
gallinarum translocation to the liver, and the production of antinuclear autoantibodies and
pro-inflammatory cytokines. However, E. gallinarum did not translocate or induce
autoimmunity in conventional B6 mice. When NxB F1 male mice were vaccinated
against E. gallinarum, serum levels of autoantibodies were reduced and survival was
increased, showing that eliminating a specific bacterial species could suppress
autoimmunity without suppressing the entire immune system. Among SLE patients, the

24

presence of E. gallinarum in the liver correlated with higher levels of autoantibodies,
suggesting that the pathobiont could play a similar role in humans as it does in the NxB
F1 mouse model [286].
Another recent study suggested commensal bacteria may promote lupus by
expressing an ortholog of the human protein Ro60. Ro60 is a nuclear antigen, and antiRo60 antibodies are often among the first to develop in SLE patients [287,288]. There is
significant cross-reactivity between human Ro60 and the bacterial Ro60 ortholog. The
bacterial Ro60 ortholog is recognized by T cells and B cells from SLE patients that have
anti-Ro60 autoantibodies. Some people have commensals that express the Ro60 ortholog
in their gut microbiota, suggesting a possible link. Additionally, GF mice monocolonized
with a Ro60 ortholog-expressing bacteria developed an anti-Ro60 autoantibody response
that led to glomerular deposition of immune complexes. This suggests that an immune
response against the bacterial Ro60 ortholog could potentially contribute to the
development of lupus. However, almost all of the SLE patients and healthy subjects in
the study had Ro60 ortholog-expressing bacteria in their microbiomes. This indicates that
the presence of the Ro60 bacteria is not enough to stimulate autoimmunity on its own.
Also, Ro60 ortholog-expressing bacteria were found at equal frequency in SLE patients
that were positive for anti-Ro60 autoantibodies and SLE patients that were negative for
anti-Ro60, showing that even in patients with active autoimmune disease the presence of
Ro60 ortholog-expressing bacteria in the gut is not enough to stimulate an anti-Ro60
antibody response. Analysis at the family level did not reveal any significant differences
in the composition of the microbiota between the anti-Ro60 positive and negative SLE
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patients [277]. Thus, while the possibility of microbiota Ro60 cross-reactivity stimulating
lupus development is possible, the events that would lead to this are still undetermined.

Gut microbiota and mouse models of lupus
A recent study found a link between microbiota tryptophan metabolism and lupus
in the BWF1-derived triple congenic B6.Sle1.Sle2.Sle3 (S123) mouse strain. Compared
to healthy control female B6, S123 microbiota is enriched for Prevotellaceae,
Paraprevotella, and Lactobacillus. When adult female S123 microbiota was transferred
to GF B6 mice, the B6 mice developed lupus-like symptoms including elevated
autoantibodies and mild glomerulonephritis. Fecal metabolite analysis found evidence
that microbiota tryptophan metabolism was altered in female S123 mice to favor
kynurenine production over serotonin production. Changing the tryptophan content of the
diet altered the S123 microbiota composition and impacted disease development; a low
tryptophan diet protected against disease, and a high tryptophan diet exacerbated disease.
A high tryptophan diet increased the ability of female S123 microbiota to cause
autoimmune phenomena in GF female B6 mice. Microbiota from mice fed a low
tryptophan diet did not induce autoimmune phenotypes in the GF B6 mice. Altering
female S123 microbiota by cohousing with female B6 mice reduced autoantibody
production, but glomerulonephritis was unchanged [289]. This study showed that changes
in the microbiota caused by changes in diet affected whether the microbiota suppresses or
promotes lupus-like disease progression. It also showed that the microbiota in the lupusprone female S123 mice have altered tryptophan metabolism and that they promote the
development of lupus-like symptoms. However, it did not determine whether female
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S123 microbiota affected the immune system and disease progression via altered
production of tryptophan metabolites. Bacterial associated tryptophan metabolites have
been found to have immunomodulatory properties [290-292], and the high kynurenine
and low serotonin in the mouse feces matches findings in SLE patient sera [293].
Inhibiting kynurenine production did not protect against disease, so the paper did show
higher kynurenine production is not responsible for disease, but additional research into
the role the other tryptophan metabolites play could be illuminating.
Diet can also affect the composition of the microbiota in the SNF1 mouse model
of lupus. Giving lupus-prone female SNF1 mice acidified water suppressed disease. It
delayed the onset of nephritis and decreased the level of antinuclear autoantibodies
compared to SNF1 mice on neutral pH water. The composition of the microbiota was
significantly changed by the acidified water, and the most significant change was in the
Rikenellaceae family, which was greatly increased in the SNF1 mice receiving acidified
water. Additionally, the level of Firmicutes was increased and the level of Bacteroidetes
was decreased in the acidified water group [294]. This mimics findings from human
studies that have found healthy controls to have higher Firmicutes and lower
Bacteroidetes levels than SLE patients [277-280,284]. In the SNF1, the changes
correlated with increased intestinal levels of Th17 cells which promote lupus progression,
suggesting that the alterations to the microbiota might decrease its Th17-stimulating
characteristics [294].
It has been shown that treating MRL/lpr mice with antibiotics after disease onset
ameliorates disease, indicating a connection between microbiota and disease [295]. A
study from the lab of Xin M. Luo investigated this connection and found lupus-prone
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MRL/lpr mice have significantly lower levels of bacteria from the family
Lactobacillaceae relative to healthy control MRL mice [296]. A later study from the
same lab followed up on this finding, and showed Cecal transfers from MRL mice into
MRL/lpr mice decreased anti-dsDNA autoantibody production. Weekly gavages with a
mixture of strains from the Lactobacillaceae genus Lactobacillus not only decreased antidsDNA production, they also slowed nephritis onset and increased survival in the
MRL/lpr mice. In both Lactobacillus gavaged and non-gavaged MRL/lpr mice,
Lactobacillus reuteri and an unknown strain were by far the most common bacteria.
Treatment with the Lactobacillus bacteria corrected the “leaky” gut that Mrl/lpr mice
normally exhibit. In addition, intestinal IL-10 production was increased and IL-6 was
decreased, promoting an anti-inflammatory environment. This resulted in decreased
deposition of IgG2a in the kidney and in changing the Treg/Th17 balance in the kidney to
skew more towards Tregs [297]. Together, these findings suggest an immunoregulatory
role for Lactobacillus bacteria in the MRL/lpr mouse model. This was suggestion is
strengthened by another recent paper that found treating MRL/lpr mice with antibiotics
before disease onset resulted in dysbiosis characterized by lower levels of Lactobacillus
and Bifidobacterium. These dysbiotic MRL/lpr mice developed more severe disease
compared to untreated controls [298].
A later paper from the Luo lab, however, found that the opposite was true for the
BWF1 mouse model of lupus. It found that in disease-prone female BWF1 mice, the gut
microbiota composition changed significantly between the pre-disease and lupus disease
stages. However, unlike in the studies of MRL/lpr mice, higher Lactobacillus abundance
in female BWF1 mice was associated with increased loss of renal function and higher

28

levels of autoantibodies [282]. This suggests that the effect of lactobacillus may depend
other factors such as the genetics of the host and the overall composition of the
microbiota.
A study from a different lab raised even more questions about the role of L.
reuteri in lupus. This study found greater abundance of L. reuteri in a subset of SLE
patients compared to healthy controls. L. reuteri was also enriched in the feces of a
TLR7-dependent models of lupus, the TLR7.1 transgenic (Tg) mouse strain. Like the
BXSB/Yaa strain, male TLR7.1 Tg mice spontaneously develop lupus-like disease due to
having an extra copy of the TLR7 gene on the Y chromosome. This was also true for
their TLR7 agonist-induced model, where C57BL/6 (B6) mice are regularly treated with
the TLR7 agonist imiquimod (IMQ) to induce a lupus-like disease. Gavaging imiquimodtreated B6 germ-free or conventional mice with cecal contents from lupus-prone TLR7.1
Tg mice significantly increased the severity of glomerulonephritis, splenomegaly, and
other lupus symptoms. Additionally, gavaging TLR 7.1 Tg mice with L. reuteri
exacerbated the spontaneous lupus-like disease. In direct contrast to what was found in
the MRL/lpr model, L. reuteri gavage worsened gut permeability in the IMQ-induced B6
model. L reuteri also translocated. The ‘leakiness’ induced by L. reuteri allowed it to
translocate across the intestinal barrier to the mesenteric lymph nodes, spleen, and liver,
suggesting this may be involved in its increasing of disease severity [299].
These differences in Lactobacillus findings underscore the importance of
biological context when investigating the microbiota. While the MRL/lpr, BWF1, and
TLR7.1 Tg mouse strains all model the same disease, the genetic differences that make
them lupus prone are quite different. Given their diversity, it is unsurprising that the
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effect of a bacterial taxon would differ between them. This is especially important to
consider when considering how microbiota findings in animal models could be applied to
human patients. The diversity of human lifestyles translates to significant heterogeneity
in microbiota. Obviously, it is not possible to replicate the diversity of human diet and
environmental exposures in lab animals, however, sex and sex hormones have a
significant effect on the microbiota and yet are often overlooked or ignored in studies.

Sex differences in the gut microbiota and the effect on autoimmune diseases
Of course, one of the major sources of microbiota heterogeneity are the effects of
sex and sex hormones. Many studies have found differences in the microbiota between
men and women, though the taxa that differ vary and often conflict from study to study
[182,300-303]. For example, one study found a higher level of Bacteroides/Prevotella in
men than women [304], while another found that Bacteroides abundance was lower in
men than women [300]. While taxa may differ, women do tend to have a higher level of
richness and α-diversity than men [305,306]. Not only does host sex affect the microbiota
directly, it also affects how other environmental factors affect it. A recent study found
that the microbiota in men and women responded differently to dietary changes [301].
Combined with the increasing evidence that the microbiota can impact lupus progression,
these differences in microbiota between men and women raise the question of whether
sex differences in microbiota might contribute to sex bias in SLE.
There is evidence that the sex of the host changes how the gut microbiota interacts
with and influences the immune system. When microbiota from male or female
conventional mice is transferred into germ-free mice, the sex of the donor affects how the
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immune system of the recipient changes after the transfer. Recipients of female
microbiota had higher levels of thymic double-negative T cell precursors than recipients
of male microbiota. Male recipients of male microbiota had higher levels of mesenteric
RORγt+Foxp3+ T cells and IgA production than males who received female microbiota
[307]. The effect of these differences has not been explored, but it does show that
microbiota has sex-specific immunoregulatory characteristics that can be transferred by
microbiota transplantation.
Like many differences between males and females, sex differences in microbiota
can be mediated by differences in sex hormones levels. In longitudinal human studies, the
changes in hormone production during puberty are associated with significant changes in
the composition of the microbiota [308] Changes in female hormones due to oral
contraceptive use or bilateral ovariectomy have been found to alter the composition of the
gut microbiota in women [305]. Additionally, in males and postmenopausal women,
urinary estrogen levels positively correlate with microbiome richness and α-diversity as
well as higher abundance of Clostridia [309,310]. Serum estrogen levels also correlate
with a more diverse microbiota, as women with higher serum levels of estradiol had a
more diverse gut microbial composition. Hormonal effects are not limited to estrogen
either, as men with higher serum levels of testosterone also exhibit greater richness and
α-diversity [311]. Mouse studies have further demonstrated the microbiota interacts with
and is affected by these hormones. Orchiectomy and ovariectomy both affect the
microbiota composition. Supplementing orchiectomized male mice with testosterone
suppressed the effect of castration on microbiota [312,313]. Clearly, sex hormones
influence the microbiota.
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Some of the effects of sex hormones are likely indirect. As described above, sex
hormones have a considerable effect on the immune system, and the immune system
exerts a great deal of influence over the composition of the microbiota. However, sex
hormones can also interact directly with the microbiota. Estrogens and estrogen-like
compounds have been found to promote the proliferation and growth of certain kinds of
bacteria [314]. Androgens like testosterone can also influence the metabolism and growth
of gut bacteria [315]. In fact, the direct interaction between hormones and microbiota
goes both ways, as there is evidence that commensal bacterial metabolic activities can
affect the levels of sex hormones of the host. Gut commensals can metabolize estrogenlike dietary compounds into active forms [316,317]. Some commensal bacteria have βglucuronidase activity that could potentially increase reabsorption of estrogens and
androgens in the intestine by converting them from the less active glucuronidated form to
the more active and absorbable non-glucuronidated form [309]. Some gut bacteria can
also convert testosterone to the more potent dihydrotestosterone [318]. A study
comparing germ-free mice that lack a microbiome to conventional mice found that in
both male and female mice, GF mice had lower intestinal levels of non-glucuronidated
androgens and lower levels of the potent androgen dihydrotestosterone compared to
conventionalized mice [319]. This suggests that the gut microbiota may play a
physiologically relevant role in the maintenance of androgen signaling. This has been
supported by the findings of other studies. Treating mice with a strain of Lactobacillus
reuteri isolated from human milk increased serum levels of testosterone, reduced ageassociated testicular atrophy, and increased spermatogenesis [320,321]. When
conventional and GF male mice were compared, it was found that GF mice had delayed

32

testis development and lower intratesticular testosterone levels, suggesting that the
microbiota may influence the development of an organ key to androgen production in
males [322]. This indicates that microbiota may also affect the immune system by
altering the levels of immunomodulatory sex hormones.
The crosstalk between male sex hormones and the microbiota can impact the
progression of autoimmune disease. Unlike most autoimmune diseases, Type 1 Diabetes
(T1D) does not exhibit a sex bias in humans. However, this is not the case in the Nonobese diabetic (NOD) model of T1D; female NOD mice and castrated male NOD mice
have a much higher incidence of disease than intact male NOD mice. GF NOD mice,
conversely, lack a sex bias as both male and female GF NOD mice have high incidence
of T1D. The microbiota composition differs significantly between male and female NOD
mice. Bacterial strains that were more abundant in male NOD mice were cultured and
transferred into GF NOD mice. One of them, an Enterobacteriaceae strain (EntS), was
able to suppress disease when transferred into GF male NOD mice, but none tested were
able to suppress disease in GF female NOD mice. Conventional male NOD mice
normally have higher serum levels of testosterone than GF male NOD mice, but
colonizing GF male NOD mice with EntS rescued serum testosterone levels. These
increased testosterone levels correlated strongly with disease protection and were not
seen in GF female NOD mice colonized with EntS [323]. Taken together these findings
suggest that both hormones and microbiota act to suppress disease in male mice and that
the microbiota-hormone interactions reinforce this disease-suppressing phenotype. This
conclusion was reinforced by another study using the NOD model. It found that
transferring in the whole gut microbiota from adult male NOD mice into young female
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NOD mice suppressed islet inflammation, reduced autoantibody titers, and increased
serum testosterone levels. This protection from disease was testosterone-dependent [324].
This raises the possibility of treating autoimmune diseases by correcting intestinal
dysbiosis via microbiota transplantation.
Not all sex differences are mediated by hormones. A study of SNF1 mice found
that the lupus-prone female mice had significantly higher numbers of proinflammatory
molecules and immune cells than the less-lupus-prone male mice before puberty or
disease onset [25]. This indicates that the immune responses that shape the microbiota in
these lupus-prone mice are also different even in the absence of differences in sex
hormone levels.
A recent study of SNF1 mice found that female SNF1 mice, which are more
susceptible to lupus than males, have a different microbiota composition than the male
SNF1 mice. When antibiotics were used to deplete the microbiota, glomerulonephritis
and autoantibody production were suppressed in female SNF1 mice, but antibiotic
depletion had no effect in male SNF1 mice. This certainly suggests that female
microbiota could be promoting disease progression. However, transferring female SNF1
microbiota into male SFN1 mice or vice versa failed to significantly affect disease
progression, which lessens the overall impact of their findings [325]. A follow-up study
by the same lab found that female SNF1 mice have higher levels of B cells producing
anti-nuclear antigen reactive IgA in the gut mucosa and higher fecal levels of nuclear
autoantigen reactive IgA than male SNF1 mice or healthy controls. Antibiotic depletion
of SNF1 female microbiota correlated with a decrease in the levels of those B cells and
fecal IgA levels, suggesting a mechanism for the antibiotic-mediated reduction in disease
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severity [326]. All of these studies illustrate that the microbiota can have a significant
impact on the progression of autoimmune disease, and the fact that female S123 antidsDNA titers could be lowered by cohousing with female B6 illustrates the possibility
that disease progression could be suppressed by transferring microbiota from healthy
individuals into sick individuals of microbiome research [289].

Gut microbiota and immunomodulatory metabolite production
One intriguing area of microbiota studies focuses not on identifying what bacteria
species are associated with disease and good health, but what bacterial functions are.
Identifying the microbial activities that drive the immune system in beneficial or harmful
ways could lead to the development of therapies that seek to mimic or to block those
mechanisms. One of the major ways that microbiota can affect the immune system is
through the production of immunomodulatory metabolites. In recent years, numerous
metabolites have been shown to alter immune activities [327].
Perhaps the most studied class of immunomodulatory metabolites is the short
chain fatty acids (SCFAs). This category, which includes acetate, butyrate, and
propionate, have potent anti-inflammatory effects. By engaging G protein-coupled
receptors and inhibiting histone deacetylases, they promote Treg induction [328],
suppress inflammasome activation [329,330], and promote anti-inflammatory activities in
macrophages and neutrophils [331,332]. Multiple autoimmune diseases including IBD,
Crohn’s disease, and spondyloarthritis have been found to be associated with decreased
levels of SCFAs and SCFA-producing bacteria [333-336]. Additionally, treatments with
SCFAs alleviate symptoms in mouse models of these diseases [334,337-339].
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Like the microbiota composition, metabolite production can be altered by changes
in diet. The clinical relevance of the diet’s effect on metabolites was demonstrated in a
recent study that examined the changes in the fecal metabolite profiles of children with
Crohn’s disease (CD) after they started a prescribed diet that has been shown to alleviate
disease. It found that the diet resulted in higher intestinal production of anti-inflammatory
SCFAs, and that this correlated strongly with a positive clinical response to the treatment.
Unfortunately, this beneficial effect was seen only in children with small/bowel colonic
CD and not in those with perianal engagement. Since different areas of the intestine have
different microbial populations, this could indicate that the success of the CD treatment
depends on which population of microbiota is dysbiotic [340].
Autoimmune diseases of the central nervous system (CNS) can also be affected
by intestinal metabolites. One recent study found decreased levels of SCFAs in the serum
of long-term multiple sclerosis (MS) patients and that SCFA treatment increased antiinflammatory IL-10-producing T cells and suppressed disease in a mouse model of
experimental autoimmune encephalitis (EAE). However, it also found that depending on
the immunological context, SCFAs could also induce inflammatory CD4 T cells that
promoted disease [336]. Another recent study of CNS autoimmunity and metabolites
emphasized that alterations in metabolite production can significantly affect disease. In a
mouse model of EAE, SCFA treatment resulted in increased induction of regulatory T
cells in the lamina propria that suppressed disease and reduce nerve damage. However,
treatment with long-chain fatty acids not only boosted the expansion of inflammatory
Th1 and Th17 cells and accelerated disease, they also decreased the levels of anti-
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inflammatory SCFAs [341]. These findings show that alterations in microbiota
metabolite production can affect immune cells well outside the intestine.
Another class of immunoregulatory metabolites are tryptophan metabolites.
Tryptophan conversion into other compounds primarily happens via one of three
pathways, the kynurenine, serotonin, and indole pathways [342]. Microbial metabolism
contributes to all three of these pathways, especially the indole pathway, and disruptions
of the balance between the pathways have been associated with autoimmune diseases
[327]. Indole derivatives activate the Aryl hydrocarbon receptor (AhR), which can
inhibit Th17 differentiation and protect against colitis [343,344], and colitis patients have
decreased intestinal AhR levels, indicating a possible connection between decreased
microbial indole production and disease [345]. A recent study found that the commensal
bacteria P. russelli, could increase production of an AhR-activating indole derivative that
increased goblet cell differentiation and decreased inflammatory signals. This resulted in
reduced susceptibility to DSS-induced colitis in mice [346]. Another autoimmune disease
that correlates with altered tryptophan metabolism is rheumatoid arthritis, as patients
have been found to have decreased indole levels [347]. SLE has also been linked to
altered tryptophan metabolism. SLE patients have increased serum levels of kynurenine
[348], which can promote the increased cellular metabolism that is characteristic of
lymphocytes in lupus [293]. Other studies have found tryptophan itself is decreased in
SLE patient serum, indicating that the disease is associated with an altered tryptophan
metabolite profile [349,350]. Also, as described above, tryptophan metabolism is altered
in the microbiota of lupus-prone female S123 mice, and the microbiota promotes lupuslike disease when transferred into GF B6 mice. The study did not establish whether this
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lupus-promoting ability was connected to the differential production of tryptophan
metabolites, though [348].
Recent studies have identified histamine as another intestinal metabolite that
could potentially affect autoimmune diseases. It has been shown that probiotic and
endogenous bacterial species can produce histamine and affect intestinal immune
responses [351-353]. Histamine is an effector molecule that can mediate either
inflammatory or regulatory responses depending on the type of histamine receptor
expressed by the target cell (i.e., H1R, H2R, H3R, H4R). While histamine is classically
associated with allergic reactions, microbe-produced histamine has been shown to
directly inhibit inflammatory factors in the gut [354-356]. Chronic low-grade intestinal
inflammation and defective intestinal barrier function are associated with lupus and a
number of autoimmune diseases [297,357], so inhibition of gut inflammation in lupusprone mice (or humans) via microbe-produced histamine could affect autoimmune
disease development and/or progression.
Many anti-inflammatory metabolites have been identified, but some metabolites
have pro-inflammatory effects. Trimethylamine (TMA), a choline metabolite, is
synthesized exclusively by the microbiota. It is transported into the liver where it is
converted to trimethylamine N-oxide (TMAO). TMAO is an inflammatory metabolite
that activates the NLRP3 inflammasome [358,359], and higher serum TMAO levels have
been linked to several human autoimmune diseases, including primary sclerosing
cholangitis [360], psoriatic arthritis [361], and RA [362].
Another class of microbial metabolites are secondary bile acid metabolites.
These are synthesized from primary bile metabolites by the microbiota, and they have
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been shown to have anti-inflammatory effects. Many secondary bile acids activate the
farnesoid X receptor (FXR) [363], which reduces secretion of the pro-inflammatory
cytokines IL-17, IFNγ, and TNFα [364]. FXR is also crucial for the development of
colonic RORγ+ regulatory T cells in mice [365]. Increased FXR stimulation has been
found to alleviate dextran sodium sulfate-induced colitis in mice [364], Higher primary
bile acid levels and lower secondary bile acid levels have been found in patients with
IBD [342]. This suggests that the microbiota’s ability to convert primary bile acids into
secondary bile acids can affect inflammatory intestinal diseases. Further supporting that
conclusion is the finding that microbiota bile acid processing can increase FXR
stimulation not only by producing FXR agonists, but also by reducing the levels of a
primary bile acid, taurine-conjugated β-muricholic acid (TβMCA) which a natural
antagonist of FXR [366]. Together these data show that alterations in the metabolism of
primary bile acids by intestinal microbes can significantly affect disease processes.
Furthermore, the effects of secondary bile acid production are not limited to the intestine.
About 95% of bile acids are reabsorbed by the epithelium of the intestine and carried into
the liver through the portal vein system [367]. There they interact with innate immune
cells, including liver-resident macrophages via the FXR and G protein-coupled bile acid
receptor 1 (GBAR1). Activation of these receptors on innate immune cells contributes to
the maintenance of a tolerogenic phenotype and the prevention of disease [363].
Disruption of bile acid homeostasis can lead to inflammation and contributes to the
development of nonalcoholic fatty liver disease, cholestatic liver injury, and other
diseases [368]. It is not fully understood what alterations in cell populations and functions
lead to disease. However, it is clear that alterations in the generation of secondary bile
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acid metabolites by the microbiota can affect macrophages and other immune cells in an
organ outside the intestine in ways that affect disease progression [363,369]. Like the
findings on SCFAs and CNS diseases described above, this finding emphasizes that
immune processes outside the intestine can be affected by altered microbiota metabolite
production. This raises the question of whether the sex bias of disease in BWF1 mice
could be due to sex-based differences in the microbiota’s production of
immunomodulatory metabolites.

Macrophage efferocytosis and systemic lupus erythematosus
The immune system has numerous mechanisms designed to prevent
autoimmune reactions. One of these is efferocytosis, which is the clearance of apoptotic
cells by phagocytes in an anti-inflammatory manner [370]. Cell turnover results in the
constant generation of apoptotic cells, and these cells contain self-antigens that could
potentially stimulate autoimmune responses [371]. To prevent this, apoptotic cells are
bound and ingested by phagocytes, primarily macrophages. This prevents the apoptotic
cells from interacting with and activating other immune cells. The ingestion of apoptotic
cells promotes macrophage production of anti-inflammatory cytokines that dampen any
inflammatory responses against the apoptotic debris [370-372]. Because apoptotic cells
are normally non-inflammatory, as long as they are swiftly cleared, they are unlikely to
provoke an immune response. However, if efferocytosis is impaired or defective,
apoptotic cells will accumulate and can undergo secondary necrosis. In this case, the
apoptotic cells undergo swelling and lysis, which results in the release of damageassociated molecular patterns. These can act as alarm signals that activate nearby immune
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cells and promote immune responses against the self-antigens they contain [373,374].
Defects in efferocytosis are thought to significantly increase susceptibility to
SLE and to promote disease progression. SLE patients exhibit accumulation of apoptotic
cells in the lymph-node germinal centers, bone marrow, and epidermis [375-377]. This
results in immune cells being exposed to nuclear self-antigens in the inflammatory
context of cells undergoing secondary necrosis. This stimulates an immune response
characterized by production of anti-nuclear autoantibodies (ANAs) against dsDNA,
ssDNA, snRNPs, and other nuclear antigens. Since apoptotic cells are constantly
generated by cell turnover, additional self-antigens are constantly being generated and
promoting disease progression [378]. Additionally, the accumulated apoptotic cells
provide ample fodder for the formation of nuclear antigen-ANA immune complexes.
These complexes lodge in the kidneys and other organs, leading to the inflammation and
kidney damage that is the primary cause of lupus morbidity and mortality [3,379]. This is
likely why disease severity in SLE patients is strongly correlated with deficient
efferocytosis [375,380]. Things that increase the number of apoptotic cells can also
trigger lupus flares. For example, excessive sun exposure can cause lupus flares, as
dermal cells undergo apoptosis in response to the damage caused by UV radiation [377].
In mouse models, it has been shown that deficiencies in components important for
efferocytosis or signaling proteins that promote efferocytosis lead to the mice developing
lupus-like disease spontaneously [381-385]. Clearly, there is a substantial amount of
evidence connecting efferocytosis deficiencies and lupus.
Macrophages isolated from patients with SLE are deficient in apoptotic cell
phagocytosis, indicating that they have an intrinsic defect in efferocytic activity [386]. As
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macrophages are the cell type primarily responsible for efferocytosis, this defect is likely
a major contributor to the accumulation of apoptotic cells [387-390]. Like SLE patients,
peritoneal macrophages from lupus-prone female BWF1 mice also have deficient
efferocytic activity compared to healthy female controls [391]. Also, in comparison to
healthy female controls, female BWF1 macrophages are also deficient in their ability to
produce anti-inflammatory cytokines in response to apoptotic cell exposure [392]. These
parallels in deficient macrophage function between SLE patients and female BWF1
female mice make the BWF1 mouse model of lupus a good choice for investigating the
factors affecting defective macrophage efferocytosis. Also, while female BWF1 mice
have deficient macrophage efferocytosis compared to female mice of other strains, no
one has investigated whether disease resistant male BWF1 mice share this defect.
Previous studies of non-disease-prone rats and mice have found female macrophages had
higher phagocytic activity than those from males [74,75]. Determining whether the same
sex-based difference exists in BWF1 mice or if macrophages from disease-resistant male
BWF1 have higher efferocytic activity could advance our understanding of the source of
the lupus sex bias in BWF1 mice.
The clear links between deficient macrophage efferocytosis and lupus
progression makes improving macrophage efferocytosis a promising therapeutic target.
There are many pathways and genes involved in efferocytosis regulation, providing many
possible ways of stimulating efferocytic activity. Three of the major pathways
responsible for promoting efferocytosis are the LXR, PPARγ and PPARδ pathways
[381,393-400].
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PPARδ knockout (KO) mice develop lupus-like autoimmune kidney disease and
their macrophages have decreased efferocytic activity. Conversely, PPARδ agonists
improve macrophage efferocytosis. This is due to the decreased production of opsonins
like C1qb, a component of the C1q trimeric complex that binds phosphatidylserine on
apoptotic cells and the C1q receptor on macrophages, bridging the two and facilitating
macrophage uptake of the apoptotic cell [400]. In humans, C1q deficiency drastically
increases lupus susceptibility; over 90% of C1q-deficient people develop lupus [401403].
PPARγ signaling can also increase expression of C1qb, as well as C1qa and
C1qc [404]. As with PPARδ, PPARγ insufficient mice develop SLE-like disease due to
increased Th17 polarization that drives autoantibody production and lymphoproliferation
[383]. Treating macrophages with a PPARγ agonist increases their ability to phagocytose
apoptotic cells [395]. Another pro-efferocytic opsonin upregulated by PPARγ is milk fat
globule-EGF factor 8 (MFG-zE8). Like C1q, MFG-E8 binds phosphatidylserine and a
macrophage surface receptor to promote apoptotic cell ingestion [404], and decreased
MFG-E8 expression inhibits efferocytosis [405]. In addition to opsonins, PPARγ
signaling also upregulates expression of the receptors AXL, MERTK, and CD36
[393,406]. AXL and MERTK bind phosphatidylserine-targeting opsonins Protein S or
GAS6, and knocking down either of them decreases macrophage efferocytic activity
[378,379]. CD36 binds calreticulin, an eat-me signal that can either be displayed by an
apoptotic cell or secreted by macrophages to bind asialoglycans on the apoptotic cell
membrane [407]. Blocking PPARγ leads to downregulation of CD36 in macrophages and
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decreased efferocytosis [393]. Conversely, increased CD36 expression correlates with
increased efferocytosis [408].
Like PPARγ, LXR signaling promotes the expression of many pro-efferocytic
genes, including the receptors MERTK and CD36 [381,409,410]. Also, like PPARγ
knockout mice, LXR knockout mice develop ANAs and glomerulonephritis, and
macrophage efferocytic activity can be increased by an LXR agonist [381,399]. In
addition to MERTK and CD36, LXR stimulation can also upregulate TIMD4 [411,412].
Unlike MERTK or CD36, TIMD4 can bind phosphatidylserine directly and promote
apoptotic cell phagocytosis without an opsonin [385,412,413]. Knocking out TIMD4
leads to decreased efferocytosis and promotes autoimmunity [385]. Not all efferocytosis
genes are directly involved in binding and ingesting apoptotic cells. The phagocytosing
of apoptotic cells means ingesting a large amount of cholesterol. Excess free cholesterol
could potentially damage the cell membrane, but the LXR-regulated cholesterol pump
ABCA1 flushes out the excess cholesterol allowing the efferocytic macrophage to remain
functional [414,415].
All three of these pathways have one thing in common. LXR, PPARγ, and PPARδ all
form a permissive heterodimer with RXR. This means that an RXR agonist would
activate all three of these pathways [416]. Unsurprisingly macrophage lineage-specific
deletion of RXR resulted in defective macrophage clearance of apoptotic cells and lupuslike autoimmune kidney disease, while treatment with an RXR agonist significantly
increased macrophage efferocytic activity [394]. Clearly, differences in the stimulation of
any one of these pathways could potentially contribute to the deficient macrophage
efferocytosis seen in lupus-prone female mice.
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MATERIALS AND METHODS
Animals and surgeries
Six-week-old female New Zealand Black (NZB) and male New Zealand White
(NZW) mice were purchased from The Jackson Laboratory (Bar Harbor, ME, USA). The
NZB and NZW mice were bred in our animal facility to produce the NZBxNZW F1
(BWF1) mice. Sixteen-week-old female BALB/c mice were purchased from the Jackson
Laboratory, and used in the RNA sequencing (RNA-seq) study. C57/BL mice were bred
in our own facility. Mice were maintained under specific pathogen-free conditions in our
animal facilities following the guidelines stipulated by the University of Louisville
Institutional Animal Care and Use Committee.
For castration, pre-pubertal (24-day-old) male BWF1 mice were anesthetized with
isoflurane, the scrotum was incised, the vas deferens and spermatic vessels were ligated,
the testes and epididymis were removed, and the skin was sutured. Sham castration was
done on age-matched males by incising the scrotum and then suturing the skin. Analgesic
(ketoprofen) was administered during the procedure and 24 hours after the procedure.
For flutamide pellet treatment, pre-pubertal (24-day-old) male BWF1 mice were
anesthetized and a time-release pellet containing vehicle or the androgen receptor blocker
flutamide was implanted subcutaneously in their upper back. (Innovative Research of
America, Sarasota, FL; #NA-152). The flutamide-containing pellet released 1.5 g of
flutamide over 90 days (16.7 mg dose/day).
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Reagent descriptions
Super complete media (SCM) is RPMI 1640 (Sigma, Burlington, MA; #R7509)
supplemented with 1000 U/mL penicillin/streptomycin, 2 mM L-glutamine (Corning,
Corning, NY; #25-005-CI), 1% Non-essential amino acids (Thermo Fisher, Waltham,
MA; #11150-060), 1 mM Sodium Pyruvate (Thermo-Fisher, #SH30239.01), 10 mM
HEPES (Corning #25-060-CI), and 10% fetal calf serum (FCS) (R&D Systems,
Minneapolis, MN; #S11150).
Clostridium histolyticum Collagenase type VIII and DNase were purchased from
Sigma C2139, d4527)
The monoclonal antibodies anti-CD16/32, anti-CD11b-PE, anti-F4/80-APC, antiCD11b-BV421, anti-F4/80-APC, anti-CD36-PECy7, anti-TIMD4-PE, anti-Thy1APC/Cy7 were purchased from Biolegend (San Diego, CA; #101301, 101208, 123115,
101251, 102615, 130005, 105328). The monoclonal antibodies anti-rabbit IgG-PE, antiMERTK-PE/Cy7 were purchased from Thermo Fisher (#12-4739-81, 25-5751-82). The
monoclonal antibody anti-LRP1 was purchased from Abcam (Cambridge, UK;
#Ab92544). The monoclonal antibody anti-CD36 was purchased from BD Biosciences
(Franklin Lakes, NJ; #552544)
Cell-trace VioletTM was purchased from Thermo Fisher (#C34557)
The RXR inhibitor HX531, the PPARγ inhibitor GW9662, the LXR inhibitor,
GSK2033, and the PPARδ inhibitor GSK0660 were purchased from Sigma (#SML2170,
M6191, SML1617, G5797).
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Microbiota composition analysis
Bacterial DNA was extracted from fecal samples using QIAamp PowerFecal DNA
Kits (Qiagen 12830-50). Extracted DNA was sent to the Genome Technology Access
Center at Washington University. There they sequenced 9 hypervariable regions of the 16S
rRNA gene and the multi-amplicon data was used to create species-level taxonomic
profiles of the microbiota [417]. In our lab, we used QIIME2 to calculate Bray-Curtis
dissimilarity matrices for the species-level microbiota compositions and to perform
Principal Coordinate Analysis (PCoA). The intra- and inter-group Bray-Curtis beta
diversity distances were compared using Permutational multivariate analysis of variance
(PERMANOVA) pairwise comparisons [418]. PCoAs were visualized using EMPeror
[419]. The inter-group differences in the abundances of specific taxa were analyzed with
two-way ANOVAs with corrections for multiple comparisons.

Metabolomic composition analysis
Three different sets of fecal samples were sent to our collaborators in the
Biochemistry department (Metabolomic Experiments #1,2,3). Our collaborators extracted
polar metabolites and analyzed them using a variety of methods. For Metabolomic
Experiment

#1,

the

samples

were

derivatized

with

N-methyl-N-

trimethylsilytrifluoroacetamide (MSTFA) and then two-dimensional gas chromatography
mass spectrometry (GC×GC-MS) was used to analyze metabolite composition and
abundance. For Metabolomic Experiment #2, the samples were analyzed with both
GC×GC-MS with MSTFA derivatization and parallel two-dimensional liquid
chromatography mass spectrometry (2DLC-MS/MS) in both negative and positive
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ionization modes. For Metabolomic Experiment #3, the most recent and comprehensive
analysis, samples were analyzed also analyzed by GC×GC-MS with N-tertButyldimethylsilyl-N-methyltrifluoroacetamide (MTBSTFA) derivatization as well as the
methods used in Metabolomic Experiment #2 [420]. We used partial least squaresdiscriminant analysis was performed to compare the metabolomic profile differences
between the groups. Pairwise two-tailed t-tests were used to compare metabolite
abundances between the groups. Quantitative pathway enrichment analysis was performed
using Metaboanalyst (version 4.0). Intensities of metabolites identified with significant
difference between intact male and female mice or between intact male and castrated male
mice were analyzed by the program. The data were auto-scaled and matched against the
KEGG pathway library for Mus musculus. The “GlobalTest” and “Betweenness centrality”
algorithms were used for pathway enrichment and topology, respectively [421].

Phytanic acid microsphere production and feeding
Poly(lactic-co-glycolic acid) microspheres were made by our collaborators at
TherapyX Inc (Buffalo, NY). Phytanic acid was encapsulated by using a modification of
the solvent evaporation technique at 10 mg phytanic acid per 1 g of microspheres
[422,423]. Vehicle microspheres were not loaded with any compound. In vitro validation
of phytanic acid release was done by suspending 100 mg of microspheres (containing a
predicted 1 mg of phytanic acid) in 1 mL of phosphate-buffered saline (PBS). At 24, 48,
and 72 hours the microspheres were spun down and the supernatant was collected and
replaced. Subsequent analysis of the collected supernatants via high pressure liquid
chromatography (HPLC) confirmed that the microspheres were releasing phytanic acid
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and continued to do so for at least 72 hours (Fig. 1). For each feeding, microspheres were
resuspended via mechanical agitation with a miniature pestle, and the resulting solution
was delivered via oral gavage using a blunt ended 22 gauge feeding needle. Each dose
consisted of 80 μg phytanic acid loaded in 2 mg of microspheres suspended in 250 μL of
PBS.
For the experiment determining the effect of oral administration of phytanic acid
on splenic macrophage efferocytic activity, female BWF1 mice received 3 doses of
phytanic acid-containing microspheres a week starting at 12 weeks of age and the spleens
were harvested at 16 weeks of age. For the experiment determining the effect of oral
administration of phytanic acid on splenic macrophage CD36 expression, female mice
were fed vehicle or phytanic acid-containing microspheres at the doses described above.
The mice were fed every other day for two weeks, then spleens were harvested and
splenic macrophage CD36 expression was measured by flow cytometry as described
below.

Cecal microbiota transfer
The cecal contents of a 16-week-old male or female BWF1 mice were harvested and
suspended in 12.5 mL of 0.03% L-cysteine in PBS. The suspension was vortexed to
suspend cecal contents and then loaded into a syringe. Mice were fed 250 μL of
suspension via oral gavage using a blunt ended 22 gauge feeding needle. Cecal feedings
were performed at 4 weeks of age, 5 weeks of age, and every 4 weeks thereafter.
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Preparation of adherent and sorted spleen cells
For all experiments, splenic macrophages were isolated and processed in the
following manner. Spleens were harvested from adult mice (12-16 weeks old) and placed
in petri dishes, and mechanically diced. The diced spleens were placed in a 10 mL
solution of 2 mg/mL Clostridium histolyticum Collagenase type VIII (Sigma #C2139), 10
KU/mL DNase (Sigma #d4527), and 10% FCS in HBSS. Spleens were digested in this
solution for 30 minutes at 37OC. EDTA was added (final concentration 0.2 mM) and the
solution was incubated at room temperature for 5 minutes to stop the digestion. The
spleen fragments were placed in a 70-micron mesh boat, mechanically pressed, and
rinsed to create a single cell suspension. The cells were washed twice with FACS buffer
(2% FCS in HBSS), and then resuspended in 5 mL RBC lysis buffer (Biolegend
#420301). After 3 minutes in the lysis buffer, the cells were washed 2 times with FACS
buffer.
For sorting macrophages, splenocytes that were disassociated as described above
were suspended in FACS buffer (2% FCS in HBSS) at 50x106 cells/100 μL in 1.5 mL
siliconized Eppendorf tubes. Nonspecific binding to FcγRs was blocked by incubating the
splenocytes with anti-CD16/32 antibody (Biolegend #101301) at room temperature for 5
minutes. They were then labeled with anti-CD11b-PE and anti-F4/80-APC (Biolegend
#101208, 123115) for 20 minutes at 4OC. The splenocytes were washed twice and then
resuspended in FACS buffer at 40x106 cells / 1 mL. A BD FACS Aria III cell sorter was
used to sort CD11b+F4/80+ splenocytes that were then used in the experiments described
below.
For the adherent macrophage experiments, splenocytes were prepared as
described above, then the cells were counted, and resuspended in super complete media
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(SCM) and 40x106 splenocytes in 3mL of SCM were placed in a 60 mm cell culture dish
and incubated at 37 OC in a 5% CO2 incubator for 2 hours to select for adherent
splenocytes. After 2 hours the dishes were gently but thoroughly washed 3 times with
room temperature HBSS to remove the nonadherent cells, taking care that the cells did
not become dry at any point. Two mL of SCM were added and these adherent
splenocytes were then used for the experiments described below.

RNA sequencing and transcriptome analysis
Individual spleens from 16-week-old female BALB/c, male BWF1, and female
BWF1 mice (n=3) were digested and prepared as described above. Splenocytes were
counted, and 5x106 cells were lysed and RNA was extracted using an RNeasy Plus Mini
Kit (Qiagen, Hilden, Germany; #74134). The rRNA was depleted with the NEBNext
rRNA Depletion Kit (New England Biolabs, Ipswich, MA; #E6350). Libraries were
prepared using the NEBNext Ultra II RNA Library Prep Kit (NEB #E7775) and the
NEBNext Multiplex Oligos for Illumina Index primers sets 1 & 2 (NEB #E7335, E7500)
according to the manufacturer’s directions. Size, purity, and semi-quantitation was done
using an Agilent BioanalyzerTM (Santa Clara, CA) and the Agilent DNA HS Kit. Samples
were diluted to 10 nM aliquots in 10mM TrisHCl, pH 8.5 supplemented with 0.1%
Tween20 buffer. The wide range of concentrations amongst samples resulted in total
volume of diluted samples varying from 10-50 µL. A pooled 10 nM library was made by
taking 3 µL of each sample and combining them in a new LowBind 1.5 mL micro
centrifuge tube for a total volume of 27 µL. The library was then diluted to 4 nM and
denatured by mixing with diluted NaOH and incubating at room temperature for 5

51

minutes before neutralizing with 200 mM Tris-HCl, pH 7. The reaction mixture was
diluted to 1.8 pM using the pre-chilled HT1 Buffer. Next, 13 µL of denatured 1.8 pM
PhiX control was added to 1287 µL of denatured 1.8 pM library to a total volume of 1.3
mL. The library was loaded onto the reagent cartridge, and the library was sequenced was
done on an Illumina NextSeq 500TM using the NextSeq 500/550 75 Cycle High Output
Kit v2.5 (Illumina, San Diego, CA #20024906). Quality control, adapter trimming, and
aligning to the Mus musculus genome were done using FastQC, Trimmomatic, and STAR
(version 2.6), respectively by the KBRIN Bioinformatics Core at the University of
Louisville. Reads were normalized using the Relative Log Expression method and
filtered to exclude genes with fewer than 20 counts among samples. Differential
expression analysis was done with DESeq2 using a P-value cutoff ≤ 0.05, a q-value
cutoff ≤ 0.05, and log2Fold Change > 0 [424].
To identify pathways enriched in healthy controls, genes upregulated in female BALB/c
or male BWF1 mice compared to female BWF1 mice were functionally classified using
the Gene Ontology:Biological Processes (GO:BP) database [425,426]. PANTHER
(version 14) was then used to identify biological processes (q-value cutoff < 0.05 and
fold enrichment cutoff ≥ 2) that were significantly enriched in the healthy controls
relative to the lupus-prone female BWF1 mice [427-430]. The list of differentially
regulated genes was also analyzed using Metacore from Clarivate Analytics to perform a
transcription factor enrichment analysis, identifying transcription factors whose target
genes were enriched in our set of differentially expressed genes. Statistical comparisons
were done using Fisher’s exact test with an FDR multiple comparison correction of 0.05.
Clustvis software was used for both Principal component analysis (PCA) and cluster
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analysis with heatmaps [431]. PCA of the transcriptomes was performed using singular
value decomposition with imputation method. The normalized read counts of all genes
differently expressed between at least two of the three groups were analyzed using
hierarchical clustering and heatmap analysis. Column and row clustering distances were
calculated as the Pearson correlation subtracted from one, and the linkage method used
was average distance of all possible pairs.

Measurement of transcript levels by qPCR
Macrophages were sorted as described above, and RNA was extracted using an
RNeasy Micro Kit (Qiagen #74004). Reverse transcription was done using a HighCapacity cDNA Reverse Transcription Kit (Thermo Fisher #4368814). PowerUp ™
SYBR™ Green Master Mix (Thermo Fisher #A25742) and IDT PrimeTime qPCR
primers were used to assay gene expression of murine LRP1 (Mm.PT.58.45834660 IDT),
AXL (Mm.PT.58.11506780), C1QA (Mm.PT.58.5375735), and Mfge8
(Mm.PT.58.9107639) using ACTB (Mm.PT.39a.22214843.g) as the reference gene. The
ΔCT for each gene was calculated using the reference gene, and Student’s t-tests were
used to assess statistical differences between experimental groups. The ΔΔCT was
calculated for each gene relative to the average ΔCT of the control group and the fold
difference relative to the control group was calculated as 2-ΔΔCT for each sample [432].
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Analysis of surface marker expression in splenic macrophages by flow cytometry
Splenocytes from individual mice were prepared as described above. Nonspecific
binding to FcγRs was blocked as described above for the sorting protocol and then the
samples were labeled with one of two panels consisting of different combinations of
antibodies. For panel 1, anti-LRP1 (rabbit IgG, Abcam Ab92544), anti-CD11b-BV421,
anti-F4/80-APC, and anti-CD36-PECy7 (Biolegend 101251, 123115, and 102615) for 20
minutes at 4OC. The samples were washed twice and then incubated with anti-rabbit IgGPE (Thermo Fisher 12-4739-81) for 30 minutes at 4OC. For panel 2, anti-TIMD4-PE
(Biolegend 130005) and anti-MERTK-PE/Cy7 (Biolegend 130005) were used instead of
anti-LRP1 and anti-CD36 and the second labeling step was skipped. The samples were
washed twice and then resuspended in 300 μL FACS buffer and analyzed on a BD
FortessaTM for geometric mean fluorescence intensity (MFI) of LRP1, CD36, MERTK,
and TIMD4 on splenic macrophages, (CD11b+F4/80+). Fluorescence-minus-one (FMO)
controls were used. Analysis of all flow cytometry data in this paper was done using
FlowJoTM software and statistical comparisons were done using Student’s t-tests.

Assay for phagocytosis of apoptotic thymocytes (efferocytosis)
For adherent macrophage efferocytosis assays, spleens from individual mice were
processed and plates of adherent splenocytes were prepared as described above. Next,
16x106 Cell-trace VioletTM (CTV)-labeled apoptotic thymocytes, prepared as described
below, were suspended in 1 mL of SCM and added to the adherent macrophage plates.
For each experiment, an extra adherent macrophage dish was made. No thymocytes were
added to that dish and it served as a negative control. The dishes were gently swirled to
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mix the cells and then were placed in a 37OC, 5% CO2 incubator for 1 hour. After 1 hour,
the dishes were gently but thoroughly washed 3 times with room temperature HBSS to
remove nonadherent thymocytes. Next, they were put on ice for 10 minutes to loosen the
adherent cells, and then scraped and rinsed to harvest the adherent cells, which were
transferred to 1.5 mL siliconized Eppendorf tubes. The samples were spun down at 3200
RPM for 3 minutes and then resuspended in 100 μL of FACS buffer. Nonspecific binding
to FcγRs was blocked with anti-CD16/32 antibody (Biolegend 101301) as described
above. The samples were then labeled with anti-CD11b-PE, anti-F4/80-APC, and antiThy1-APC/Cy7 (Biolegend 101208, 123115, and 105328) for 20 minutes at 4OC. The
samples were washed twice and then resuspended in 300 μL FACS buffer and analyzed
on a BD FortessaTM for the percentage of splenic macrophages, (F4/80+CD11b+) that
were positive for the CTV label, indicating that they were in the process of phagocytosis
apoptotic thymocytes. The well that received no thymocytes served as a negative control.
CTV-labeled apoptotic thymocytes were prepared in the following manner.
Thymi were harvested from 4 to 8-week-old C57/BL mice, placed in a 70-micron mesh
boat, mechanically pressed, and rinsed with FACS buffer to create a single cell
suspension. This was spun down at 1500 RPM for 5 minutes, then resuspended in 3 mL
RBC lysis buffer (Biolegend 420301). After 3 minutes, the suspension was washed 2
times with FACS buffer and counted, then resuspended in SCM+β-ME (SCM with 0.1%
β-mercapto-ethanol (Sigma #M3148)) at 20x106 cells/mL. An equal volume of 2 μM
dexamethasone (Sigma #D4902) in SCM was prepared and added to the thymocyte
suspension, placed in a petri dish, and then placed in a 37OC, 5% CO2 incubator for 16
hours. After 16 hours, the suspension was washed 2 times with PBS and then
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resuspended in room-temperature PBS to 40x10^6 cells/mL in a 15 mL conical, and the
cells were labeled with Cell-trace VioletTM (Thermo Fisher #C34557). A 2 μM solution
of CTV in room-temperature PBS solution was prepared by adding 0.4 µL of 5 mM stock
per 1 mL of room temperature PBS and mixing thoroughly. Immediately after making the
CTV solution, an equivalent volume was added to the thymocyte suspension for a final
concentration of 1 μM and the mixture was vortexed thoroughly, then incubated at room
temperature in the dark for 20 minutes. The cells were washed 3 times with FACs buffer,
counted, and resuspended in SCM at 8x106 cells/mL. To verify the thymocytes were
apoptotic and CTV-labeled, a 100 μL aliquot was taken, 5 μL of AnnexinV-FITC
(Biolegend 640945), and 5 μL of 7-AAD (BD Biosciences 559925) was added and the
aliquot was incubated at room temperature in the dark for 15 minutes. The aliquot was
then diluted to 300 μL with FACS buffer and analyzed in a BD FortessaTM for apoptosis
(AnnexinV and 7-AAD) and CTV label.
For assays of sorted splenic macrophage efferocytic activity, spleens from
individual mice were digested and macrophages were sorted as described above and
resuspended in SCM. For each sample, 200,000 (0.5 mL) of the sorted macrophages were
put in a separate well of a 24 well plate. CTV-labeled apoptotic thymocytes were
prepared as described above and to each experimental well, 2x106 CTV-labeled apoptotic
thymocytes in 0.25 mL of SCM were added. An additional control well had macrophages
but no thymocytes. The plate was gently swirled to mix the cells and then was placed in a
37OC, 5% CO2 incubator for 1 hour. The plate was then placed on ice for 5 minutes, and
the wells were scraped and rinsed to harvest the cells, which were transferred to 1.5 mL
siliconized Eppendorf tubes. Samples were then labeled for F4/80, CD11b, and Thy1 and
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analyzed for the percentage of splenic macrophages (F4/80+CD11b+) that were positive
for the CTV label, as described above.

Assays of the effect of phytanic acid treatment on splenic macrophages
For analysis of the effect of phytanic acid treatment on splenic macrophage
marker expression, spleens from individual mice were digested and processed as
described above, and suspended in super complete media (SCM). SCM is RPMI 1640
(Sigma E#7509) supplemented with 1000 U/mL penicillin/streptomycin, 2 mM Lglutamine (Corning #25-005-CI), 1% Non-essential amino acids (Gibco #11150-060), 1
mM Sodium Pyruvate (HyClone #SH30239.01), 10 mM HEPES (Corning #25-060-CI),
and 10% FCS. Two 5x106 cell aliquots from each sample were put in the wells of a 24well plate, and either phytanic acid (final concentration = 50 μM) or vehicle (ethanol,
final concentration = 0.06% v/v) was added. The plates were placed in a 37OC, 5% CO2
incubator for 24 hours. Next, the plates were placed on ice for 5 minutes, and then the
wells were scraped and rinsed to harvest the cells. Staining for macrophage markers and
analysis was done as described above.
For the experiments examining the effect of phytanic acid on adherent female
BWF1 macrophage efferocytosis, the adherent macrophages were prepared as described
before, with the exception that spleens were pooled, and after the 2-hour incubation and
removal of non-adherent cells, SCM containing 50 μM phytanic acid was added to the
dish, and the cells were placed back in the incubator for an additional 24 hours. After 24
hours, the phagocytosis assay proceeded as described above.
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For the experiments examining the effect of phytanic acid on sorted BWF1
macrophage efferocytosis, spleens were pooled and digested and macrophages were
sorted as described above. Sorted macrophages were then resuspended in SCM
containing, vehicle (ethanol, final concentration = 0.06% v/v), 50 μM phytanic acid
(Cayman 90360), a nuclear receptor inhibitor. Macrophages were divided into 200,000
cells/0.5 mL aliquots and placed in a 24 well plate and incubated at 37OC at 5% CO2 for
48 hours. After 48 hours, the phagocytosis assay proceeded as described above.

Assays for effect of nuclear receptor inhibition on efferocytic activity
Spleens from adult female BWF1 mice were pooled and digested as described
above. Macrophages were sorted, split into two groups, and resuspended in SCM
containing, vehicle (ethanol, final concentration = 0.06% v/v), 50 μM phytanic acid
(Cayman 90360), a nuclear receptor inhibitor. Macrophages were divided into 200,000
cells/0.5 mL aliquots and placed in a 24 well plate and incubated at 37OC at 5% CO2 for
48 hours. After 48 hours, the phagocytosis assay proceeded as described above. The
following concentrations of nuclear receptor inhibitors were used: The RXR inhibitor,
HX531 (Sigma SML2170), was used at a concentration of 10 μM. The PPARγ inhibitor,
GW9662 (Sigma M6191), was used at a concentration of 10 μM. The LXR inhibitor,
GSK2033 (Sigma SML1617), was used at a concentration of 5 μM. The PPARδ
inhibitor, GSK0660 (Sigma G5797), was used at a concentration of 10 μM.
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Assays for the effect of CD36 inhibition on macrophage efferocytic activity
The CD36 neutralizing antibody was validated with a titration experiment where
macrophages were sorted as described above and treated with 0.5, 1, or 2 μg/mL of antiCD36 for 30 minutes (Clone CRF D-2712, BD Biosciences #552544) [372].
Macrophages were then cultured with CTV-labeled apoptotic thymocytes for one hour
and the efferocytosis assay proceeded as described above. A dose-dependent reduction in
efferocytosis after anti-CD36 treatment was observed (Fig. 2)
For the phytanic acid and anti-CD36 co-treatment experiment, sorted
macrophages were treated for 48 hours with 50 μM phytanic acid. Macrophages were
then treated with 2 μg/mL of anti-CD36 for 30 minutes. CTV-labeled apoptotic
thymocytes were then added for one hour and the efferocytosis assay proceeded as
described above.

Statistical analyses
Statistical analysis of disease scores was performed using two-way ANOVA and
two-tailed Student’s t-tests. Statistical analyses of incidence and survival curves were
performed using the Log rank (Mantel-Cox) test. For Intra- and inter-group microbiota
Bray-Curtis beta diversity distances were compared using PERMANOVA statistical
analyses [418]. The inter-group differences in the abundances of specific taxa were
analyzed with two-way ANOVAs with corrections for multiple comparisons. For
comparisons of metabolite abundance, metabolites were filtered for those that had an
abundance change of over 20% between two groups and were present in more than 75%
of the samples for at least one group. Student’s t-tests with sample permutation were used
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to determine if the abundance change was significant. Grubbs’ test was used to detect and
remove outliers. For comparisons of gene expression as measured by flow cytometry or
qPCR, Student’s t-tests were used. For comparisons of efferocytic activity as measured
by fold change %CTV+ macrophages, statistical comparisons between groups were
performed using Student’s t-tests if only two groups were compared. If three or more
groups were compared, then one-way ANOVAs with multiple comparisons were
performed, using the Tukey post-analysis method to correct for multiple comparisons.
For comparing expression of genes by qPCR or flow cytometry, Student’s t-tests were
used to assess statistical differences between experimental groups.
GraphPad Prism 9 (Sand Diego, CA) was used for all statistical analysis unless
stated otherwise. All error bars shown are +/- standard error of the mean. A cutoff of 0.05
was used for significance for analyses, and significance was indicated as follows:
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001
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Figure 1. Validation of Phytanic acid release by microspheres. Phytanic acid was
encapsulated in poly(lactic-co-glycolic acid) microspheres at 10 mg phytanic acid per 1 g
of microspheres. Release of phytanic acid was assayed by suspending 100 mg of
microspheres in 1 mL of PBS and incubated at 37 OC. At 24, 48, and 72 hours the
microspheres were spun down and the supernatant was collected and replaced. Phytanic
acid levels in the supernatants were measured by HPLC (n=3).
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Figure 2 Blocking CD36 with a neutralizing antibody decreases splenic macrophage
phagocytosis in a dose-dependent manner. Splenocytes from 16-week-old female
BWF1 mice were collected and sorted for CD11b+F4/80+ cells by FACS. Sorted cells
were cultured without (Ctl) or with varying concentrations of blocking anti-CD36
antibody for 30 mins then phagocytosis of apoptotic cells was assayed by culture with
CellTraceTM Violet (CTV)-labeled apoptotic thymocytes for one hour followed by
analysis of percentages of CD11b+F4/80+ cells that were CTV+. Data are reported as fold
change (FC) in %CTV+ cells (n=2).
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SPECIFIC AIM 1
Sex-based differences in gut microbiota composition associated
with protection from lupus
Introduction
Like many autoimmune diseases, systemic lupus erythematosus (SLE) has a
significant sex bias, with women comprising over 90% of SLE patients with autoimmune
diseases [1,2]. This sex bias is also present in the NZBxNZWF1 (BWF1) mouse model of
lupus. Female mice develop severe disease early in life, often having elevated
autoantibodies at 16 weeks of age and beginning to develop glomerulonephritis between
20 to 25 weeks of age; virtually all female mice die of this disease by 50 weeks of age.
Male BWF1 mice on the other hand only rarely develop a mild form of disease late in life
[16]. Male resistance to disease is androgen dependent, as males who undergo androgen
depletion by castration develop more severe disease at a younger age [17]. This is also
similar to what is seen in humans, as female and male SLE patients have decreased levels
of androgens, and treatment with androgens can suppress disease activity [115,138,141144,149-152]. The BWF1 mouse strain is an excellent model of lupus particularly for the
study of mechanisms underlying the sex bias in lupus.
Sex differences in the commensal bacteria in the intestine could potentially
contribute to the sex bias of lupus in humans and in lupus-prone mice. A complex
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network of interactions exists between these bacteria, called the gut microbiota, and the
immune system. These interactions shape both microbiota composition and immune
responses and they are vital for the proper development and function of the immune
system [181-187]. When the microbiota is disrupted or imbalanced, it is said to be in
dysbiosis. A dysbiotic microbiota can have a pro-inflammatory effect on the immune
system and promote the development of autoimmune diseases [184,218,219].
Many autoimmune diseases have been linked to dysbiotic microbiota. Patients
with inflammatory bowel disease (IBD) have been found to have dysbiotic microbiota
[225-235]. No clear causal links between alterations in bacterial taxa and disease have
been established in human IBD, but mouse models have shed some light on possible
mechanisms. Bacteroides fragilis and some Clostridia strains have been shown to
suppress IBD in mice by promoting Treg induction [433-435]. On the other hand,
Helicobacter muridarum, Helicobacter hepaticus, and segmented filamentous bacteria
can exacerbate disease by promoting pro-inflammatory activity in Th17 cells [250-252].
Non-intestinal autoimmune diseases such as rheumatoid arthritis can also be
affected by the microbiota [184,256,257]. SLE is a systemic disease that has been linked
to dysbiotic microbiota. The microbiota of SLE patients differ significantly from healthy
controls [276-283]. While the specific taxa altered in SLE patients vary from study to
study, their findings have still increased our understanding of how the gut microbiota can
affect disease progression. For example, Ruminococcus gnavus abundance was five times
higher in SLE patients, and higher levels of antibodies against R. gnavus correlated with
overall antibody levels and kidney damage [276]. This suggests that R. gnavus may
stimulate immune responses that increase SLE activity. Another study found SLE

64

patients with Enterococcus gallinarum in the liver had higher levels of autoantibodies. In
further experiments using the lupus-prone NxB F1 mouse strain, E. gallinarum
stimulated disease by translocating across the intestinal barrier to the liver and
stimulating pro-inflammatory cytokine production [286]. Lupus-prone B6.Sle1.Sle2.Sle3
mice were also found to exhibit dysbiosis, with higher levels of Prevotellaceae,
Paraprevotella, and Lactobacillus compared to healthy controls. Cohousing the
B6.Sle1.Sle2.Sle3 mice with the healthy control mice reduced autoantibody production,
suggesting that the differences in microbiota could affect processes involved in disease
[293]. A study of the MRL/lpr lupus mouse model had a similar finding, as cecal
transfers from healthy control MRL mice decreased autoantibody production [297]. The
MRL/lpr study found that Lactobacillus, which was enriched in healthy controls,
protected against disease, but studies in SLE patients and BWF1 mice found that higher
Lactobacillus was associated with more severe lupus [282,297,299]. This demonstrates
that the effect of a given taxa of microbiota is highly dependent on the overall context of
the microbiota.
Sex and sex hormone levels also significantly affect the microbiota, suggesting
that sex-based differences in microbiota function could potentially contribute to the sex
bias of lupus [182,300-303,315]. Recently, two studies found evidence to support this
theory. In the NOD mouse model of type 1 diabetes (T1D), female mice are more
susceptible and male mice are more resistant to disease. However, the studies found that
male mice possessed a distinct microbiota that conferred this protection in an androgendependent manner [323,324]. Also, a recently published paper on the SWRxNZB F1
(SNF1) mouse model of lupus found differences in microbiota composition between
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intact male, androgen-depleted male, and female mice. Kidney disease wasn’t affected by
these sex-based microbiota changes, but it also wasn’t affected by androgen depletion
(i.e., castration), suggesting that their model may not have been effective at investigating
sex differences [325]. Nevertheless, these studies suggest that sex-based differences in
microbiota could influence immune functions associated with lupus progression.
Previous studies have found microbiota from healthy control female mice can
suppress disease in lupus-prone female mice, but none have shown the same effect
between male and female mice of a lupus-prone strain. The goal of the present study was
to investigate differences in the gut microbiota composition in female and male BWF1
mice and their impact on disease. We have shown that transferring microbiota from
disease-resistant BWF1 mice into female BWF1 mice delays disease onset and improves
survival. However, changes in mouse facilities resulted in a period of time where the
transfer of male microbiota was no longer protective. The protective phenotype was
eventually restored, and we have used this opportunity to compare the sex differences in
the microbiota between periods when male microbiota was protective and periods when it
was not, with the goal of identifying what male-enriched species are associated with
protection against lupus.

Results
Disease susceptibility and microbiota composition in the BWF1 mouse model of
lupus
The findings of recent studies suggested sex differences in the microbiota might
contribute to the lupus sex bias in BWF1 mice [16,323,324]. To investigate this, our lab
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first examined microbiota composition in female and male BWF1 mice as well as
confirmed that disease incidence and progression in our colony is accelerated and more
severe in female than male BWF1 mice as has been previously reported [16,17]. As
expected, the incidence and level of glomerulonephritis severity were significantly higher
in females, and survival was significantly decreased (Fig. 3A-C). We analyzed the
bacterial composition of feces from female and male BWF1 mice to compare the
intestinal microbiota. We used Bray-Curtis analysis of beta-diversity to analyze how
different the microbiota composition of each sample was from the other samples. The
principal coordinate analysis (PCoA) visualization of this analysis showed that the
microbiota profiles formed two distinct groups based on sex (Fig. 4A). Permutational
multivariate analysis of variance (PERMANOVA) of the beta-diversity values confirmed
the female and male BWF1 gut microbiota profiles were significantly different (Fig. 4B).
This showed that in addition sex-based differences in disease, there were also sex-based
differences in the microbiota in BWF1 mice. As with human SLE patients, androgens
suppress disease in BWF1 mice, and depleting androgens in male BWF1 mice makes
them more susceptible to disease [133,134]. Castrated male BWF1 mice have
significantly increased incidence and severity of glomerulonephritis and a dramatic
decrease in survival (Fig. 5; [420]). Comparison of intact and castrated male BWF1
microbiota showed that androgen depletion caused a major shift in the microbiota profile
(Fig. 6). These results showed that lupus-susceptible female and castrated male BWF1
mice have divergent microbiota profiles from lupus-resistant intact male BWF1 mice.
In order to investigate whether the sex-based differences in the microbiota could
affect lupus progression, our laboratory carried out microbiota transfer experiments,
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where BWF1 mice were fed cecal contents from female or male BWF1 mice (Fig. 7A).
Since dysbiotic microbiomes have been linked to autoimmune diseases [184,218,219],
our lab tested whether the female BWF1 microbiota could promote lupus progression in
male recipients. Transfer of cecal contents from female BWF1 mice did not increase
disease in male BWF1 mice (data not shown). Interestingly, when the opposite
experiment was performed, and male microbiota was transferred via cecal contents to
female BWF1 recipients, the transfer of male microbiota significantly delayed disease
onset and improved survival in female BWF1 mice (Fig. 7B-D). Our lab has also found
that this protective effect is androgen dependent, as shown in experiments where
microbiota from castrated male mice transferred into female mice had no protective effect
on disease incidence or progression, or survival (data not shown). Taken together, these
data indicate that female and male gut microbiota differ in composition and the male
microbiota may contain bacterial populations that can protect against lupus.

Alterations in mouse facilities/animal husbandry procedures resulted in changes in
the ability of male BWF1 microbiota to suppress lupus progression in female BWF1
mice and in microbiota composition.
The disease progression, and initial microbiota analysis and transfer experiments
in BWF1 mice described above were performed in our animal facility in the A Tower
building on the University of Louisville campus from 2014 through late 2016. However,
in January 2017, due to circumstances beyond our control, our mouse colony was moved
to the barrier animal facility in the Center for Translational Research Building (CTRB).
We first monitored disease in female and male BWF1 mice produced in the CTRB
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facility, and found no differences in disease kinetics, severity, or incidence, or mortality
in either sex compared to our colony in the A Tower facility, i.e., female BWF1 mice
exhibited accelerated and severe glomerulonephritis and increased mortality by
comparison to male BWF1 mice (data not shown). We also conducted experiments to
confirm that male microbiota transferred into female BWF1 mice delayed disease, and
decreased severity and mortality in CTRB as we had found in the A Tower. We
conducted three microbiota transfer experiments between January 2017 and Fall 2018
(designated the "CTRB Early" period), but were unable to replicate the protective
phenotype that we had seen in the A Tower. We found no difference in the onset and
progression of glomerulonephritis between female BWF1 mice receiving male
microbiota and those receiving female microbiota (Fig. 8A,B). Survival was also not
different between these two groups of recipients (Fig. 8C). A Bray-Curtis analysis
comparing microbiota compositions in feces collected from female and male BWF1 mice
from the A Tower and the CTRB Early period showed that the microbiota compositions
differed between the A Tower and the CTRB Early mouse colonies (Fig. 9A). Analysis
of Bray-Curtis beta-diversity distances between female and male profiles from the CTRB
Early colony found that they were only slightly statistically different (Fig. 9B; p=0.043)
by comparison to the differences found between female and male microbiota composition
found in the A Tower (Fig. 4; p=0.001). This suggests that not only did the microbiota
profiles differ between the A Tower and the CTRB Early period, but also that the CTRB
Early female and male microbiota compositions are less different from each other than
female and male compositions were in the A Tower facility.
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To attempt to recover our protective transfer phenotype, several changes were
made in Fall 2018 to the animal husbandry of our mice in the CTRB facility that included
a change in animal room (we did not actually have a choice in this, since we were moved
out of the room that eventually became part of the new germ-free facility), a change in
disinfecting protocols used by our animal care technician, and a change in water source,
from either autoclaved tap water or water purified by sterile filtration to water purified by
reverse osmosis (RO) then autoclaved directly in the water bottles. Although we cannot
conclude with any certainty which if any of these changes had an effect, we have found
that since these changes were implemented, transfers of male microbiota again
consistently suppress disease in female BWF1 recipients. In microbiota transfer
experiments performed during this more recent time period in the CTRB (designated
"CTRB Recent" and covering the period of 2019 to present), disease onset is significantly
delayed and incidence is decreased, and survival is increased in female BWF1 recipients
of male microbiota compared to recipients of female microbiota (Fig. 10). Additionally,
Bray-Curtis analysis of beta-diversity shows that the female and male microbiota profiles
form distinct groups based on sex (Fig. 11A), and are again highly significantly different
(Fig. 11B; p=0.001). Taken together, our preliminary analysis strongly suggests that the
microbiota populations were altered after the move from the A Tower (A Tower - 20142016) to the CTRB (CTRB Early - 2017-2018) and then again after the modification of
the animal husbandry practices in the CTRB (CTRB Recent - 2019-present) and these
changes correlated with changes in the protective phenotype we observed in our male
microbiota transfer experiments. These observations presented us with the opportunity to
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explore whether and which sex-based differences in commensal abundance at the
genus/species level are associated with protection from disease.

The change in mouse facilities/animal husbandry procedures resulted in genus and
species level changes in the male and female BWF1 microbiota
We first analyzed female and male BWF1 microbiota down to the genus and
species levels in feces collected shortly before the move from the A Tower (2016) and in
the months following the move to the CTRB (CTRB Early - 2017-2018). Our findings
showed that the change in facilities had a dramatic and destabilizing impact on the
composition of the microbiota. In the A Tower, Bacteroides abundance, in general, was
high (~20-30%) and significantly higher in adult male BWF1 mice than in adult female
BWF1 mice (Fig. 12A). However, this was not the case in the CTRB Early experiments.
In three of the CTRB Early experiments, Bacteroides levels were almost undetectable in
both female and male BWF1 mice (Fig. 13A,C,E). Moreover, the levels of Clostridium
abundance in the CTRB Early experiments (~40-60%) were three to four times greater
than was seen in the A Tower (~15-20%; Fig. 12A; 13A,C,E). In a fourth CTRB Early
experiment, Bacteroides was present, but was actually higher in female than male BWF1
mice, and Clostridium was still considerably higher than had been seen in the A Tower
(Fig. 12A; 14A). This experiment (CTRB Early Exp 4) took place four months after the
first CTRB Early experiment (Exp 1) and two months after CTRB Early Experiments 2
and 3, so the wildly disparate levels of Bacteroides abundance between CTRB Early
Experiments 1-3 and CTRB Early Experiment 4 could indicate that the microbiota
composition of the mice was still in flux, although it should be noted that the Clostridium
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levels remained very high in all four CTRB Early experiments. The microbiota analysis
also identified another genus, Alistipes (Alistipes putredinis and Alistipes timonensis),
that was present in A Tower, but was undetectable in the CTRB Early experiments (Fig.
12-14). Species analysis of the microbiota showed that Bacteroides acidifaciens and
Clostridium leptum were the predominant Bacteroides and Clostridium species,
respectively. These species, when present, exhibited the same patterns as their genera in
both the A Tower and CTRB Early experiments (Fig. 12B; 13B,D,F; 14B). Clearly the
change in facilities and the loss of the ability of male microbiota to suppress lupus
coincided with significant alterations, both decreases and increases, in the relative
abundances of bacteria in the female and male mice.

Mice microbiota compositions are affected by how their drinking water is sterilized.
During the CTRB Early period, experiments were conducted to evaluate the effect
of different drinking water sources on the microbiota. Female and male BWF1 mice
received either tap water autoclaved in bottles (Autoclaved Tap H2O; this was the same
water that was provided to mice in the A Tower) or sterile filtered (but not de-ionized)
water (Filtered H2O) from birth through the end of the experiment. Feces were collected
and mice were monitored for disease incidence and severity, and survival. There were no
differences in disease or mortality for either the female or male mice compared to the A
Tower (data not shown). A side-by-side comparison shows there were subtle differences
in genus/species abundance that were dependent on the water source. This experiment
showed that changes in environmental (e.g., water source) and genetic factors (e.g., sex)
affect different bacterial taxa differently. Lachnoanaerobaculum abundance (primarily,
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the L. umeaense species) was affected by the water source, but less so by sex.
Conversely, Lactobacillus abundance (primarily the L. gasseri and johnsonii species) was
affected by the sex of the mice but not the water source. Clostridium abundance was
affected by the water source and by the sex at the genus level (Fig. 15A), but the
predominant species, C. leptum, was only affected by the water source (Fig. 15B). These
data highlight the complexities and challenges of studying the gut microbiota and how
changes in mouse facility conditions can alter microbiota compositions.

During the CTRB Recent period, Bacteroides and Clostridium abundances returned
to levels similar to the A Tower
As described above, we had found that the loss of the protective phenotype of the
male microbiota during the CTRB Early period (2017-2018) corresponded to decreases
or absence of both Bacteroides and Alistipes abundances and/or an increased abundance
of Clostridium, in general, by comparison to the A Tower. We next turned to the in-depth
analysis of the microbiota in the feces collected from mice during the CTRB Recent
period (2019-2020) when the protective transfer phenotype was re-established in the
CTRB (Fig. 10). We found that the CTRB Recent period coincided with another shift of
the microbiota composition to one that more resembled that seen in the A Tower. In two
experiments (CTRB Recent Experiments 1 & 2) conducted during the CTRB Recent time
period, Bacteroides (Fig. 16A,C), particularly the Bacteroides acidifaciens species (Fig.
16B,D), is once again present and at high levels, and was found at consistently greater
abundance in male compared to female BWF1 mice. Also, the levels of Clostridium (Fig.
16A,C), again particularly C. leptum (Fig. 16B,D), are back down to levels at or even
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below (~5-10%) those seen in the A Tower in both female and male BWF1 mice
compared to the considerably elevated levels (40-60%) found during the CTRB Early
period. Additionally, Alistipes, which had been present in the A Tower, but undetectable
in the CTRB Early experiments (Fig. 12; 13; 14), was detected in all of the CTRB Recent
experiments (Fig. 16). The same species of Alistipes that were predominant in the A
Tower, A. putredinis and A. timonensis, were also predominant in the CTRB Recent
experiments. (Fig. 12B; 16B,D).
Interestingly, the high levels of Bacteroides (and also the B. acidifaciens species)
found in male BWF1 mice appeared to be androgen-dependent. In experiments also
conducted during the CTRB Recent period, we found that when androgen was depleted
by castration, the abundance of Bacteroides was significantly decreased, although still
present at detectable levels. In addition, as was found in the experiments comparing
microbiota composition in female and male BWF1 mice described above, both castrated
and intact male mice had relatively low Clostridium levels in comparison to the CTRB
Early period and also had detectable levels of Alistipes. (Fig. 17).
In summary, Bacteroides was consistently present and levels of Bacteroides
abundance were consistently higher in males compared to females during both the A
Tower and CTRB Recent periods (when the protective transfer experiments were
working) and this was mostly due to differences in the B. acidifaciens species.
Conversely, during the CTRB early period (when the protective transfer experiments
were not working), Bacteroides levels were either barely detectable in female and male
BWF1 mice or significantly lower in females compared to males. Furthermore,
Clostridium (primarily C. leptum) levels were much higher during the CTRB Early

74

period than either the A Tower and CTRB Recent periods. While the same Alistipes
species, A. timonensis and A. putredinis were predominant in mice during the A Tower
and CTRB Recent periods, no members of the genus Alistipes were detectable in mice
during the CTRB Early period. The shift in microbiota profiles that coincided with the
change in our mouse facility from the A Tower to the CTRB had reverted during the
CTRB recent period to be more similar to the profiles seen in the A Tower.

Protection from disease by male to female microbiota transfer correlates with
elevated levels of Bacteroides in the recipients
The fact that male BWF1 microbiota can be protective suggests that the bacteria
that are more abundant in male BWF1 mice may be acting to suppress disease. The only
taxa consistently enriched in male BWF1 mice during the A Tower and CTRB Recent
periods, periods during which the male microbiota protected against disease (Fig. 7; 10),
were the genus Bacteroides and in particular, the species Bacteroides acidifaciens (Fig.
12; 16). This makes Bacteroides a possible candidate for a mediator of male microbiota
disease suppression. However, if increased Bacteroides does promote protection against
disease, then suppression of disease in female recipients of male microbiota should
correlate with the presence of high levels of Bacteroides (received via transfer of cecal
contents). To evaluate this possibility, we performed an in-depth analysis of microbiota
data from microbiota transfer experiments conducted during the CTRB Early period
(when transfer was not protective) and the CTRB Recent period (when transfer mediated
protection was reestablished). We saw several of the same differences in microbiota
abundances between the CTRB Early and Recent microbiota transfer experiments that we
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saw between the CTRB Early and Recent experiments comparing female and male
BWF1 mice. In the CTRB Early cecal transfer experiment, where male microbiota failed
to protect (Fig. 8), Bacteroides levels (which were predominantly the Bacteroides
acidifaciens species) were actually high in all of the groups, but they were lower in
female recipients of male microbiota compared to recipients of female microbiota (Fig.
18). However, similar to the microbiota profiles female and male mice in the four CTRB
Early experiments described above (Fig. 13; 14), all of the groups had very high levels of
Clostridium (30-40%), and undetectable levels of Alistipes (Fig. 18). In contrast, analysis
of a microbiota transfer experiment from the CTRB Recent period found that recipients
of male microbiota had significantly higher Bacteroides abundances compared to the
female BWF1 recipients of female microbiota (Fig. 19A). The levels of Clostridium were
considerably lower for all groups (10-20%) in comparison to the levels found in CTRB
Early transfer experiment (30-40%) (Fig. 18A; 19A). Furthermore, unlike the CTRB
Early period when Alistipes was completely absent (Fig. 13; 14), Alistipes was detected
in all recipients during the CTRB Recent period and the same species were predominant
as in the A Tower female and male mice (A. timonensis and A. putredinis). (Fig. 19B).
This microbiota profile in the CTRB Recent cecal transfer experiment was highly stable,
as we tested the microbiota composition again 4 weeks later and found the same higher
levels of Bacteroides in the recipients of male microbiota as well as lower levels of
Clostridium and detectable Alistipes in all groups (Fig. 19C). Taken together, these data
show that higher Bacteroides and lower Clostridium levels consistently correlated with
delay and decrease in severity of disease and increase in survival. Additionally, specieslevel analysis of the CTRB Early and CTRB Recent transfer experiments showed that as
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in the other experiments, Bacteroides acidifaciens and Clostridium leptum comprised
almost all of the Bacteroides and Clostridium present, respectively (Fig. 19B,D).
In conclusion, during periods when transfers of male microbiota were shown to
suppress lupus in female recipients (A Tower and CTRB Recent), Bacteroides was
consistently present and more abundant in male than female BWF1 mice (Figs. 16; 20A).
Bacteroides also correlated with protection in the microbiota transfer experiments, as
female recipients of male microbiota that were protected from disease (CTRB Recent)
had elevated levels of Bacteroides compared to female recipients of female microbiota
(Figs. 19; 21). This suggests that Bacteroides may play a role in suppressing lupus
progression. Failure to protect also correlated with high abundance of Clostridium in both
female and male mice and in the microbiota transfer recipients during the CTRB Early
period (Figs. 13; 14; 18) compared to the A Tower (Fig. 12) and CTRB Recent
Experiments (Figs. 16; 19; 20; 21). The fact that higher levels of Clostridium correlate
with a failure of the male microbiota to protect against disease raises the possibility that
an overabundance of Clostridium might interfere with the disease-suppressing activities
of other bacteria, and that the ratio of Bacteroides to Clostridium may be critical. We
calculated the Bacteroides/Clostridium ratio, and found that during periods when the
male microbiota was protective the Bacteroides/Clostridium ratio was higher in male
than female BWF1 mice. (Fig. 22A). Additionally, when we compared the CTRB Early
and Recent transfer experiments, the Bacteroides/Clostridium ratio differed little in the
female recipients of female microbiota, but for recipients of male microbiota, the
Bacteroides/Clostridium ratio was much higher in the CTRB Recent transfer experiment
(Fig. 22B). In addition, Alistipes was present in BWF1 mouse microbiota during periods
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(i.e., A Tower and CTRB Recent) when the male microbiota protected against disease
when transferred into female recipient, and absent during the period when the male
microbiota failed to protect (i.e., CTRB Early). Taken together, these data suggest that
there might be some type of cooperation or collaboration occurring between several
bacterial species in the gut community that confer protection that can only occur when
other species are in low abundance.

Discussion
One new paradigm in autoimmune disease that has emerged in recent years is the
ability of the microbiota to significantly affect immune functions. The intestinal
microbiota is significantly affected by immune activities and it can significantly affect the
immune system via a variety of mechanisms [218,436]. When a microbiome has been
disrupted, it is said to be in dysbiosis, and patients with autoimmune diseases have been
found to exhibit dysbiotic microbiomes [184,256,257,276-280,282,283] as well as altered
metabolite production [333-336,348,360-362]. This includes SLE, as many studies have
found the intestinal microbiota of SLE patients differs significantly from those of healthy
controls [276-283,437]. The microbiota of lupus prone mouse strains like
B6.Sle1.Sle2.Sle3 and BWF1 has also been found to differ from sex-matched healthy
control strains [282,289]. However, despite the fact that BWF1 mice exhibit a similar sex
bias as human SLE patients [16], the microbiota of female and male BWF1 mice had not
been compared until our lab found that lupus-susceptible female BWF1 mice and lupusresistant male BWF1 mice had divergent microbiota compositions (manuscript in
preparation). Our lab has also found that transferring adult male BWF1 microbiota into
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female BWF1 mice suppressed the progression of lupus (manuscript in preparation). Our
lab has repeated the finding that transfer of male microbiota suppresses disease in several
experiments, and we have since performed new microbiota analysis experiments
confirming that female and male BWF1 microbiota composition differs. The initial
experiments were performed during the period of 2014 to 2016, while our mouse colony
was located in the A Tower. At the end of 2016, however, we moved our mouse colony
to a different facility on the University of Louisville campus, the barrier facility located
in the CTR Building (CTRB), and we observed that, in experiments begun after that
point, transferring male microbiota to female BWF1 mice no longer suppressed disease.
This period, which we have termed the CTRB Early period, lasted from early 2017 to
2018. When we compared female and male BWF1 microbiota from the A Tower period
(2014-2016) and the CTRB Early period (2017-2018), we saw a clear difference between
the two periods. Additionally, while the female and male BWF1 microbiota from the
CTRB Early period were still significantly different, the degree of significance was
considerably less than had been seen in the A Tower. Later, following changes in mouse
facilities and animal husbandry procedures in the CTRB facility, the protective ability of
male microbiota was restored. During this later period, termed the CTRB Recent period
(2019-present), the male and female microbiota profiles were again highly significantly
different. Figure 23 provides a timeline of microbiota composition, microbiota transfer
results and animal facility/husbandry changes. Comparison of CTRB Early Experiments
2 and 3, which were contemporaneous but received water that had been purified using
different methods, showed that sterilization using filtering or autoclaving techniques had
some effect on the abundance of microbiota taxa illustrating the sensitivity of the
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microbiota to environmental changes. In the time between the CTRB Early and CTRB
Recent periods, one of the changes we made was a switch to water that was purified by
reverse osmosis (RO) and also autoclaved. This and other changes that were made to the
animal housing and husbandry in the CTRB very likely have had a significant impact on
the microbiota composition, including making it more stable.
Our first aim centered around investigating what changes in microbiota
composition correlated with the loss of the protective ability of the male microbiota to
suppress disease in female recipients. During the A tower period, Bacteroides
(predominantly B. acidifaciens) abundance was significantly higher in male than female
BWF1 mice. This is similar to what has been found in patients with autoimmune
rheumatoid arthritis. Multiple studies have shown that healthy controls have significantly
higher abundance of Bacteroides than rheumatoid arthritis patients [269,438]. However,
in the CTRB Early experiments, male BWF1 mice did not have higher Bacteroides
abundance, and in fact, in CTRB Early Experiments 1, 2, and 3, Bacteroides levels were
almost undetectable, although in CTRB Early Experiment 4, Bacteroides was higher in
female than male BWF1 mice. The samples from CTRB Early Experiment 1 were
collected 2 months before the samples for CTRB Early Experiments 2 and 3 were
collected and 4 months before the samples from CTRB Early Experiment 4. For the
levels of Bacteroides to change so drastically in mice from the same colony in such a
short span of time suggests that the microbiota profiles were in a state of flux. Together
with the differences found between the A Tower and CTRB Early microbiota profiles, the
data indicate that moving the mouse colony and setting up at the new facility resulted in
significant changes to the microbiota. Another change that highlighted the differences
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between the A Tower and CTRB Early mice was the disappearance of the entire Alistipes
genus. Whereas in the A Tower the Alistipes abundance was ~10-20%, it was completely
undetectable in the microbiota of all CTRB Early experiments. Additionally, in the
CTRB Early Experiments, 30-40% of all bacteria were from the Clostridium genus
(predominantly C. leptum), which was 2 to 3 times higher than in the A Tower mice. This
suggests a possible explanation for why high Bacteroides in female mice in CTRB Early
Experiment 4 did not correlate with protection against disease. It is possible that high
levels of Clostridium may promote lupus progression and/or block any beneficial effect
of high Bacteroides. There is some evidence in the literature supporting this possibility.
A longitudinal analysis of SLE patient gut microbiota found that C. leptum was enriched
in SLE patient gut microbiota compared to healthy controls, and that after treatment that
successfully reduced disease activity, C. leptum abundance was decreased [439].
Furthermore, in a recent study, bacteria from the class Clostridia, which includes
Clostridium, were able to suppress retinoic acid synthesis in the intestine [440]. Retinoic
acid is important for the induction of tolerance-promoting T regulatory cells (Tregs)
[441], and SLE is associated with lower levels of Tregs [442]. This suggests that an
overabundance of Clostridia could potentially increase susceptibility to lupus by
suppressing retinoic acid-dependent Treg induction. Further study will be required to
determine if Clostridium is playing a similar role in the BWF1 mice.
Analysis of the female and male microbiota compositions in the CTRB Recent
period (when the male microbiota was again able to suppress disease in female
recipients) strengthened the association of high Bacteroides and low Clostridium with
protection from disease. In both CTRB Recent female vs male experiments, Bacteroides
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is higher in male than female BWF1 mice, and Clostridium abundance is very low (~510%). The two genera have the same predominant species, B. acidifaciens and C. leptum,
as the A Tower, further supporting the similarities between the CTRB Recent and A
Tower microbiota profiles. Additionally, analysis of a CTRB Recent intact vs castrated
male experiment found lupus-resistant intact male BWF1 mice had higher Bacteroides,
and specifically B. acidifaciens, abundance than the lupus-susceptible castrated male
BWF1 mice, which further supports the connection between higher Bacteroides and
disease resistance. The finding that B. acidifaciens is the predominant Bacteroides
species is interesting, as B. acidifaciens has been associated with anti-inflammatory
phenotypes. A previous study found that in the non-obese diabetic (NOD) mouse model,
a therapeutic diet increased both the survival rate and B. acidifaciens abundance. The
increase in B. acidifaciens correlated with changes in multiple changes in immune
parameters that shifted systemic immunity towards a more anti-inflammatory profile
[443]. Similarly, in a study examining the colitis-suppressing activities of a Lactobacillus
probiotic, it was found that treatment with the Lactobacillus resulted in a massive
increase in B. acidifaciens abundance, and this correlated with suppression of colitic
inflammation and restoration of gut homeostasis [444]. This supports the theory that
increased abundance of B. acidifaciens could suppress the inflammatory immune
responses seen in lupus.
Alistipes, which had been absent in CTRB Early experiments, was present in all
of CTRB Recent experiments, and the same species (A. putredinis and A. timonensis)
were predominant as in the A Tower. This further supports the conclusion that the return
of the protective effect of male to female microbiota transfers coincides with a shift of the
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microbiota taxa abundances to become more similar to that seen in the A Tower. It also
suggests that the presence of Alistipes could potentially be required for the protective
effect of the male microbiota.
It is also worth noting that the samples from CTRB Recent Experiments 1 and 2
were collected about 2 months apart, similar to the length of time separating CTRB Early
Experiments 2 and 3 from CTRB Early Experiment 4. However, while Bacteroides went
from being undetectable in CTRB Early Experiments 2 and 3 to up to 30-40% abundance
in CTRB Early Experiment 4, the Bacteroides abundances of CTRB Recent Experiments
1 and 2 varied far less. This suggests that the Bacteroides population during the CTRB
Recent time period is more stable than it was during the CTRB Early time period.
Further evidence of the correlation of high Bacteroides and low Clostridium with
protection from disease was found when the microbiota profiles of CTRB Early and
CTRB Recent cecal transfer experiments were compared. In the CTRB Recent transfer
experiment, the female and male BWF1 recipients of male BWF1 microbiota had higher
Bacteroides abundance compared to female recipients of female microbiota, and this
higher level of Bacteroides corresponded with suppression of disease. This fits with
previous studies that have found adoptive transfer of Bacteroides suppresses
inflammatory diseases. One study showed that transferring Bacteroides vulgatas into IL2 knockout mice protected them against Escherichia coli-triggered colitis [445]. In
another study, Bacteroides fragilis transfer conferred resistance to EAE [446]. More
recently, a study found that administering B. acidifaciens to mice fed a high fat diet
protected them against obesity and the development of obesity-derived inflammation
[447]. Taken together with our findings, these data suggest species within the Bacteroides
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genus can suppress inflammatory diseases.
However, female recipients of female microbiota in the CTRB Early transfer
experiment were not protected from disease, despite having higher Bacteroides
abundance than recipients of male microbiota. This could potentially be because, as with
the female vs male experiments, the CTRB Early transfer experiment had substantially
higher levels of Clostridium than the CTRB Recent transfer experiments. A comparison
of the Bacteroides/Clostridium ratios suggested that the combination of high Bacteroides
with low Clostridium may be key to the protective effect of male microbiota. Also, like
the male vs female experiments, Alistipes was absent in the CTRB Early and present in
the CTRB Recent cecal transfer experiments supporting the idea that Alistipes and
Bacteroides could potentially be acting in concert. Findings like this not only could
potentially lead to the development of new lupus therapies, but could also inform the use
of current treatments. For example, the current frontline treatment for lupus is
corticosteroids, but a recent study comparing SLE patients who had and had not
undergone glucocorticoid treatment found glucocorticoid treatment was associated with
decreased Bacteroides abundance [285]. If further research showed that higher
Bacteroides abundance was beneficial for human SLE patients, the effects of a therapy on
the microbiota might need be considered when designing a treatment plan.
Taken together, our results emphasize that no single taxon can be considered in
isolation, and that examination of the entire microbiological profile is essential for studies
of the microbiota. For our data, male microbiota suppression of disease does not track
with any one taxon, but with a combination of high Bacteroides, low Clostridium and the
presence of Alistipes.
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Figure 3. Female, but not male, NZBxNZWF1 (BWF1) mice develop severe
glomerulonephritis spontaneously. Female and male BWF1 mice were monitored for
kidney disease (glomerulonephritis) bi-weekly by measuring proteinuria in the urine.
Proteinuria was scored on a scale of 1-5 with a score of 5 indicating death (n=5). (A)
Kidney disease score (B) Incidence of kidney disease (% mice with a proteinuria score of
≥3 for two consecutive biweekly readings). (C) Survival curve. Kidney disease scores
were compared with two-way ANOVAs, and incidence and survival curves were
compared using the Log rank (Mantel-Cox) test. *p<0.05, **p<0.01, ***p<0.001
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Figure 4. Adult female and male BWF1 mice have significantly different microbiota
compositions. Feces were collected from 16-week-old female (F) and male (M) BWF1
mice during the A Tower period (2014-16) and bacterial DNA was extracted. The 9
hypervariable regions of the 16S rRNA gene were sequenced and used to determine
microbiota taxonomic composition. (A) Principal coordinate analysis (PCoA) plot of
female and male BWF1 microbiota beta diversity using the Bray-Curtis dissimilarity
metric. Each symbol represents one fecal sample. (B) Female and male microbiota beta
diversity distances were compared with the permutational multivariate analysis of
variance (PERMANOVA) pairwise statistical test (n=7). (p=0.001)
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Figure 5. Androgen depletion increases incidence and time of onset of kidney disease
and decreases survival in male BWF1 mice. Female, intact male, and castrated (at ~
24-days of age) male BWF1 mice were monitored for kidney disease
(glomerulonephritis) bi-weekly by measuring proteinuria in the urine. Proteinuria was
scored on a scale of 1-5 with a score of 5 indicating death (n=8) [420]. (A) Kidney
disease score. (B) Incidence of kidney disease (% mice with a proteinuria score of ≥3 for
two consecutive biweekly readings). (C) Survival curve. Kidney disease scores were
compared with two-way ANOVAs, and incidence and survival curves were compared
using the Log rank (Mantel-Cox) test [420]. *p<0.05, **p<0.01, ***p<0.001
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Figure 6. Adult intact and castrated male BWF1 mice have significantly different
microbiota compositions. Feces were collected from 16-week-old intact (Intact M) and
castrated (at ~24 days of age; Cast M) BWF1 mice and bacterial DNA was extracted. The
9 hypervariable regions of the 16S rRNA gene were sequenced and used to determine
microbiota taxonomic composition. (A) Principal coordinate analysis (PCoA) plot of
intact and castrated male BWF1 microbiota beta diversity using the Bray-Curtis
dissimilarity metric. (B) Intact and castrated male microbiota beta diversity distances
were compared with the permutational multivariate analysis of variance (PERMANOVA)
pairwise statistical test (n=8). (p=0.0015)
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Figure 7. Transfer of male microbiota significantly suppresses kidney disease and
enhances survival in female BWF1 mice. Female BWF1 mice were fed cecal contents
(i.e., microbiota) via gavage from 16-week-old female or male BWF1 mice. Female-tofemale (F-F, n=6) and male-to-female (M-F, n=5) cecal transfer recipients were
monitored for kidney disease (glomerulonephritis) bi-weekly by measuring proteinuria in
the urine. Proteinuria was scored on a scale of 1-5 with a score of 5 indicating death.
Experiments were conducted during the A Tower period (2014-16). (A) Cecal transfer
regimen. (B) Kidney disease score. (C) Incidence of kidney disease (% mice with a
proteinuria score of ≥3 for two consecutive biweekly readings). (D) Survival curve.
Kidney disease scores were compared with two-way ANOVAs, and incidence and
survival curves were compared using the Log rank (Mantel-Cox) test. **p<0.01
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Figure 8. Transfer of male microbiota did not suppress kidney disease or enhance
survival in female BWF1 mice during the CRTB Early period. Female BWF1 mice
were fed cecal contents (i.e., microbiota) via gavage from 16-week-old female or male
BWF1 mice. Female-to-female (F-F) and male-to-female (M-F) cecal transfer recipients
were monitored for kidney disease (glomerulonephritis) bi-weekly by measuring
proteinuria in the urine. Proteinuria was scored on a scale of 1-5 with a score of 5
indicating death (n=6). Experiments were conducted during the CTRB Early period
(2017-18). (A) Kidney disease score. (B) Incidence of kidney disease (% mice with a
proteinuria score of ≥3 for two consecutive biweekly readings). (C) Survival curve.
Kidney disease scores were compared with two-way ANOVAs, and incidence and
survival curves were compared using the Log rank (Mantel-Cox) test.
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Figure 9. Female and male microbiota compositions differ between the A Tower and
CTRB Early periods. Feces were collected from 16-week-old female and male BWF1
mice during either the A Tower (2014-16; n=6) or the CTRB Early (2017-18; n=7)
periods, and bacterial DNA was extracted. The 9 hypervariable regions of the 16S rRNA
gene were sequenced and used to determine microbiota taxonomic composition. (A)
Principal coordinate analysis (PCoA) plot of female and male BWF1 microbiota beta
diversity using the Bray-Curtis dissimilarity metric. Each symbol represents one fecal
sample. (B) Female and male microbiota beta diversity distances for samples collected
during the CTRB Early period were compared with the permutational multivariate
analysis of variance (PERMANOVA) pairwise statistical test (p = 0.043).
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Figure 10. Transfer of male microbiota suppressed kidney disease and enhanced
survival in female BWF1 mice in during the CRTB Recent period. Female and male
BWF1 mice were fed cecal contents (i.e., microbiota) via gavage from 16-week-old
female or male BWF1 mice. Female BWF1 mice were fed cecal contents from adult male
or female BWF1 mice. Female-to-female (F-F), male-to-female (M-F), and male-to-male
(M-M) cecal transfer recipients were monitored for kidney disease bi-weekly by
measuring proteinuria in the urine on a scale of 1-5 with a score of 5 indicating death
(n=6). Experiments were conducted during the CTRB Recent period (2019-present). (A)
Kidney disease score. (B) Incidence of kidney disease (% mice with a proteinuria score
of ≥3 for two consecutive biweekly readings). (C) Survival curve. Kidney disease scores
were compared with two-way ANOVAs, and incidence and survival curves were
compared using the Log rank (Mantel-Cox) test. *p<0.05, **p<0.01
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Figure 11. Female and male BWF1 mice have highly significantly different
microbiota compositions during the CTRB Recent period. Feces were collected from
16-week-old female and male BWF1 mice during the CTRB Early (2019-present) period
and bacterial DNA was extracted. The 9 hypervariable regions of the 16S rRNA gene
were sequenced and used to determine microbiota taxonomic composition (n=7). (A)
Principal coordinate analysis (PCoA) plot of adult male and female BWF1 fecal
microbiota beta diversity using the Bray-Curtis dissimilarity metric. (B) Female and male
microbiota beta diversity distances were compared with the permutational multivariate
analysis of variance (PERMANOVA) pairwise statistical test. Outliers are indicated as
triangles. (p = 0.001).
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Figure 12. Abundance of Bacteroides was higher in adult male than female BWF1
mice during the A Tower period. Feces were collected from 16-week-old female and
male BWF1 mice during the A Tower period (2016) and bacterial DNA was extracted.
The 9 hypervariable regions of the 16S rRNA gene were sequenced and used to
determine microbiota taxonomic composition (n=7). Abundances were compared with
One-way ANOVAs. (A) Genus level microbiota from the A Tower – Female vs Male
experiment genus (n=6). (B) Species level microbiota from the A Tower – Female vs
Male experiment species (n=6). *p<0.05, **p<0.01, ***p<0.001

95

(A)

(B)

CTRB Early – Experiment 1 – Genus

CTRB Early – Experiment 1 – Species

96

(C)

(D)

CTRB Early – Experiment 2 – Genus

CTRB Early – Experiment 2 – Species

97

(E)

(F)

CTRB Early – Experiment 3 – Genus

CTRB Early – Experiment 3 – Species

98

Figure 13. Bacteroides is virtually absent and abundance of Clostridium is very high
in both females and males in most CTRB Early Experiments. Feces were collected
from 16-week-old female and male BWF1 mice during the CTRB Early (2017-18) period
and bacterial DNA was extracted. The 9 hypervariable regions of the 16S rRNA gene
were sequenced and used to determine microbiota taxonomic composition. Abundances
were compared with One-way ANOVAs. (A) Genus level microbiota from Experiment 1
(n=8). (B) Species level microbiota from Experiment 1 (n=8). (C) Genus level microbiota
from Experiment 2 (n=7). (D) Species level microbiota from Experiment 2 (n=7). (E)
Genus level microbiota from Experiment 3; (n=7). (F) Species level microbiota from
Experiment 3 (n=7). *p<0.05, **p<0.01, ***p<0.001
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Figure 14. In the final CTRB Early, Experiment 4, unlike in other CTRB early
experiments, abundance of Bacteroides was high, while abundance of Clostridium
also continued to be high in both female and male adult BWF1 mice. Feces were
collected from 16-week-old female and male BWF1 mice during the CTRB Early (201718) period and bacterial DNA was extracted. The 9 hypervariable regions of the 16S
rRNA gene were sequenced and used to determine microbiota taxonomic composition
(n=6). Abundances were compared with One-way ANOVAs. (A) Genus level microbiota
from Experiment 4. (B) Species level microbiota from Experiment 4. *p<0.05, **p<0.01,
***p<0.001
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Figure 15. Both sex and drinking water source affect microbiota compositions. Feces
were collected from 16-week-old female and male BWF1 mice during the CTRB Early
(2017-18) period and bacterial DNA was extracted. The 9 hypervariable regions of the
16S rRNA gene were sequenced and used to determine microbiota taxonomic
composition (n=7). Mice received either autoclaved tap H2O (also see Experiment 2 in
Figure 13C,D) or filtered H2O (also see Experiment 3 in Figure 13E,F) drinking water
for the entire period of the experiment. Abundances were compared with One-way
ANOVAs. (A) Genus level microbiota; (B) Species level microbiota. *p<0.05, **p<0.01,
***p<0.001
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Figure 16. Abundance of Bacteroides was considerably higher in adult male than
female BWF1 mice, and abundance of Clostridium levels was low in CTRB Recent
experiments. Feces were collected from 16-week-old female and male BWF1 mice
during the CTRB Recent (2019-present) period and bacterial DNA was extracted. The 9
hypervariable regions of the 16S rRNA gene were sequenced and used to determine
microbiota taxonomic composition. Abundances were compared with One-way
ANOVAs. (A) Genus level microbiota from Experiment 1 (n=7). (B) Species level
microbiota from Experiment 1 (n=7). (C) Genus level microbiota from Experiment 2
(n=6). (D) Species level microbiota from Experiment 2 (n=6). **p<0.01, ***p<0.001
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Figure 17. Androgen depletion through castration reduces Bacteroides abundance.
Feces were collected from 16-week-old intact and castrated (at ~24 days of age) BWF1
mice during the CTRB Recent period and bacterial DNA was extracted. The 9
hypervariable regions of the 16S rRNA gene were sequenced and used to determine
microbiota taxonomic composition (n=8). Abundances were compared with One-way
ANOVAs. (A) Genus level microbiota; (B) Species level microbiota. **p<0.01,
***p<0.001
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Figure 18. In CTRB Early microbiota transfer experiments, Bacteroides was present
but abundance was lower in the Male to Female transfers and Clostridium was high
in all experimental groups. During the CTRB Early (2017-18) period, female BWF1
mice were fed cecal contents (i.e., microbiota) from 16-week-old female (Female-toFemale) or male (Male-to-Female) BWF1 mice via gavage. Feces were collected from
16-week-old cecal transfer recipients (4 weeks after cecal transfer), and bacterial DNA
was extracted. The 9 hypervariable regions of the 16S rRNA gene were sequenced and
used to determine microbiota taxonomic composition. Abundances were compared with
One-way ANOVAs (n=6). (A) Genus level microbiota; (B) Species level microbiota.
*p<0.05, **p<0.01, ***p<0.001
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Figure 19. In CTRB Recent microbiota transfer experiments, abundance of
Bacteroides was higher in the recipients of male microbiota, and abundance of
Clostridium was low at two different time-points. During the CTRB Recent (2019 present) period, female BWF1 mice were fed cecal contents (i.e., microbiota) from 16week-old female (Female-to-Female) or male (Male-to-Female) BWF1 mice via gavage.
Male mice (Male to Male) were fed male cecal contents as a control. Feces were
collected from 16-week-old cecal transfer recipients and bacterial DNA was extracted.
The 9 hypervariable regions of the 16S rRNA gene were sequenced and used to
determine microbiota taxonomic composition. Abundances were compared with One-way
ANOVAs (n=6). (A) Genus level microbiota in feces collected at 15 weeks of age (4
weeks after cecal transfer); (B) Species level microbiota in feces collected at 15 weeks of
age (4 weeks after cecal transfer); (C) Genus level microbiota in feces collected at 19
weeks of age (4 weeks after cecal transfer); (D) Species level microbiota in feces
collected at 19 weeks of age (4 weeks after cecal transfer). *p<0.05, **p<0.01,
***p<0.001
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Figure 20. Comparison of Bacteroides and Clostridium abundance data in female
and male BWF1 mice from experiments conducted during the A Tower, CTRB
Early, and CTRB Recent periods. Feces were collected from female and male BWF1
mice during the A Tower (2014-16), CTRB Early (2017-2018), and CTRB Recent (2019present) periods and bacterial DNA was extracted. The 9 hypervariable regions of the 16S
rRNA gene were sequenced and used to determine microbiota taxonomic composition.
Abundances were compared with One-way ANOVAs. Data were compiled from
experiments shown in Figures 12, 13, 14 and 16. (A) Compilation of data for Bacteroides
abundances in females and males; (B) Compilation of data for Clostridium abundances in
females and males. *p<0.05, ***p<0.001
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Figure 21. Comparison of Bacteroides and Clostridium abundance data in cecal
transfer experiments conducted during the CTRB Early and CTRB Recent periods.
During the CTRB Early (2017-2018) and CTRB Recent (2019-present) periods, female
BWF1 mice were fed cecal contents (i.e., microbiota) from 16-week-old female (Femaleto-Female) or male (Male-to-Female) BWF1 mice via gavage. Feces were collected from
16-week-old cecal transfer recipients (4 weeks after cecal transfer), and bacterial DNA
was extracted. The 9 hypervariable regions of the 16S rRNA gene were sequenced and
used to determine microbiota taxonomic composition. Abundances were compared with
One-way ANOVAs. Data were compiled from experiments shown in Figures 18 and 19.
(A) Compilation of data for Bacteroides abundances in cecal recipients; (B) Compilation
of data for Clostridium abundances in cecal recipients. *p<0.05, ***p<0.001
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Figure 22. Ratios between Bacteroides and Clostridium abundance in female vs
male and cecal transfer experiments. Fecal samples from (A) female and male
collected during the A Tower, CTRB Early (2017-2018) and CTRB Recent (2019present) periods and (B) cecal transfer recipients collected during the CTRB Early (20172018) and CTRB Recent (2019-present) periods and bacterial DNA was extracted. The 9
hypervariable regions of the 16S rRNA gene were sequenced and used to determine
microbiota taxonomic composition. The Bacteroides/Clostridium ratios were calculated
from the data shown in Figure 20 for the female and male comparisons and Figure 21
for the cecal transfer comparisons by dividing average Bacteroides abundance by average
Clostridium abundance. (A) Bacteroides/Clostridium ratios for the female to male
comparisons; (B) Bacteroides/Clostridium ratios for the cecal recipient comparisons.
*p<0.05, **p<0.01, ***p<0.001
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Figure 23. Timeline of facility, disease phenotype, and microbiota composition
changes.
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SPECIFIC AIM 2
Comparison of metabolomic profiles in lupus-prone versus lupusresistant BWF1 mice
Introduction
Lupus exhibits a considerable sex bias with women having a much higher
incidence [1,2], and sex hormone levels can significantly affect lupus progression
[115,138,141-144,149-152]. Additionally, lupus has been linked to dysbiotic
microbiomes in both human SLE patients and in mouse models of lupus [276283,286,293,297,299]. Alterations in the microbiome have been shown to affect lupus
progression [282,297,299], and microbiome composition can be affected by sex and sex
hormones [182,300-303,315]. Consequently, sex-based differences in the microbiota
have been proposed as a potential contributor to the sex bias of lupus. This is supported
by recent studies showing that sex-based microbiota differences contributed to the sex
bias in the NOD mouse model of type 1 diabetes [323,324]. As described above, we have
found differences in microbiota composition between female and male BWF1 mice and
between intact and castrated male BWF1 mice (Fig. 4; 6). Furthermore, we have found
that transfer of male microbiota to female recipients protects them from disease (Fig. 7;
10). The mechanisms underlying this protection are currently not known.
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One way that the gut microbiota can affect immune response is by producing
immunomodulatory metabolites. These come in many different classes and have been
shown to be able to affect the progression of autoimmune diseases [327]. Short chain
fatty acids (SCFAs) including acetate, butyrate, and propionate, are one class that have
been repeatedly shown to promote anti-inflammatory immune activities in dendritic cells,
macrophages, and neutrophils [328-332]. Low levels of SCFAs and SCFA-producing
bacteria are associated with multiple auto-inflammatory diseases including IBD, Crohn’s
disease, and spondyloarthritis [333-336], and SCFAs can ameliorate symptoms in mouse
models of auto-inflammatory diseases [334,337-339]. SFCAs can also affect diseases
outside the intestine. Multiple sclerosis patients have lower levels of SCFAs in their
serum [448] and treating a mouse model of experimental autoimmune encephalomyelitis
(EAE) with SCFAs reduces disease severity [341].
Not all gut metabolites have anti-inflammatory effects. Trimethylamine (TMA) is
a choline metabolite synthesized exclusively by the microbiota. It is transported into the
liver where it is converted to trimethylamine N-oxide (TMAO). Unlike SCFAs, TMAO
promotes inflammatory responses. It activates the NLRP3 inflammasome [358,359], and
higher serum TMAO levels have been linked to several human autoimmune diseases,
including primary sclerosing cholangitis [360], psoriatic arthritis [361], and RA [362].
Another category of gut metabolites are secondary bile acid metabolites which
are synthesized from primary bile metabolites by the microbiota. Like SCFAs, they have
been shown to have anti-inflammatory effects. Disruption of secondary bile acid
production can contribute to the development of IBD, nonalcoholic fatty liver disease,
cholestatic liver injury, and other diseases [342,363,368]. As with the studies on SCFAs
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and described above, these studies emphasize that immune processes both inside and
outside the intestine can be affected by altered microbiota metabolite production.
In the current study, we have found that the fecal metabolomic profiles of female
and male BWF1 mice differ. Androgen depletion via castration also causes a shift in
metabolite composition. In three separate experiments, we found phytol, a gut metabolite
with RXR and PPARγ agonist activities, to be more abundant in male than female BWF1
feces. In the most recent and comprehensive analysis, phytol was also elevated in intact
vs castrated male BWF1 feces [420], and phytol’s derivative, phytanic acid which is a
very potent RXR and PPARγ agonist [449-453], was detected in intact male BWF1 feces,
but not female or castrated male BWF1 feces. This indicates that lupus-resistant male
BWF1 mice and lupus-susceptible female and castrated male BWF1 mice have
differences in intestinal metabolites that may be linked to the differences in microbiota
profiles we have found and possibly to the ability of the male microbiota to suppress
disease.

Results
Lupus-prone female and castrated male BWF1 mice have significantly different gut
metabolite profiles from lupus-resistant male BWF1 mice
Differences in microbiota composition between female and male, and between
intact and castrated male mice such as we have found could lead to differential
production of gut metabolites that could have an impact on the immune response and/or
disease. To evaluate this possibility, we compared the intestinal metabolomic profiles of
adult lupus-prone female and lupus-resistant male BWF1 mice by analyzing fecal
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metabolite compositions. Metabolites were extracted from the feces, derivatized with Nmethyl-N-trimethylsilytrifluoroacetamide (MSTFA), and analyzed using twodimensional gas chromatography mass spectrometry (GC×GC-MS). Retention time and
mass spectra of compounds detected were compared to those of known metabolites to
determine the composition and abundance of gut metabolites (Fig. 24A; Table 1). Partial
least squares-discriminant analysis (PLS-DA) was performed to visualize the differences
between female and male metabolite profiles. We observed a clear sex-based difference
in metabolite profiles (Fig. 24B). In the time since that initial experiment (Metabolomic
Experiment #1), our collaborators have upgraded their metabolite detection platforms,
and this experiment was repeated. In the second experiment, (Metabolomic Experiment
#2), in addition to the analysis using GC×GC-MS with MSFTA derivatization, metabolite
composition was analyzed using two-dimensional liquid chromatography mass
spectrometry (2DLC-MS/MS) with either negative or positive ionization. This expanded
the range of metabolites that could be detected, since 2DLC-MS/MS is more efficient at
detecting less polar metabolites. Combined with improvements to the GC×GC-MS
reference database, Experiment #2 identified 76 metabolites significantly different
between female and male BWF1 mice (Table 2), compared with 16 in Experiment #1
(Table 1). The ionization mode, which is the charge metabolites are given before
entering the detector, also influences which metabolites can be detected. Positive
ionization allows the detection of a greater range of compounds, but negative ionization
lowers background noise and is useful for detecting low-abundance metabolites [454]. In
a third experiment (Metabolomic Experiment #3), we compared the metabolomic profiles
of lupus-resistant intact male BWF1 mice not only to lupus-prone female mice, but also
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to lupus-prone castrated male BWF1 mice. In Metabolomic Experiment #3, the samples
were analyzed via four different methods: GC×GC-MS with either MSTFA or N-tertButyldimethylsilyl-N-methyltrifluoroacetamide (MTBSTFA) derivatization, and twodimensional liquid chromatography mass spectrometry (2DLC-MS/MS) with either
negative or positive ionization (Tables 3-5). The use of multiple derivatization reagents
further increased the range of metabolites that could be detected. The derivatization
reagent MSTFA is more efficient at facilitating detection of larger metabolites, while
MTBSTFA is more efficient at facilitating detection of smaller metabolites [455]. Using
multiple methods therefore increases the number and types of metabolites detected. For
all four of the methodologies, PLS-DA analysis indicated that there were differences
between the intact male, castrated male, and female BWF1 metabolomic profiles (Fig.
25), strongly suggesting that both sex and sex hormone levels affect the composition of
intestinal metabolites. In addition, there was considerable overlap between the
metabolites that differed between the female and intact male BWF1 mice and the
metabolites that differed significantly between the castrated and intact male BWF1 mice.
Side-by-side comparison of the fold changes in these sets of metabolites showed that not
only did they overlap, but the direction of the fold change compared to the male mice was
often the same (Fig. 26). These data suggest that the male sex hormones, androgens, have
a significant impact on metabolomic profiles. In addition, quantitative pathway
enrichment analysis of the two sets of significantly different metabolites showed several
pathways were significantly altered in intact male BWF1 mice compared to both female
and castrated male BWF1 mice (Fig. 27). This suggests that lupus-resistant intact male
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BWF1 may have functional metabolic differences from lupus-susceptible female and
castrated male BWF1 mice.

Specific immunomodulatory metabolites are increased in lupus-resistant intact male
BWF1 mice compared to lupus-susceptible female and castrated male BWF1 mice.
Differences in the production of microbial metabolites with immunomodulatory
properties are known to affect the progression of autoimmune diseases [327]. We studied
the known properties of the metabolites that were significantly different between female
and male BWF1 mice to determine whether any could potentially affect the development
and/or progression of disease. Pathway analysis of Metabolomic Experiment #3
identified histidine metabolism as being significantly altered both between the female and
male BWF1 mice, and the intact and castrated male BWF1 mice (Fig. 27). In this
pathway, histidine is converted into histamine, a molecule with potent effector activities.
2DLC-MS/MS with positive ionization (2DLC-MS/MS (+)) showed that compared to
female and castrated male BWF1 mice, intact males had lower levels of the histamine
precursor, histidine (Fig. 28A), and higher levels of histamine (Fig. 28B), and the
histamine breakdown product, methylimidazoleacetic acid (Fig. 28C). This suggests that
intestinal histamine production may be higher in intact male than female or castrated
male BWF1 mice. The gut microbiota is a known producer of histamine, so the higher
production in intact males could be due to the altered microbiota profiles seen in male
BWF1 mice [351-353]. This theory is supported by our previous results from positive
ionization 2DLC-MS/MS (2DLC-MS/MS(+)) analysis in Experiment #2, which also
found histamine was more abundant in male than female BWF1 mice (Fig. 28D). In this
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prior analysis, neither histidine or methylimidazoleacetic acid were detected, but this is
likely due to improvements in metabolite detection ability and reference databases
between Experiments #2 and #3.
Many findings of significant metabolite differences between female and male
BWF1 feces in one experiment were not repeated in other experiments. For example,
butyrate and niacin, both well-documented immunomodulators, were both found to be
significantly higher in male than female BWF1 mice in Experiment #2 (Fig. 29A,B,
Table 2). However, in Experiment #3, although both were detected, neither of these
metabolites was found to be significantly different between male and female BWF1 mice
(Fig. 29C,D). Neither butyrate nor niacin was detected in Experiment #1, but this could
be due to the more limited detection capabilities of the platform at that time. This
inconsistency in findings between experiments is a major obstacle in the study of
metabolomics.
However, there was one metabolite that was consistently higher in male than
female BWF1 mice across all three metabolomic experiments. This metabolite, phytol,
was more abundant in lupus-resistant male than lupus-prone female BWF1 mice in all
three analyses (Fig. 30). Phytol is an acyclic diterpene alcohol which is produced from
the breakdown of chlorophyll and has known RXR and PPARγ agonist activity,
[449,450,456], and there is evidence in animal models that signaling through RXR and
PPARγ receptors can, in general, alter immune responses in ways that could potentially
suppress lupus [394,457-459]. This correlation between lower phytol levels and lupus
susceptibility was also found in lupus-prone castrated male BWF1 mice which also have
lower abundance of phytol than intact male BWF1 mice and similar levels as female
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BWF1 mice (Fig. 31A). Phytol is produced exclusively by the gut microbiota [460-462],
but once absorbed by the intestine, host enzymes convert it to phytanic acid, which has
even more potent RXR and PPARγ agonist activity than phytol, and is more easily
transported in esterified form through the circulatory system [449-453,463]. For the most
recent experiment, Metabolite Experiment #3, improvements in detection capabilities and
reference databases allowed us to detect phytanic acid. We found high levels of phytanic
acid in feces from intact male mice compared to feces from female and castrated male
BWF1 mice, and in fact, no phytanic acid was detected in female and castrated male
feces (Fig. 31B). Taken together, the data show that both phytol and its derivative,
phytanic acid, are more abundant and/or only present in intact male BWF1 mice. The
known RXR and PPARγ agonist activity of these metabolites raises the question of
whether this could contribute to the protective capability of the male microbiota and
whether one or both of these molecules could be used as a potential therapeutic for the
treatment of lupus. lupus.

Discussion
While our bacterial taxa findings are promising, one of the challenges in
microbiota research is the fact that the effects of bacterial taxa are context dependent.
What microbiota are associated with a disease can vary between mouse strains. For
example, low abundance of Lactobacillus is associated with increased lupus symptoms in
the MRL/lpr mouse model [297,298], but in the BWF1 mouse model of lupus, high
abundance of Lactobacillus is associated with more severe renal disease [282]. Mouse
models and human patients can also differ in the bacteria that are associated with disease,
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as a study found that, unlike MRL/lpr mice, Lactobacillus was elevated in SLE patients
compared to healthy controls.
Due to this complexity, it is useful to use multiple approaches when studying the
relationship between microbiota and disease. In addition to using 16S rRNA sequencing
to determine the bacterial species that make up the BWF1 microbiota, we also used
metabolomic analyses to identify the fecal metabolite profiles. This approach allowed us
to investigate differences in gut metabolism between lupus-susceptible female and lupusresistant male BWF1 mice. The influence of the gut microbiota on the host is likely
mediated in part via the metabolites they produce [464]. Our aim was to characterize the
gut metabolomic profiles of disease susceptible female and disease-resistant male BWF1
mice. To this end, we performed three metabolomic experiments (Metabolomic
Experiments #1, 2, & 3) analyzing female and male BWF1 fecal metabolites. The
platforms used to analyze the fecal metabolites increased from analysis to analysis, so
each analysis was more thorough than the last. While Experiment #1 only used GC×GCMS with MSTFA derivatization, Experiment #2 also used 2DLC-MS/MS, which is more
efficient at detecting less polar metabolites. In Experiment #3, GC×GC-MS with
MTBSTFA derivatization was added, which is more effective at detecting small
metabolites. For Experiment #3, castrated male BWF1 feces were analyzed in addition to
the male and female BWF1 feces, and PLS-DA visualization of their metabolomic
profiles showed that for all four platforms, the profiles of the three groups were
divergent. This matches our findings that lupus-resistant intact male mice have
significantly different microbiota compositions compared to both female and castrated
male BWF1 mice. Furthermore, a side-by-side comparison of metabolites significantly
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different between intact male compared to female or castrated male BWF1 mice, shows
considerable overlap between the two sets, suggesting that androgens may have
considerable influence on metabolite production. This fits with the findings of previous
studies, which have shown that androgen levels affect the microbiota [323,324,465,466].
Also, androgens are known to suppress lupus progression [103,122-125], and alterations
of production of immunomodulatory metabolites can influence autoimmune diseases
[464]. In this context therefore, our findings suggest that androgens could potentially
suppress lupus by altering microbiota metabolite production in addition to their direct
effects on immune cells.
The increased coverage of metabolites in Metabolomic Experiment #3 also
enhanced our ability to identify differentially regulated metabolic pathways that could be
relevant to the development and/or progression of lupus. We therefore used the
metabolites with significant abundance difference between groups for pathway analysis.
The metabolic pathway analysis showed that the differences in pathways between
castrated and male mice closely resembled the differences between female and male
mice. Of the 41 pathways differentially regulated in castrated vs intact male mice, 28
were also differentially regulated in female vs male mice (Tables 6,7). Thus, the data
showed that depleting androgens in castrated male mice causes shifts in intestinal
metabolites toward a female-like phenotype that correlates with an increase in
susceptibility of the castrated male mice to lupus.
Androgen does not account for all biological differences between male and
female mice. The changes in the 28 common pathways differentially regulated in both the
castrated vs intact male analysis and the female vs male analysis of Metabolomic
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Experiment #3 could be due to androgen depletion or due to other sources of sex
differences (i.e., Y chromosome effects). This is evident from the fact that there were 43
metabolites significantly different between castrated male mice and female mice (Table
5). To narrow our pathway analysis to identify metabolic pathways that are dependent on
androgen, we performed a pathway analysis on the set of metabolites that were
significantly different between both castrated and intact male mice as well as between
female and male mice, but were not significantly different between female and castrated
male mice (i.e., metabolites present in both Tables 3 and 4 but not in Table 5). We found
that after removing the metabolites that were significantly different between female and
castrated male mice, 18 of the 28 common pathways remained (Table 8). These
pathways are the most likely to be different as a result of androgen depletion.
The significance of the pathway analysis is that it identifies potential areas of
study for how the differences in intestinal metabolite production could affect lupus
progression. One of the pathways differentially affected in Experiment #3 in both female
and castrated male mice compared with intact male mice was histidine metabolism.
Histidine is a precursor to histamine, an effector molecule that can mediate either
inflammatory or regulatory responses depending on the target cell and type(s) of
histamine receptor expressed. Recent studies have found that probiotic and endogenous
bacterial species could produce histamine and affect intestinal immune responses [351353]. In Experiment #3, both castrated and female mice had lower levels of histamine and
higher levels of the precursor, histidine than intact male mice. Additionally, castrated and
female mice had lower levels of methylimidazoleacetic acid (methylimid), which is the
end-product of histamine breakdown and is used as an indicator of histamine production
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[467]. While histidine and methylimidazoleacetic acid were not detected in Experiment
#2, likely due to the lower range of detection and poorer reference database, histamine
was detected and was higher in male than female BWF1 feces. Therefore, our results
clearly show intact male mice have a higher production of histamine in the gut that
correlates with their lower susceptibility to lupus. However, whether altered histamine
metabolism is simply a consequence of lupus or if it actually plays a role in the
progression of disease has not been established. Gut-generated histamine could
potentially affect the development or progression of lupus via local effects on the
intestine. While histamine is classically associated with allergic reactions, microbeproduced histamine has been shown to directly inhibit inflammatory factors in the gut
[354-356]. Because lupus is associated with low-grade intestinal inflammation and the
“leaky gut” that this causes [297,357], inhibition of gut inflammation in lupus-prone mice
(or humans) via microbe-produced histamine could potentially affect the development
and/or progression of the disease. Additionally, suppressing intestinal inflammation could
also inhibit disease by promoting the ability of intestinal DCs to induce
immunosuppressive Tregs in the mesenteric lymph node (mLN) since inflammatory
impairs this ability in intestinal DCs [468-475]. Multiple studies have found links
between lupus and decreases in regulatory T cell frequency or function in both humans
and mouse models [476-482], so this could clearly impact the progression of lupus in
BWF1 mice. Bacterial histamine can also directly inhibit intestinal DC production of
TNFα [483], an inflammatory cytokine that suppresses DC induction of Tregs in the
mLN [475,484]. In summary, the higher levels of histamine in intact male intestine could
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affect the development and/or progression of lupus via indirect or direct effects on DCs
that increase Treg induction by DCs in the mLN.
However, while the finding of elevated histamine in male BWF1 mice repeated in
Experiments #2 and #3, many metabolites did not. For example, niacin and butyrate are
both known to induce Tregs, and therefore the finding in Experiment #2 that they were
more abundant in male than female BWF1 feces was very interesting. However, in
Experiment #3, both were detected but neither were significantly different between
female and male BWF1 mice. This inconsistency between experiments has been a major
challenge in our metabolomic studies. Therefore, it is very significant that a metabolite,
phytol, was more abundant in male than female BWF1 mice in all three experiments and
was higher in intact than castrated male BWF1 mice in Experiment #3. Phytol is an
acyclic diterpene alcohol produced by the breakdown of chlorophyll by bacteria in the
gut, and it can bind and activate the RXR and PPARγ nuclear receptors [449,450,456].
Once phytol is absorbed, by the host, it is broken down into phytanic acid by the liver and
other tissues [485]. Phytanic acid has even more potent PPARγ and RXR agonist activity
compared to its parent compound, phytol, and it is more readily transported throughout
the body in an esterified form [449-453,463]. In Experiment #3, improvements in
metabolite detection allowed us to test phytanic acid levels, and we found that while male
BWF1 feces had significant levels, no phytanic acid was detected in female or castrated
male BWF1 feces. Increased levels of phytanic acid could potentially affect lupus
progression in a number of ways, since RXR and PPARγ stimulation promote a number
of immune processes that could potentially suppress lupus autoimmunity
[383,400,457,459,486]. One possibility is that phytol and or phytanic acid could enhance
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CD103 positive dendritic cell (CD103+DC) production of retinoic acid (RA), which
would enhance their induction of immunosuppressive Tregs. Intestinal CD103+DCs are
important for Treg induction [487], and defects in this process can significantly impact
systemic immune responses and inhibit tolerance induction [441,488,489]. This process
requires CD103+DC RA production [441], and RXR agonists can promote expression of
the enzymes that produce RA [490]. Another lupus-suppressing process that could be
enhanced by phytol and/or phytanic acid is the phagocytosis of apoptotic cells by
macrophages, which is called efferocytosis [371,491,492]. Apoptotic cells are a source of
nuclear self-antigens that can stimulate production of the anti-nuclear autoantibodies
characteristic of lupus, and deficiencies in the ability of macrophages to clear apoptotic
cells correlate with increased disease severity in SLE patients [380,493]. Due to its strong
ability to activate RXR and PPARγ, phytanic acid could potentially enhance macrophage
efferocytosis through these pathways [381,393-400]. Our subsequent experiments point
towards a strong connection between efferocytosis and phytanic acid.
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Figure 24. The gut metabolomic profile of adult female and male BWF1 mice differ.
For Metabolite Experiment #1 feces were collected from 16-week-old female (n=9) and
male (n=7) BWF1 mice and metabolites extracted using 80% methanol, derivatized with
MSTFA, and analyzed by GCxGC-MS. (A) Representative GCxGC-MS chromatogram.
(B) Partial least squares discriminant analysis (PLS-DA) of the metabolite profiles.
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Figure 25. Multiple metabolomic analysis techniques show the BWF1 gut
metabolomic profile differs with both sex and androgen depletion. For Metabolite
Experiment #3, feces were collected from 16-week-old female (n=8), intact male (Male;
n=6), and castrated male (Castrated; n=6) BWF1 mice (castrations were done at ~24 days
of age). Metabolites were extracted using 80% methanol [420]. Partial least squares
discriminant analysis (PLS-DA) was performed for the metabolite profiles analyzed via:
(A) GCxGC-MS with MSTFA derivatization. (B) GCxGC-MS with MTBSTFA
derivatization. (C) 2DLC-MS with negative ionization. (D) 2DLC-MS with positive
ionization.
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Figure 26. The metabolomic profile in castrated male mice is more similar to female
than to intact male mice. For Metabolite Experiment #3, female (n=8), intact male (n=6),
and castrated male (n=6) feces were collected and metabolites were analyzed as described
in Figure 25. For each analysis method, pairwise Student’s t-tests were used to identify
metabolites that were significantly different between at least two of the groups (Tables
3,4). The direction and fold change (FC) of metabolites significantly different between
females vs intact males and/or between castrated males vs intact males are shown in a
heatmap.
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Figure 27. Metabolic pathways that are different in female vs intact male mice are
also often altered in castrated vs intact male BWF1 mice. For Metabolite Experiment
#3, female (n=8), intact male (n=6), and castrated male (n=6) feces were collected and
metabolites were analyzed as described in Figure 25. Metabolites that were significantly
different between intact male and female or castrated male BWF1 mice were identified
using pairwise Student’s t-tests (Tables 3,4). Using Metaboanalyst (v4.0), quantitative
pathway enrichment analysis was performed on the metabolites that were significantly
different between female and intact male BWF1 mice (Table 3) and on the metabolites
that were significantly different between intact and castrated male BWF1 mice (Table 4).
The metabolites were matched against the KEGG database for Mus musculus and
analyzed for pathway enrichment and topology [420]. (A) Pathway enrichment of
metabolites that were significantly different between female and intact male BWF1 mice.
(B) Pathway enrichment of metabolites that were significantly different between castrated
vs intact male BWF1 mice.
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Figure 28. Histamine is more abundant in intact male than female or castrated male
BWF1 mice. For Metabolite Experiment #3, feces were collected from 16-week-old
female (n=8), and intact (Intact Male; n=6) and castrated (at ~24 days of age; n=6) male
BWF1 mice. For Metabolite Experiment #2, feces were collected from 16-week-old
female and male (Intact Male) BWF1 mice (n=9). Metabolites were extracted using 80%
methanol, analyzed with 2DLC-MS/MS. Significantly different metabolites were
identified using pairwise Student’s t-tests (Tables 2,3). (A) Metabolomic Experiment #3 Histidine abundance. (B) Metabolomic Experiment #3 - Histamine abundance. (C)
Metabolomic Experiment #3 - Methylimidazoleacetic acid (Methylimid) abundance. (D)
Metabolomic Experiment #2 - Histamine abundance. *p<0.05, **p<0.01, ***p<0.001
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Figure 29. Niacin and butyrate were more abundant in male than female BWF1
mice in Metabolomic Experiment #2, but not Metabolomic Experiment #3. For
Metabolite Experiments #2 & #3, feces were collected from 16-week-old female and
male BWF1 mice. Metabolites were extracted from feces using 80% methanol,
derivatized with MSTFA, analyzed by GCxGC-MS. Significantly different metabolites
were identified using pairwise Student’s t-tests (Tables 2,3). (A) Metabolomic
Experiment #2 - Niacin abundance (n=9). (B) Metabolomic Experiment #2 - Butyrate
abundance (n=3). (C) Metabolomic Experiment #3 - Niacin abundance (female n=8, male
n=6). (D) Metabolomic Experiment #3 - Butyrate abundance (female n=8, male n=6).
Outliers are indicated as triangles. ns=not significant, *p<0.05
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Figure 30. Three separate metabolomic analyses of female and male BWF1 feces
have found phytol elevated in male BWF1 mice. For Metabolite Experiments #1, #2 &
#3, feces were collected from 16-week-old female and male BWF1 mice. Metabolites
were extracted from feces using 80% methanol, derivatized with MSTFA, analyzed by
GCxGC-MS. Significantly different metabolites were identified using pairwise Student’s
t-tests (Tables 1-3). (A) Metabolomic Experiment #1 - Phytol abundance (female n=9,
male n=8). (B) Metabolomic Experiment #2 - Phytol abundance (n=9). (C) Metabolomic
Experiment #3 - Phytol abundance (female n=8, male n=6). **p<0.01, ***p<0.001
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Figure 31. Phytol and the phytol derivative, phytanic acid, are both upregulated in
intact male compared to both female and castrated male BWF1. For Metabolite
Experiment #3, feces were collected from 16-week-old female (n=8), intact male (Male;
n=6), and castrated (at ~24 days of age; n=6) male BWF1 mice. Metabolites were
extracted from feces using 80% methanol, derivatized with MSTFA, analyzed by
GCxGC-MS. Significantly different metabolites were identified using pairwise Student’s
t-tests (Tables 3-5). (A) Metabolomic Experiment #3 - Phytol abundance [420]. (B)
Metabolomic Experiment #3 – Phytanic Acid (PA) abundance. **p<0.01, ***p<0.001,
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Table 1. Metabolomic Experiment #1. Metabolites with significantly different abundance
between female and male BWF1 mice (female n=9, male n=8).
Name
Pentadecanoic acid
Methyl stearate
Phytol
1-Dichloromethyl(dimethyl)
silyloxyhexadecane
Arachidonic acid; cis-5,8,11,14Eicosatetraenoic acid
Paullinic acid
2-Hydroxysuccinic acid, Malic
acid
Succinic acid
Ferulic acid
Kynurenic acid; 4Hydroxyquinaldic acid
6-Hydroxynicotonic acid
3-Hydroxy-4methoxybenzaldehyde
3-Methylglutaconic acid
5-Hexen-1-ol,hex-5-en-1-ol
(E)-2-Butenoic acid, transCrotonic acid
5-Aminovaleric acid; Pentanoic
acid, 5-amino-

p-value
0.0027
0.0008
0.0005
0.0000

Fold change
Platform
(Male/Female)
3.23
GC×GC-MS_MSTFA
3.03
GC×GC-MS_MSTFA
2.22
GC×GC-MS_MSTFA
1.89
GC×GC-MS_MSTFA

0.0346

1.69

0.0395
0.0425

1.61
1.56

GC×GC-MS_MSTFA

0.0264
0.0230
0.0361

1.52
1.49
1.39

GC×GC-MS_MSTFA
GC×GC-MS_MSTFA

0.0032
0.0451

1.35
1.32

GC×GC-MS_MSTFA

0.0156
0.0300
0.0149

1.32
0.85
0.48

GC×GC-MS_MSTFA
GC×GC-MS_MSTFA

0.0193

0.47
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GC×GC-MS_MSTFA
GC×GC-MS_MSTFA

GC×GC-MS_MSTFA
GC×GC-MS_MSTFA

GC×GC-MS_MSTFA
GC×GC-MS_MSTFA

Table 2. Metabolomic Experiment #2. Metabolites with significantly different abundance
between female and male BWF1 mice (n=8).
Name

p-value

Nicotinic Acid
3-Hydroxy-3-methylglutaric
Acid
Nipecotic acid
11-Octadecenoic acid, methyl
ester
2-Pyrrolidone-5-carboxylic acid
4-Acetamidobenzaldehyde
7-Hexadecenoic acid, methyl
ester, (Z)Diethylene glycol
Glutamic Acid
Hexadecanoic acid, 15-methyl-,
methyl ester
6-Aminocaproic Acid
9,12-Octadecadienoic acid
(Z,Z)-, methyl ester
9,12,15-Octadecatrienoic acid
(Z,Z,Z)-, methyl ester
Benzotriazole
Hypoxanthine
N-Acetylputrescine
Phytol
Proline
cis-7-Tetradecenol
DL-α-Methoxyphenylacetic
Acid
Hypoxanthine
5-Aminovaleric acid
d-Mannose
Lysine
Malic Acid
Parabanic acid
Butyric Acid
L-Aspartic Acid
Niacin
Cerulenin
Hydroxy-L-Proline
Cadaverine
Serine
2-Aminobutyric Acid
Cyanuric acid

2.50E-03
2.63E-03

Fold change
(Male/Female)
12.50
5.26

1.10E-04
1.70E-04

4.35
4.00

2DLC-MS/MS (+)
GC×GC-MS_MSTFA

1.20E-02
2.82E-03
5.53E-05

2.78
2.70
2.56

GC×GC-MS_MSTFA
2DLC-MS/MS (+)
GC×GC-MS_MSTFA

0.00E+00
2.83E-02
6.80E-04

2.56
2.50
2.50

GC×GC-MS_MSTFA
2DLC-MS/MS (+)
GC×GC-MS_MSTFA

2.49E-03
5.31E-05

2.38
2.38

2DLC-MS/MS (+)
GC×GC-MS_MSTFA

1.10E-03

2.27

GC×GC-MS_MSTFA

1.04E-02
5.10E-03
2.70E-03
0.00E+00
9.64E-03
4.50E-03
7.72E-03

2.22
2.17
2.13
2.04
2.00
1.96
1.92

2DLC-MS/MS (+)
GC×GC-MS_MSTFA
GC×GC-MS_MSTFA
GC×GC-MS_MSTFA
2DLC-MS/MS (-)
GC×GC-MS_MSTFA
2DLC-MS/MS (-)

1.39E-02
4.30E-03
3.90E-02
1.28E-02
2.89E-02
6.80E-03
2.60E-02
1.71E-02
4.30E-02
2.70E-03
2.37E-02
4.20E-04
3.58E-05
4.15E-02
2.30E-02

1.89
1.72
1.72
1.69
1.69
1.69
1.61
1.61
1.61
1.59
1.59
1.54
1.54
1.52
1.52

2DLC-MS/MS (-)
GC×GC-MS_MSTFA
GC×GC-MS_MSTFA
2DLC-MS/MS (-)
2DLC-MS/MS (-)
GC×GC-MS_MSTFA
GC×GC-MS_MSTFA
2DLC-MS/MS (-)
GC×GC-MS_MSTFA
GC×GC-MS_MSTFA
2DLC-MS/MS (-)
GC×GC-MS_MSTFA
2DLC-MS/MS (-)
2DLC-MS/MS (+)
GC×GC-MS_MSTFA
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Platform
2DLC-MS/MS (+)
2DLC-MS/MS (-)

d-Galactose
D-Pinitol
3-tert-Butyladipic Acid
Histamine
Ribitol,
Serine
1,3-Propanediol
Tartaric Acid
Glycerol
1-Aminocyclohexanecarboxylic
Acid
D-Ribose
β-D-Talopyranose
Diethylamine
d-Glucose
Glycerol-3-phosphate
p-Coumaric acid
N,N-Diisopropylethylamine
Adipic Acid
4-Guanidinobutyric Acid
6-Hydroxypicolinic Acid
Pentadecanoic acid
Carnitine
6-Chloro-5-methyl-1H-1,2,3Benzotriazole
6-Hydroxycaproic Acid
Quinic Acid
Creatinine
Taurine
Pyridoxine
Linoleic Acid
Deoxycholic Acid
2-Aminonicotinic Acid
L-Histidinol
Pyridoxal
Glycylproline
8Z,11Z,14Z-Eicosatrienoic
Acid
4-Pyridoxic Acid
O-Phosphoethanolamine,
Triethanolamine
Taurine
Oleic Acid
β-Hydroxybutyric acid

5.90E-03
3.30E-03
3.11E-02
1.61E-02
4.00E-02
2.97E-02
1.20E-02
2.44E-02
2.00E-02
2.19E-02

1.47
1.47
1.43
1.41
1.39
1.37
1.35
1.33
1.32
1.30

GC×GC-MS_MSTFA
GC×GC-MS_MSTFA
2DLC-MS/MS (-)
2DLC-MS/MS (+)
GC×GC-MS_MSTFA
2DLC-MS/MS (+)
GC×GC-MS_MSTFA
2DLC-MS/MS (-)
GC×GC-MS_MSTFA
2DLC-MS/MS (+)

3.50E-02
4.30E-02
1.70E-02
4.00E-02
1.20E-02
2.20E-02
2.93E-02
2.17E-02
1.11E-02
2.97E-02
1.50E-02
1.53E-02
1.21E-02

1.28
1.27
1.16
0.87
0.80
0.71
0.62
0.60
0.58
0.58
0.58
0.52
0.51

GC×GC-MS_MSTFA
GC×GC-MS_MSTFA
GC×GC-MS_MSTFA
GC×GC-MS_MSTFA
GC×GC-MS_MSTFA
GC×GC-MS_MSTFA
2DLC-MS/MS (+)
2DLC-MS/MS (-)
2DLC-MS/MS (+)
2DLC-MS/MS (-)
GC×GC-MS_MSTFA
2DLC-MS/MS (+)
2DLC-MS/MS (-)

3.92E-02
4.03E-02
3.58E-02
4.48E-02
2.04E-02
4.87E-02
1.02E-04
4.62E-02
2.47E-03
3.81E-02
5.55E-03
3.53E-02

0.50
0.49
0.47
0.47
0.44
0.41
0.38
0.37
0.37
0.35
0.34
0.31

2DLC-MS/MS (-)
2DLC-MS/MS (-)
2DLC-MS/MS (+)
2DLC-MS/MS (-)
2DLC-MS/MS (+)
2DLC-MS/MS (-)
2DLC-MS/MS (-)
2DLC-MS/MS (+)
2DLC-MS/MS (+)
2DLC-MS/MS (+)
2DLC-MS/MS (+)
2DLC-MS/MS (-)

6.23E-04
1.50E-02
8.77E-05
1.05E-03
3.81E-02
1.80E-02

0.30
0.29
0.29
0.28
0.27
0.26

2DLC-MS/MS (-)
GC×GC-MS_MSTFA
2DLC-MS/MS (+)
2DLC-MS/MS (+)
2DLC-MS/MS (-)
GC×GC-MS_MSTFA
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Table 3. Metabolomic Experiment #3. Metabolites with significantly different abundance
between female and male BWF1 mice. (female n=8, male n=6)
Name
Phytanic acid
Phytanic acid
Benzoic acid
Adenine
5-Hydroxytryptophan
Ursolic acid
Adenine
Linolenic acid
Palmitelaidic acid
Phytol
Adenosine
Phytol
Xylose
Aminoadipic acid
Methylimidazoleacetic acid
Valine
2-Hydroxycaproic acid
Histamine
Myristic acid
Eicosapentaenoic acid
Valine
Isoleucine
Linoelaidic acid
Myristic acid
Isoleucine
Leucine
Rhamnose
Nonanoic acid
Palmitic acid
Pentadecanoic acid
Stearic acid
Methionine
Histidine
Glycerol-3-phosphate
Dodecanoic acid
Threonine
Alanine
Methionine
Alanine
Benzyl alcohol
Creatinine
N-Acetyl-histamine

Fold change
(Male/Female)
7.05E-03
Male only
1.51E-03
Male only
0.00E+00
5.26
1.26E-02
4.00
9.92E-03
3.33
3.48E-03
3.03
4.74E-02
2.50
1.73E-02
2.33
1.41E-03
2.33
3.58E-04
2.22
3.05E-02
2.17
2.95E-03
2.13
1.66E-02
2.08
1.20E-02
2.00
4.42E-02
2.00
3.42E-04
2.00
1.08E-02
1.96
1.73E-04
1.82
6.48E-04
1.82
3.13E-02
1.79
4.10E-04
1.79
2.32E-03
1.75
2.82E-02
1.72
3.30E-03
1.69
1.72E-02
1.64
3.19E-03
1.54
4.79E-02
1.52
3.50E-02
1.47
1.98E-02
1.39
2.92E-02
1.37
1.48E-02
1.30
7.80E-03
0.81
8.52E-03
0.76
3.47E-02
0.74
4.15E-02
0.73
1.57E-02
0.72
3.37E-02
0.71
4.58E-02
0.71
2.87E-03
0.70
1.21E-02
0.69
1.08E-02
0.69
1.37E-02
0.69
p-value
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Platform
GC×GC-MS_MSTFA
GC×GC-MS_MTBSTFA
GC×GC-MS_MTBSTFA
2DLC-MS/MS (+)
GC×GC-MS_MSTFA
2DLC-MS/MS (+)
2DLC-MS/MS (-)
GC×GC-MS_MSTFA
GC×GC-MS_MSTFA
GC×GC-MS_MSTFA
2DLC-MS/MS (+)
GC×GC-MS_MTBSTFA
GC×GC-MS_MSTFA
2DLC-MS/MS (-)
2DLC-MS/MS (+)
GC×GC-MS_MTBSTFA
2DLC-MS/MS (-)
2DLC-MS/MS (+)
GC×GC-MS_MSTFA
GC×GC-MS_MSTFA
GC×GC-MS_MSTFA
GC×GC-MS_MTBSTFA
GC×GC-MS_MSTFA
GC×GC-MS_MTBSTFA
GC×GC-MS_MSTFA
GC×GC-MS_MTBSTFA
GC×GC-MS_MSTFA
GC×GC-MS_MTBSTFA
GC×GC-MS_MSTFA
GC×GC-MS_MSTFA
GC×GC-MS_MSTFA
GC×GC-MS_MTBSTFA
2DLC-MS/MS (+)
GC×GC-MS_MTBSTFA
GC×GC-MS_MTBSTFA
2DLC-MS/MS (-)
2DLC-MS/MS (+)
2DLC-MS/MS (-)
GC×GC-MS_MTBSTFA
GC×GC-MS_MTBSTFA
2DLC-MS/MS (+)
2DLC-MS/MS (+)

Alanine
Maleic acid
5-Hydroxyindole-3-acetic
acid
Benzeneacetic acid
Choline
Glycine
Threonine
Isobutyric acid
Palmitoleic acid
Tryptophan
beta-Hydroxypyruvic acid
Azelaic acid
Histidine
Proline
Tryptophan
Lysine
3-Hydroxyphenylacetic acid
Fumarate
Proline
4-Hydroxy-proline
Methionine
Isovaleric acid
Lysine
Ornithine
Glucuronic acid
Heptadecanoic acid
Malate
Sucrose
Urea
Vanillin
Tyramine
Lactic acid
Malate
Uracil
2-Hydroxyisocaproic acid
Maltol
N-Acetyl-glutamic acid
Deoxycholic acid

2.62E-02
1.66E-02
3.30E-03
4.53E-02
1.96E-02
7.13E-03
4.28E-02
2.20E-02
2.32E-02
1.07E-02
1.07E-03
1.01E-02
2.67E-04
6.23E-03
1.83E-02
1.47E-03
2.22E-02
1.80E-05
1.01E-02
5.45E-03
2.55E-02
3.17E-03
6.06E-03
4.94E-02
2.78E-02
2.55E-03
2.54E-03
1.34E-03
3.29E-03
3.13E-02
8.80E-03
2.93E-02
4.19E-02
3.26E-02
2.01E-05
8.34E-04
3.44E-02
2.84E-06
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0.68
0.67
0.65
0.65
0.65
0.64
0.64
0.63
0.63
0.63
0.62
0.61
0.61
0.61
0.61
0.58
0.57
0.57
0.56
0.54
0.52
0.51
0.50
0.50
0.47
0.47
0.47
0.44
0.44
0.43
0.42
0.40
0.38
0.38
0.19
0.18
0.13
0.09

GC×GC-MS_MSTFA
GC×GC-MS_MTBSTFA
2DLC-MS/MS (+)
GC×GC-MS_MTBSTFA
2DLC-MS/MS (+)
GC×GC-MS_MTBSTFA
2DLC-MS/MS (+)
GC×GC-MS_MTBSTFA
GC×GC-MS_MTBSTFA
2DLC-MS/MS (+)
GC×GC-MS_MSTFA
GC×GC-MS_MTBSTFA
2DLC-MS/MS (-)
GC×GC-MS_MSTFA
2DLC-MS/MS (-)
2DLC-MS/MS (+)
GC×GC-MS_MTBSTFA
GC×GC-MS_MTBSTFA
GC×GC-MS_MTBSTFA
2DLC-MS/MS (-)
2DLC-MS/MS (+)
GC×GC-MS_MTBSTFA
2DLC-MS/MS (-)
2DLC-MS/MS (+)
2DLC-MS/MS (-)
GC×GC-MS_MTBSTFA
GC×GC-MS_MTBSTFA
2DLC-MS/MS (-)
GC×GC-MS_MTBSTFA
GC×GC-MS_MTBSTFA
GC×GC-MS_MSTFA
GC×GC-MS_MTBSTFA
2DLC-MS/MS (-)
GC×GC-MS_MTBSTFA
GC×GC-MS_MTBSTFA
GC×GC-MS_MTBSTFA
2DLC-MS/MS (-)
2DLC-MS/MS (-)

Table 4. Metabolomic Experiment #3. Metabolites with significantly different abundance
between intact male (Male) and castrated male (Castrated) BWF1 mice (n=6).
Name
Phytanic acid
Phytanic acid
3-Hydroxybutyric acid
2-Hydroxybutyric acid
Benzoic acid
Xylose
N6-Acetyl-lysine
Phytol
Isoleucine
Leucine
Adenosine
Valine
Isoleucine
Valine
Leucine
Asparagine
Phenylalanine
Leucine
5-Hydroxytryptophan
Glycerol
Phytol
Aminoadipic acid
Valine
Nonanoic acid
Thiamine
3-Hydroxybutyric acid
Phenylalanine
Methylimidazoleacetic
acid
Rhamnose
Tyrosine
Carnosine
Phenylalanine
Methionine
Phloretic acid
Cadaverine
Myristic acid
Glutamine
1-Methyl-histidine
2-Aminobutyric acid
N-Acetyl-glucosamine
Pinitol

p-value
9.30E-03
6.99E-03
3.05E-02
4.64E-02
5.08E-06
2.79E-06
5.83E-03
6.35E-06
6.70E-05
3.93E-05
6.08E-05
5.22E-04
8.52E-05
4.19E-05
4.45E-05
2.21E-02
4.52E-04
3.10E-04
1.93E-02
3.16E-04
7.47E-03
9.58E-05
4.29E-05
5.97E-05
2.08E-02
4.81E-02
1.57E-02
6.63E-03

Fold change
(Male/Castrated)
Male only
Male only
12.50
11.11
9.09
9.09
5.88
5.56
5.26
5.00
4.76
4.76
4.35
4.35
4.17
3.85
3.85
3.70
3.57
3.45
3.03
2.94
2.94
2.78
2.70
2.63
2.38
2.33

8.66E-05
1.02E-02
3.32E-04
2.41E-03
9.40E-03
3.44E-02
2.88E-02
8.52E-05
1.43E-02
7.82E-03
6.75E-03
1.88E-03
2.82E-03

2.33
2.33
2.27
2.27
2.13
2.13
2.08
2.08
2.04
1.96
1.96
1.92
1.89
149

Platform
GC×GC-MS_MSTFA
GC×GC-MS_MTBSTFA
2DLC-MS/MS (-)
2DLC-MS/MS (-)
GC×GC-MS_MTBSTFA
GC×GC-MS_MSTFA
2DLC-MS/MS (+)
GC×GC-MS_MTBSTFA
GC×GC-MS_MSTFA
2DLC-MS/MS (+)
2DLC-MS/MS (+)
GC×GC-MS_MSTFA
GC×GC-MS_MTBSTFA
GC×GC-MS_MTBSTFA
GC×GC-MS_MTBSTFA
2DLC-MS/MS (+)
GC×GC-MS_MTBSTFA
GC×GC-MS_MSTFA
GC×GC-MS_MSTFA
GC×GC-MS_MTBSTFA
GC×GC-MS_MSTFA
2DLC-MS/MS (-)
2DLC-MS/MS (+)
GC×GC-MS_MTBSTFA
2DLC-MS/MS (-)
GC×GC-MS_MSTFA
2DLC-MS/MS (-)
2DLC-MS/MS (+)
GC×GC-MS_MSTFA
2DLC-MS/MS (-)
2DLC-MS/MS (-)
2DLC-MS/MS (+)
GC×GC-MS_MSTFA
GC×GC-MS_MTBSTFA
GC×GC-MS_MSTFA
GC×GC-MS_MTBSTFA
2DLC-MS/MS (+)
2DLC-MS/MS (+)
GC×GC-MS_MTBSTFA
2DLC-MS/MS (+)
GC×GC-MS_MSTFA

Tyrosine
Histamine
Serine
Glyceric acid
Palmitelaidic acid
Aceturic acid
Carnosine
Ribose
Methionine
Diacetic acid
Methionine
Oleic acid
Oxalic acid
Methionine
Glutamine
Serine
Cytosine
4-Pyridoxic acid
Azelaic acid
Histidine
Azelaic acid
Fumarate
Proline
Glutaric acid
Creatinine
Creatinine
N6,N6,N6-Trimethyllysine
Pipecolic acid
Uracil
Pipecolic acid
2-Hydroxyphenylalanine
4-Hydroxy-Proline
N-Acetyl-histamine
Heptadecanoic acid
Lactic acid
Urocanic acid
3-Hydroxyphenylacetic
acid
Histidine
4-Hydroxy-proline
Succinate
Sucrose
Glutaric acid
Lysine
Threonine

2.49E-02
2.25E-04
1.67E-03
7.64E-03
2.15E-02
5.80E-03
4.00E-03
1.20E-02
2.17E-02
3.30E-03
3.17E-03
3.42E-02
7.86E-03
3.32E-03
6.05E-03
1.47E-02
1.00E-02
4.40E-02
4.02E-02
1.26E-02
4.04E-02
1.06E-02
1.98E-02
4.34E-02
9.66E-05
2.00E-03
2.50E-02
7.31E-04
4.26E-02
2.96E-03
8.32E-03
2.56E-02
5.29E-04
2.36E-03
1.63E-03
7.58E-04
4.58E-03
1.53E-04
3.32E-03
1.06E-02
3.23E-03
9.92E-04
3.08E-04
5.03E-03
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1.89
1.85
1.85
1.82
1.82
1.75
1.72
1.72
1.64
1.61
1.61
1.61
1.61
1.56
1.45
1.37
1.30
0.80
0.76
0.75
0.72
0.72
0.71
0.69
0.68
0.66
0.66

GC×GC-MS_MSTFA
2DLC-MS/MS (+)
GC×GC-MS_MTBSTFA
GC×GC-MS_MTBSTFA
GC×GC-MS_MSTFA
GC×GC-MS_MTBSTFA
2DLC-MS/MS (+)
2DLC-MS/MS (-)
2DLC-MS/MS (-)
GC×GC-MS_MTBSTFA
GC×GC-MS_MTBSTFA
GC×GC-MS_MSTFA
GC×GC-MS_MTBSTFA
2DLC-MS/MS (+)
2DLC-MS/MS (-)
2DLC-MS/MS (-)
GC×GC-MS_MTBSTFA
2DLC-MS/MS (+)
GC×GC-MS_MSTFA
2DLC-MS/MS (+)
2DLC-MS/MS (-)
GC×GC-MS_MTBSTFA
2DLC-MS/MS (+)
2DLC-MS/MS (-)
2DLC-MS/MS (+)
2DLC-MS/MS (-)

0.64
0.64
0.63
0.62
0.61
0.60
0.59
0.59
0.59
0.57

GC×GC-MS_MTBSTFA
GC×GC-MS_MSTFA
GC×GC-MS_MSTFA
2DLC-MS/MS (+)
2DLC-MS/MS (+)
2DLC-MS/MS (+)
GC×GC-MS_MTBSTFA
2DLC-MS/MS (-)
2DLC-MS/MS (+)

0.56
0.54
0.54
0.54
0.53
0.52
0.51

2DLC-MS/MS (-)
2DLC-MS/MS (-)
GC×GC-MS_MSTFA
2DLC-MS/MS (-)
GC×GC-MS_MSTFA
2DLC-MS/MS (+)
2DLC-MS/MS (-)

2DLC-MS/MS (+)

GC×GC-MS_MSTFA

Citrulline
Lysine
4-Hydroxybenzeneacetic
acid
Citrulline
Taurine
Pyroglutamic acid
Urocanic acid
beta-Hydroxypyruvic acid
Succinate
Aspartic acid
5-Hydroxyindole-3-acetic
acid
Maltol
Malate
Malate
Malate
2-Hydroxyisocaproic acid
N-Acetyl-glutamic acid

3.41E-02
5.43E-03
9.31E-03
2.67E-02
1.75E-03
4.52E-02
4.07E-05
7.63E-03
5.40E-04
2.78E-02
5.37E-05
1.58E-03
9.11E-04
4.44E-04
9.58E-06
3.62E-04
3.19E-06
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0.50
0.50
0.47

2DLC-MS/MS (-)
2DLC-MS/MS (-)

0.47
0.46
0.44
0.44
0.43
0.43
0.40
0.28

2DLC-MS/MS (+)
GC×GC-MS_MTBSTFA
GC×GC-MS_MSTFA
GC×GC-MS_MTBSTFA
GC×GC-MS_MSTFA
2DLC-MS/MS (-)
GC×GC-MS_MSTFA

0.26
0.23
0.20
0.19
0.18
0.06

GC×GC-MS_MTBSTFA
GC×GC-MS_MTBSTFA
GC×GC-MS_MSTFA
2DLC-MS/MS (-)
GC×GC-MS_MTBSTFA
2DLC-MS/MS (-)

GC×GC-MS_MSTFA

2DLC-MS/MS (+)

Table 5. Metabolomic Experiment #3 (2018). Metabolites with significantly different
abundance between female and castrated male BWF1 mice (female n=8, castrated n=6).
Name

p-value

Phenylalanine
Isoleucine
Methionine
Phenylalanine
3-Aminobutyric acid
Tyrosine
Phenylalanine
Leucine
Leucine
3-Hydroxybutyric acid
Norvaline
3-Hydroxybutyric acid
Isoleucine
Tyrosine
Leucine
Carnosine
Methionine
Hydroxyphenyllactic acid
Valine
Valine
Tryptophan
Oxalic acid
Carnosine
Methionine
4-Hydroxybenzoic acid
Methionine
Nonanoic acid
Tryptophan
Dodecanoic acid
Ornithine
Serine
Glycine
Urea
Citrate
Benzoic Acid
Benzeneacetic acid
Ribose
Diacetic acid
Tyrosine
N-Acetylneuraminic acid
Glutamine
Alanine

4.74E-05
1.78E-04
2.19E-03
5.66E-05
3.13E-03
9.92E-04
7.50E-06
9.65E-06
2.43E-04
3.65E-02
6.79E-03
1.17E-02
1.09E-03
1.27E-02
2.68E-03
3.06E-06
1.68E-04
4.54E-03
7.43E-04
2.97E-03
2.80E-04
1.48E-03
1.50E-05
9.48E-05
2.78E-02
2.96E-04
6.16E-03
3.47E-04
3.35E-03
2.82E-02
8.56E-05
5.82E-03
4.17E-02
2.84E-02
1.37E-02
1.79E-02
8.92E-04
8.22E-03
4.36E-03
4.22E-02
1.73E-03
5.86E-04

Fold change
(Female/Castrated)
3.37
3.21
3.12
3.03
2.98
2.98
2.86
2.75
2.74
2.68
2.68
2.56
2.48
2.37
2.36
2.31
2.31
2.29
2.25
2.15
2.02
2.01
1.98
1.98
1.92
1.91
1.87
1.87
1.83
1.82
1.81
1.79
1.77
1.74
1.73
1.69
1.68
1.66
1.66
1.65
1.60
1.54
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Platform
GC×GC-MS_MTBSTFA
GC×GC-MS_MSTFA
GC×GC-MS_MSTFA
2DLC-MS/MS (-)
GC×GC-MS_MTBSTFA
2DLC-MS/MS (-)
2DLC-MS/MS (+)
GC×GC-MS_MSTFA
GC×GC-MS_MTBSTFA
GC×GC-MS_MSTFA
GC×GC-MS_MSTFA
2DLC-MS/MS (-)
GC×GC-MS_MTBSTFA
2DLC-MS/MS (+)
2DLC-MS/MS (+)
2DLC-MS/MS (-)
2DLC-MS/MS (-)
2DLC-MS/MS (-)
2DLC-MS/MS (+)
GC×GC-MS_MTBSTFA
2DLC-MS/MS (-)
GC×GC-MS_MTBSTFA
2DLC-MS/MS (+)
GC×GC-MS_MTBSTFA
GC×GC-MS_MTBSTFA
2DLC-MS/MS (+)
GC×GC-MS_MTBSTFA
2DLC-MS/MS (+)
GC×GC-MS_MTBSTFA
2DLC-MS/MS (+)
GC×GC-MS_MTBSTFA
2DLC-MS/MS (-)
GC×GC-MS_MTBSTFA
GC×GC-MS_MTBSTFA
GC×GC-MS_MTBSTFA
GC×GC-MS_MTBSTFA
GC×GC-MS_MSTFA
GC×GC-MS_MTBSTFA
GC×GC-MS_MSTFA
2DLC-MS/MS (+)
2DLC-MS/MS (+)
GC×GC-MS_MTBSTFA

Glutamine
Ribose
Phloretic acid
Serine
Glycine
5-Aminovaleric acid
1-Methyl-L-histidine
Alanine
Serine
2-Hydroxyphenylalanine
Azelaic acid
Creatinine
Maleic acid
2-Hydroxyvaleric acid
N-Acetylhistamine
Pentadecanoic acid
Succinate
Succinate
4-Hydroxybenzeneacetic
acid
Malate
N-Acetyl-glutamic acid
alpha-Ketoglutaric acid
Malate

2.52E-03
1.36E-02
4.24E-02
9.09E-03
1.16E-02
1.86E-02
1.91E-04
4.18E-02
2.18E-03
2.71E-02
2.39E-02
9.63E-05
2.13E-02
3.05E-03
8.31E-04
3.45E-03
1.61E-04
3.49E-04
7.24E-03

1.53
1.50
1.49
1.45
1.44
1.37
1.36
1.31
1.30
0.79
0.79
0.74
0.74
0.63
0.62
0.55
0.55
0.53
0.52

2DLC-MS/MS (-)
2DLC-MS/MS (-)
GC×GC-MS_MTBSTFA
2DLC-MS/MS (+)
GC×GC-MS_MTBSTFA
2DLC-MS/MS (+)
2DLC-MS/MS (+)
2DLC-MS/MS (+)
2DLC-MS/MS (-)
2DLC-MS/MS (+)
2DLC-MS/MS (-)
2DLC-MS/MS (-)
2DLC-MS/MS (-)
2DLC-MS/MS (-)
2DLC-MS/MS (+)
GC×GC-MS_MSTFA
2DLC-MS/MS (-)
GC×GC-MS_MSTFA
GC×GC-MS_MSTFA

1.88E-02
1.73E-02
1.11E-02
2.41E-03

0.50
0.44
0.37
0.26

2DLC-MS/MS (-)
2DLC-MS/MS (-)
2DLC-MS/MS (-)
GC×GC-MS_MSTFA
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Table 6. Pathways affected by the metabolic differences between female and male
groups (female n=8, male n=6).
Name
Aminoacyl-tRNA biosynthesis
Glyoxylate and dicarboxylate metabolism
Tyrosine metabolism
Alanine, aspartate and glutamate metabolism
Citrate cycle (TCA cycle)
Glycine, serine and threonine metabolism
Arginine and proline metabolism
Purine metabolism
Fatty acid biosynthesis
Pantothenate and CoA biosynthesis
Histidine metabolism
Valine, leucine and isoleucine biosynthesis
Valine, leucine and isoleucine degradation
Lysine biosynthesis
Lysine degradation
Tryptophan metabolism
Selenoamino acid metabolism
Nitrogen metabolism
Pentose and glucuronate interconversions
Galactose metabolism
Glycerophospholipid metabolism
Pyruvate metabolism
Starch and sucrose metabolism
Cysteine and methionine metabolism
Biosynthesis of unsaturated fatty acids
alpha-Linolenic acid metabolism
Primary bile acid biosynthesis
Cyanoamino acid metabolism
Methane metabolism
Porphyrin and chlorophyll metabolism
Fatty acid elongation in mitochondria
Fatty acid metabolism
Glycerolipid metabolism
Glutathione metabolism
Biotin metabolism
Ascorbate and aldarate metabolism
Inositol phosphate metabolism
Glycolysis or Gluconeogenesis
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p-value

-LOG(p)

Impact

8.48E-07
1.10E-05
1.66E-05
4.42E-05
4.74E-05
4.96E-05
5.44E-05
3.75E-04
6.32E-04
7.11E-04
8.78E-04
9.35E-04
9.35E-04
1.65E-03
1.65E-03
2.25E-03
2.52E-03
2.72E-03
2.98E-03
3.44E-03
3.61E-03
3.94E-03
4.59E-03
7.08E-03
8.41E-03
9.99E-03
1.38E-02
1.38E-02
1.38E-02
1.38E-02
1.76E-02
1.76E-02
2.86E-02
2.89E-02
3.01E-02
3.18E-02
3.18E-02
3.20E-02

13.98
11.42
11.01
10.03
9.96
9.91
9.82
7.89
7.37
7.25
7.04
6.98
6.98
6.41
6.41
6.10
5.98
5.91
5.81
5.67
5.62
5.54
5.38
4.95
4.78
4.61
4.28
4.28
4.28
4.28
4.04
4.04
3.55
3.54
3.50
3.45
3.45
3.44

0.0000
0.0645
0.0269
0.0032
0.0721
0.2688
0.1914
0.0057
0.0000
0.0000
0.4624
1.0000
0.0000
0.0000
0.0000
0.1772
0.0000
0.0000
0.1333
0.0407
0.0889
0.0000
0.0000
0.0869
0.0000
1.0000
0.0298
0.0000
0.0000
0.0000
0.0000
0.0000
0.0256
0.0057
0.0000
0.4000
0.0000
0.0000

Table 7. Pathways affected by the metabolic differences between castrated and intact
male groups (n=6).
Name

p-value

Valine, leucine and isoleucine biosynthesis
Aminoacyl-tRNA biosynthesis
Lysine degradation
Valine, leucine and isoleucine degradation
Lysine biosynthesis
Histidine metabolism
Glyoxylate and dicarboxylate metabolism
Alanine, aspartate and glutamate metabolism
Pyruvate metabolism
Arginine and proline metabolism
Glycine, serine and threonine metabolism
Citrate cycle (TCA cycle)
Phenylalanine, tyrosine and tryptophan
biosynthesis
Phenylalanine metabolism
Nitrogen metabolism
Butanoate metabolism
Galactose metabolism
Tyrosine metabolism
Purine metabolism
Tryptophan metabolism
Propanoate metabolism
Biotin metabolism
Amino sugar and nucleotide sugar metabolism
Fatty acid biosynthesis
Taurine and hypotaurine metabolism
Primary bile acid biosynthesis
Cysteine and methionine metabolism
Glycerolipid metabolism
Methane metabolism
Cyanoamino acid metabolism
Sphingolipid metabolism
beta-Alanine metabolism
Glutathione metabolism
Starch and sucrose metabolism
Pyrimidine metabolism
D-Glutamine and D-glutamate metabolism
Pentose phosphate pathway
Thiamine metabolism
Synthesis and degradation of ketone bodies
Glycolysis or Gluconeogenesis
Vitamin B6 metabolism
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Impact

8.29E-07
9.30E-07
5.19E-06
1.28E-05
3.13E-05
4.66E-05
7.23E-05
7.84E-05
1.58E-04
1.75E-04
2.64E-04
2.92E-04

LOG(p)
14.00
13.89
12.17
11.27
10.37
9.97
9.54
9.45
8.75
8.65
8.24
8.14

3.86E-04
3.86E-04
4.00E-04
4.62E-04
4.64E-04
5.33E-04
6.17E-04
6.96E-04
8.92E-04
1.05E-03
1.09E-03
1.16E-03
1.80E-03
1.80E-03
2.39E-03
2.65E-03
3.63E-03
3.63E-03
3.63E-03
5.15E-03
5.29E-03
7.30E-03
9.26E-03
9.26E-03
1.17E-02
1.39E-02
1.78E-02
3.34E-02
3.91E-02

7.86
7.86
7.82
7.68
7.67
7.54
7.39
7.27
7.02
6.86
6.83
6.76
6.32
6.32
6.04
5.93
5.62
5.62
5.62
5.27
5.24
4.92
4.68
4.68
4.45
4.28
4.03
3.40
3.24

0.5000
0.4074
0.0000
0.1015
0.0407
0.0000
0.0010
0.0000
0.0000
0.0000
0.0692
0.0000
0.4286
0.0298
0.1122
0.3857
0.4000
0.0000
0.0000
0.0000
0.0143
0.0000
0.0000
0.0000
0.0000
0.4000
0.6000
0.0000
0.0000

0.6667
0.1290
0.0000
0.0000
0.0000
0.4624
0.1290
0.3460
0.0000
0.0944
0.2385
0.0977

Table 8. Pathways affected by the metabolic differences between female and castrated
male groups (female n=8, castrated n=6).
Name

p-value

Aminoacyl-tRNA biosynthesis
Histidine metabolism
Alanine, aspartate and glutamate metabolism
Valine, leucine and isoleucine degradation
Cysteine and methionine metabolism
Arginine and proline metabolism
Valine, leucine and isoleucine biosynthesis
Phenylalanine metabolism
D-Glutamine and D-glutamate metabolism
Sphingolipid metabolism
Phenylalanine, tyrosine and tryptophan biosynthesis
Butanoate metabolism
Tyrosine metabolism
Glycine, serine and threonine metabolism
Methane metabolism
Cyanoamino acid metabolism
Citrate cycle (TCA cycle)
Synthesis and degradation of ketone bodies
Selenoamino acid metabolism
Purine metabolism
Propanoate metabolism
Pentose phosphate pathway
Nitrogen metabolism
Tryptophan metabolism
Pyruvate metabolism
Pyrimidine metabolism
Fatty acid biosynthesis
Glyoxylate and dicarboxylate metabolism
Glutathione metabolism
Pantothenate and CoA biosynthesis
Primary bile acid biosynthesis
Porphyrin and chlorophyll metabolism
Ubiquinone and other terpenoid-quinone biosynthesis

2.15E-08
3.08E-06
3.22E-06
3.68E-06
5.71E-06
8.61E-06
1.17E-05
1.98E-05
3.78E-05
4.12E-05
4.19E-05
4.80E-05
5.04E-05
5.27E-05
5.27E-05
5.27E-05
1.21E-04
1.44E-04
1.45E-04
1.82E-04
4.87E-04
6.36E-04
1.03E-03
1.20E-03
1.20E-03
1.85E-03
1.97E-03
2.46E-03
2.81E-03
3.73E-03
7.80E-03
7.80E-03
8.80E-03
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-LOG(p) Impact
17.66
12.69
12.65
12.51
12.07
11.66
11.36
10.83
10.18
10.10
10.08
9.94
9.90
9.85
9.85
9.85
9.02
8.84
8.84
8.61
7.63
7.36
6.87
6.73
6.73
6.29
6.23
6.01
5.88
5.59
4.85
4.85
4.73

0.1290
0.0000
0.2131
0.0000
0.1122
0.1274
1.0000
0.4074
0.0000
0.0000
1.0000
0.1015
0.1405
0.5073
0.4000
0.0000
0.1924
0.6000
0.0000
0.0000
0.0000
0.0000
0.0000
0.1772
0.0000
0.0000
0.0000
0.2581
0.0057
0.0000
0.0298
0.0000
0.0000

SPECIFIC AIM 3
Sex-based differences in splenic macrophage efferocytosis may be
mediated by a male microbiota associated metabolite
Introduction
Like most autoimmune diseases, the multi-organ autoimmune disease systemic
lupus erythematosus (SLE) has a pronounced sex bias, as about 9 in every 10 people
affected by SLE are women [1,2,4-8]. There are complex genetic and environmental
factors that predispose individuals to SLE, and the mechanisms that play a role in its
development are still not completely understood. Cells and molecules of both the innate
and adaptive immune responses are clearly involved in the pathogenesis [494]. Lupus is
characterized by the activation of autoreactive T and B cells resulting in the production of
anti-nuclear autoantibodies that form immune complexes that are deposited in the skin,
kidneys, and other organs. The resulting inflammation is multiorgan can manifest as
lupus nephritis, vasculitis, pulmonary hypertension, or stroke, and over 50% of lupus
patients eventually develop one or more of these complications, and although there are
treatments that mitigate symptoms, there is no cure [3,5,9-13]. The NZBxNZW F1
(BWF1) mouse strain is an excellent spontaneous model of lupus, and exhibits many of
the features of the human disease including a definite sex bias. Female BWF1 mice
spontaneously develop anti-dsDNA autoantibodies, glomerulonephritis,
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lymphadenopathy, splenomegaly in a manner that resembles the progression of disease in
humans whereas male BWF1 have much lower disease incidence and severity [16].
Many innate immune activities play a major role in the initiation and progression
of lupus. Dendritic cells (DCs) present self-antigens to T cells, which then promote B cell
maturation [495]. Deficiencies in complement proteins result in impaired clearance of the
immune complexes that drive kidney inflammation [496], and plasmacytoid DCs produce
IFNα in response to these immune complexes, which promotes autoantibody production
[497]. However, all of these activities depend on the deficient macrophage phagocytosis
of apoptotic cells [371]. This process, known as efferocytosis, sequesters nuclear antigen
containing apoptotic debris away from other immune cells, suppressing the stimulation of
anti-nuclear autoantibody production [370]. Macrophages isolated from SLE patients or
lupus-prone female BWF1 mice are defective at phagocytosing apoptotic cells (i.e.,
efferocytosis) compared to healthy controls [386,391,392,498], and disease severity in
SLE patients is strongly correlated with deficient efferocytosis [380,493].
Several factors are thought to play roles in the higher incidence of SLE in
females. One is the incomplete inactivation of the X chromosome that can result in
overexpression of X-linked genes that are involved in the immune response and promote
autoimmunity [90-92]. Sex hormones are also thought to play a major role in both human
and BWF1 mouse sex bias. Female sex hormones, estrogens, are generally
immunostimulatory, and there is evidence that they promote lupus progression
[58,102,103]. On the other hand, male sex hormones, androgens, are strongly
immunosuppressive and anti-inflammatory and are believed to protect against lupus
[103,122-125]. Both women and men with SLE have decreased levels of androgens
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[115,138-144]. Additionally, SLE is more prevalent in men with Klinefelter syndrome,
who naturally have lower androgen levels and higher estrogen levels than XY males
[146,147]. Many innate and adaptive immune cells express androgen receptor, including
macrophages, monocytes, mast cells, neutrophils, B cells, and T cells [499]. The effects
of androgen signaling on immune cells are many and diverse. They include promoting
neutrophil differentiation, suppressing macrophage inflammatory responses to pathogens,
limiting T cell proliferation, promoting Treg expansion, and decreasing the numbers of
circulating B cells [499,500].
Accumulating evidence indicates that the gut microbiota can have a major impact
on immune functions systemically as well as locally. Consequently, the gut microbiota
can affect the progression of a large variety of diseases including autoimmune diseases.
[218,436]. Most autoimmune diseases, including SLE, are associated with dysbiosis, an
imbalance between beneficial microbes and potential pathobionts [184,256,257,276280,282,283], as well as altered microbial metabolite production [333-336,348,360-362].
An increasing number of studies have found that the intestinal microbiota of SLE patients
differs significantly from those of healthy controls [276-283,437]. Clearly, there is a
strong connection between lupus and the microbiota. Furthermore, sex also significantly
affects the microbiota, suggesting that sex-based differences in microbiota function could
potentially contribute to the sex bias of lupus [182,300-303]. We and others have found
sex differences in the gut microbiota in mouse models of autoimmune disease, including
lupus (Fig. 11) [323-325].
One of the major ways the microbiota can affect autoimmune diseases is via the
production of immunoregulatory metabolites [327], e.g., short chain fatty acids (SCFAs).
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Among many other anti-inflammatory effects, SCFAs can promote regulatory T-cell
induction and suppress inflammasome activation [328-332]. Multiple autoimmune
diseases including multiple sclerosis, IBD, and spondyloarthritis have been found to be
associated with decreased levels of SCFAs and SCFA-producing bacteria and
reconstitution of these metabolites can alleviate disease in mouse models of these
diseases [333-339]. Also, production of SCFAs and other metabolites can be affected by
androgens [218,324,420,436,501,502]. Considering the significant effect alterations in
immunomodulatory metabolites can have on autoimmune diseases, this suggests that sexbased differences in metabolites could contribute to the sex bias in lupus-prone BWF1
mice [327]. For this reason, we previously compared the fecal metabolomic profiles of
disease-prone female and castrated male BWF1 mice and disease-resistant intact male
BWF1 mice. The metabolomic profiles of these mice differed significantly, and we
identified several immunomodulatory metabolites that were elevated in the intact male
BWF1 mice compared to the female and castrated male BWF1 mice [420]. One of these
was phytol, which is produced from the breakdown of chlorophyll and has RXR and
PPARγ agonist activities [449,450]. Phytol is converted by host enzymes to phytanic
acid, which was completely absent from the female and castrated male BWF1 feces but
present in the BWF1 feces (manuscript in preparation). Phytanic acid has even more
potent agonist activity compared to its parent compound, phytol, and it strongly activates
the PPARγ/RXR, LXR/RXR, and PPARδ/RXR signaling complexes [449-453,463].
Phytanic acid could potentially affect disease progression in a number of ways, as these
pathways are involved in a wide range of immune processes central to lupus progression
[383,400,457,459,486].
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In this paper, we further investigate the functional differences in immune
activities between female and male BWF1 mice. The splenocyte transcriptomes of
disease-susceptible female BWF1 mice, and disease-resistant male BWF1 and female
BALB/c mice were compared using RNA sequencing (RNA-seq), and we found disease
resistance was associated with enrichment of phagocytosis-promoting genes. Based on
these data, we compared efferocytic activity in splenic macrophages from female and
male BWF1 mice and found that male macrophages were significantly more effective at
phagocytosing apoptotic cells than macrophages from female BWF1 mice. We found
similar differences in macrophage efferocytosis between intact and castrated male BWF1
mice, where macrophages from intact male BWF1 mice were significantly more effective
at phagocytosing apoptotic cells than macrophages from castrated male BWF1 mice.
Additional analysis of the RNA-seq data suggested that increased PPARγ and LXR
signaling might play a role in higher male efferocytic activity [393-399,503]. Our
previous metabolomic study had found that male BWF1 mice had higher than either
female or castrated male mice of a metabolite, phytol, which can activate those pathways
(Fig. 31A) [420,456]. Phytol’s derivative, phytanic acid, was also elevated in intact male
BWF1 mice and is an even more potent activator of the PPARγ and LXR pathways (Fig.
31B) [449-453,463]. In vitro and in vivo treatments with phytanic acid increased
macrophage efferocytosis and expression of the efferocytosis-promoting gene CD36. We
show that this effect is dependent on both LXR/RXR and PPARγ/RXR signaling. These
findings shed new light on how the microbiota can influence disease progression in the
BWF1 mouse model and could have implications on the development of novel lupus
therapies.
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Results
Splenic transcriptome and macrophage gene expression analysis suggests that male
BWF1 macrophages mice may have greater efferocytic activity
To investigate the sex differences in immune functions in BWF1 mice, we first
compared the splenocyte gene expression profile of adult disease-prone female BWF1
mice to disease-resistant male BWF1 and female BALB/c mice by RNA sequencing
(RNA-seq) [16,420]. Hierarchical clustering analysis of differentially expressed genes
revealed three prominent clusters of genes that varied between the three groups based on
strain, sex, or disease susceptibility (Fig. 32A). The heatmap of relative gene expression
shows that despite differing in sex and genetics, there is a significant cluster of genes
differentially regulated in both the disease-resistant male BWF1 and female BALB/c
mice compared to the disease-prone female BWF1 mice. This suggests that the lower
susceptibility to lupus in male BWF1 and female BALB/c mice is associated with
differential expression of a set of splenic genes. To investigate what specific biological
processes differed in the disease-prone and non-disease-prone mice, we performed Gene
ontology: Biological Process (GO:BP) analysis of the genes significantly upregulated in
male BWF1 or female BALB/c mice compared to the female BWF1 mice (Fig. 32B).
Functional analysis revealed similarities in some upregulated pathways between the
disease resistant male BWF1 and BALB/c female mice relative to female BWF1 mice.
Interestingly, both male BWF1 and female BALB/c spleens had increased levels of genes
that positively regulate phagocytosis. This matches previous studies which have shown
that apoptotic cell clearance by phagocytosis is deficient in SLE patients and mouse
models of lupus. There is significant evidence that this deficiency promotes lupus onset
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and progression [371,491,492]. Macrophages are the cells primarily responsible for
apoptotic cell phagocytosis, referred to as efferocytosis, and macrophages isolated from
SLE patients and lupus-prone mice have been shown to be intrinsically defective at
efferocytosis compared to healthy controls [379,387,504,505]. We examined the
phagocytosis-related genes that were enriched in male BWF1 mice (Table 9). One of
them, LRP1, is known to be expressed by macrophages and directly involved in
efferocytosis. It is a surface receptor that is specifically involved in binding apoptotic
cells and promoting their phagocytosis [506]. The RNA-seq analysis showing that the
expression of LRP1 is doubled in male macrophages (Fig. 32C) was confirmed using
qPCR and flow cytometry; male BWF1 CD11b+F4/80+ splenic macrophages express
higher levels of LRP1 than female BWF1 splenic macrophages (Fig. 32D,E; 33A; 40A).
Androgens have been associated with protection from lupus [115,140,143], and
we and others have found that castration dramatically accelerates and increases severity
of disease and decreases survival of male BWF1 mice [17,133,420]. To determine if
androgens affect LRP1 expression, male BWF1 mice were castrated and LPR1 mRNA
and protein expression were evaluated. Androgen depletion resulted in lower levels of
LRP1 mRNA and protein expression in castrated compared to intact male BWF1 splenic
macrophages (Fig. 32F,G; 40B). This lower expression of LRP1 correlates with the
greater susceptibility to lupus in castrated male BWF1 [420]. Taken together, these data
suggest that disease resistant intact male BWF1 mice appear to have more efficient
macrophage efferocytosis than disease-prone female and castrated male BWF1 mice.
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Splenic macrophages from intact male BWF1 mice have higher efferocytic activity
than macrophages from either female or androgen-depleted male BWF1 mice
Both SLE patients and lupus-prone mice exhibit deficient macrophage clearance
of apoptotic cells (efferocytosis), which results in accumulation of nuclear antigencontaining debris that promotes disease progression [371,391,491,492]. The spleen is a
major site of apoptotic cell clearance [379,387,504,505], and our analyses of splenocyte
and splenic macrophage gene expression suggested that macrophages from lupus-prone
female BWF1 mice might have deficient efferocytic activity compared to males (Fig. 32).
To investigate this, we compared the ability of splenic macrophages from female and
male BWF1 mice to phagocytose apoptotic cells. Adherent cells from digested spleens
were incubated with CTV-labeled apoptotic thymocytes and were analyzed by flow
cytometry to determine the percentage of F4/80+CD11b+ macrophages that had
phagocytosed the labeled apoptotic cells. Representative figures for this flow cytometry
assay are shown in Figure 34. As shown in Figure 35A, male BWF1 splenic
macrophages were significantly more efficient than female macrophages as shown by the
fold change of CTV+ macrophages. To control for the possibility of a bystander effect of
another adherent cell type, we repeated the assay using sorted F4/80+CD11b+ cells, and
confirmed that the male splenic macrophages had higher efferocytic activity compared to
female splenic macrophages (Fig. 35B).
Since we had found that androgen depletion via castration resulted in decreased
expression of the efferocytic receptor LRP1, we tested whether castration also reduced
macrophage efferocytosis using either adherent or sorted splenic macrophages from adult
castrated or intact male mice. We found that androgen depletion decreases splenic
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macrophage phagocytosis of apoptotic cells (Fig. 35C,D). Additionally, when mice were
treated with the androgen receptor blocker, flutamide, splenic macrophage efferocytosis
was decreased by comparison to vehicle-treated male controls (Fig. 35E). Since multiple
studies have found that androgen signaling either has no effect or even decreases
phagocytic activity in macrophages [507-511], the positive effect of androgen (as
indicated by our findings that both androgen depletion and androgen receptor signaling
blockade impair efferocytosis) on macrophage efferocytosis that we find in our studies
may not be due to a direct effect of androgen on macrophages. One way that androgen is
known to indirectly affect immune responses is by altering the production of
immunomodulatory metabolites produced by gut bacteria [218,436,501,502].

Treatment with a male microbiota-associated metabolite increases the ability of
female splenic macrophages to phagocytose apoptotic cells
Having established that male BWF1 macrophages are more efficient at efferocytosis, and
efferocytosis is impaired by androgen depletion, we next investigated the underlying
mechanisms. Transcription factor enrichment analysis of our RNA-seq data showed the
set of genes upregulated in male BWF1 vs female BWF1 spleens was enriched for genes
stimulated by LXR and PPARγ signaling (Fig. 36A; Table 10,11). PPARγ and LXR
stimulation are known to upregulate many efferocytosis-promoting genes, but this raised
the question of what was stimulating the LXR and PPARγ genes in the male splenocytes.
In a previous study, we found that feces from female, and intact and castrated male
BWF1 mice exhibit different metabolite profiles. In that study, we found differences in
the levels of a potentially immunomodulatory metabolite that could affect PPARγ and
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LXR signaling. The acyclic diterpene alcohol, phytol can activate both the PPARγ and
the LXR pathways [449,450,456], and was elevated in intact male BWF1 mice compared
to female and castrated male BWF1 mice [420]. Phytol is converted by host enzymes to
phytanic acid, which has similar but even more potent agonist activity compared to its
parent compound phytol, and strongly activates PPARγ/RXR, LXR/RXR, and
PPARδ/RXR signaling [449-453,463]. We have found that phytanic acid is completely
absent from female and castrated male BWF1 feces but present in intact male BWF1
feces (Unpublished data). Since signaling via the PPARγ/RXR, LXR/RXR or
PPARδ/RXR pathways is known to promote efferocytosis [381,393-400], we
hypothesized that phytanic acid could potentially increase the ability of splenic
macrophages to phagocytose apoptotic cells. To test this, female BWF1 adherent or
sorted splenic macrophages were pre-treated with phytanic acid then cultured with CTVlabeled apoptotic cells. Phytanic acid (PA) significantly increased the ability of female
BWF1 splenic macrophages to phagocytose apoptotic cells (Fig. 36B,C). Phytanic acid
also increased efferocytosis in macrophages from castrated male BWF1 mice (Fig. 36D).
These findings suggested that higher levels of phytanic acid and its precursor, phytol,
found in the male gut microbiota could contribute to the higher levels of splenic
macrophage efferocytosis found in males. If this is the case, then treating female BWF1
mice with phytanic acid in vivo should increase splenic macrophage efferocytosis. To test
this, female BWF1 mice were fed phytanic acid-containing microspheres that are taken
up by the gut and slowly release their payload [422,423]. After 4 weeks of treatment,
spleens were harvested and macrophage efferocytosis was evaluated in vitro.
Macrophages from female BWF1 mice fed phytanic acid-containing microspheres were
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significantly more efficient at efferocytosis than macrophages from female control mice
fed empty microspheres (Fig. 36E).
The intestinal production of phytanic acid’s precursor, phytol, is completely
dependent on gut microbiota metabolism [460-462]. Therefore sex-based differences in
the BWF1 microbiota are the most likely source of the elevated fecal levels of both
phytol and phytanic acid in male BWF1 mice compared to female BWF1 mice [420]. If
the male microbiota is the source of these metabolites, then transfer of male microbiota
into female mice should also enhance macrophage-mediated efferocytosis after transfer
into recipient female mice. To determine whether male microbiota could affect
macrophage function in female BWF1 mice, we transferred adult male BWF1 cecal
contents (containing the microbiota) into female BWF1 mice at regular intervals starting
at weaning and continuing until 16 weeks of age. At that time, we harvested the spleens
and assayed the efferocytic activity of the macrophages. We found that transfer of adult
male, but not female (negative control), cecal contents into female BWF1 mice increased
the ability of female splenic macrophages to phagocytose apoptotic cells to levels found
in positive control male mice that received male cecal contents (Fig. 36F). Altogether,
these data suggest that the male-upregulated microbiota metabolite, phytol and its
derivative phytanic acid could play a role in the sex differences in BWF1 macrophage
efferocytosis.
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Phytanic acid affects macrophage efferocytosis via LXR/RXR and PPARγ/RXR
pathways
Phytanic acid can stimulate PPARδ/RXR, LXR/RXR, and PPARγ/RXR signaling [449453,463], and each of these pathways can potentially stimulate macrophage phagocytosis
of apoptotic cells [381,393-400]. To investigate which pathways phytanic acid stimulates
to enhance macrophage efferocytosis, splenic macrophages from female BWF1 mice
were treated with phytanic acid along with inhibitors that block one or all of those
signaling pathways. We found that when RXR-mediated pathways were blocked with the
RXR antagonist HX531, phytanic acid treatment could no longer enhance macrophage
efferocytosis, suggesting that RXR pathways are required for phytanic acid action on
macrophages (Fig. 37A). Similarly, blocking the PPARγ/RXR heterodimer-mediated
pathway with the PPARγ antagonist, GW9662 or the LXR/RXR heterodimer-mediated
pathway with LXR antagonist, GSK2033 also prevented phytanic acid treatment from
increasing macrophage efferocytosis (Fig. 37B,C). These data indicate that activation of
both the PPARγ/RXR and LXR/RXR pathways is required for phytanic acid to increase
macrophage ability to phagocytose apoptotic cells, and their activities are not redundant.
However, inhibiting the PPARδ/RXR-mediated pathway with the PPARδ antagonist,
GSK0660 did not affect the enhancement of efferocytosis by phytanic acid, indicating
that phytanic acid does not act via the PPARδ pathway (Fig. 37D). In summary, phytanic
acid increases macrophage efferocytosis via a PPARγ and LXR pathway dependent
mechanism.

168

Phytanic acid may increase macrophage phagocytosis by upregulating the
expression of the pro-efferocytic receptor CD36
As described earlier (Fig. 32C-G), we have found that the efferocytosisassociated receptor, LRP1, was upregulated in intact male compared to female and
castrated male BWF1 mice. Interestingly, LRP1 has been shown to potentiate the effects
of LXR and/or PPARγ signaling, including the upregulation of other molecules
associated with efferocytosis in macrophages [415,512]. These data suggest that LXR
and/or PPARγ signaling could act, possibly in concert with LRP1 that is expressed at
higher levels in males, by upregulating surface receptors involved in efferocytosis. CD36,
MERTK, and TIMD4 are all surface receptors that are known to be directly involved in
efferocytosis in macrophages, and have been shown to be upregulated by LXR and/or
PPARγ signaling [372,384,393,396,404,408-410,412,413,513-521]. To determine
whether expression of any of these surface markers differs between female and intact and
castrated male macrophages and, could, therefore, potentially contribute to the
differences in efferocytosis between splenic macrophages from female and intact and
castrated male BWF1 mice, we analyzed their expression via flow cytometry. We found
that while MERTK and TIMD4 expression did not differ between female and male
BWF1 macrophages, CD36 was expressed at higher levels in male BWF1 splenic
macrophages compared to female mice (Fig. 38A; 33B; 40C-E). AXL, MFGE8, and
C1QA are also involved in efferocytosis and upregulated by LXR and/or PPARγ, and
defects in them are associated with lupus [375,382,393,400,405,522-533]. To evaluate
AXL, MFGE8, and C1QA expression, we compared mRNA levels of these molecules by
qPCR in sorted splenic macrophages from female and male BWF1 mice, but found no
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differences in expression (Fig. 39). Additionally, CD36 was also expressed at higher
levels in intact male compared to castrated male BWF1 mice (Fig. 38B; 40F). CD36 can
be regulated by LXR and/or PPARγ signaling [393,409,410], and we have found that
phytanic acid can affect efferocytosis via signaling through one or both of these pathways
(Fig. 37A-C). For these reasons, we determined whether in vitro treatment of female or
castrated male macrophages with phytanic acid could upregulate CD36. Treatment with
phytanic acid in vitro induced increased CD36 expression in both female and castrated
male BWF1 macrophages. (Fig. 38C,D; 40G,H), and feeding microspheres containing
phytanic acid to female BWF1 mice also increased CD36 expression in splenic
macrophages (Fig. 38E, 40I). Since CD36 is involved in phagocytosis of apoptotic cells
and phytanic acid increases both CD36 and phagocytosis of apoptotic cells, we wondered
whether phytanic acid could be enhancing phagocytosis of apoptotic cells by
upregulating CD36 expression. To determine whether CD36 is required for phytanic acid
mediated enhanced phagocytosis of apoptotic cells, we cultured female macrophages
with phytanic acid and a CD36-blocking antibody. When CD36 was blocked, there was
no difference in the ability to phagocytose apoptotic cells between phytanic acid and
vehicle treated-macrophages (Fig. 38F), suggesting that CD36 is, at least, required for
phytanic acid's effects on macrophage phagocytic activity. Taken together, these data
suggest that a male microbiota-associated metabolite, phytanic acid, can enhance
efferocytosis in female and castrated male BWF1 macrophages. This effect is dependent
on LXR and PPARγ signaling and is abrogated by blocking the pro-efferocytic receptor
CD36 (Fig. 41).
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Discussion
The incidence of severe glomerulonephritis and kidney failure in SLE patients has
changed little since the 1990s as progress in the development of new treatments for SLE
has plateaued [177-179]. A more complete understanding of the factors contributing to
lupus incidence and progression could potentially allow the development of new
paradigms of SLE management. One area that is not fully understood is what factors
make women and males with Klinefelter’s much more susceptible to SLE [1,4,6-8].
Higher dosage of X-linked immune genes due to incomplete X-inactivation has been
proposed as a cause of this sex bias [90-92]. The higher levels of immune-promoting
estrogen hormones and lower levels of immunosuppressive androgen hormones have also
been shown to contribute to the higher incidence in women and men with Klinefelter’s
syndrome [146,147,149-152]. The BWF1 mouse model of lupus as the course of disease
closely mimics the characteristics of SLE humans. Incidence of autoantibodies and
glomerulonephritis is much higher in female BWF1 mice, and androgens protect against
disease [16,17,133]. However, while the sex differences in disease progression are well
characterized, the immunological differences that make BWF1 female mice susceptible
and male BWF1 mice resistant are largely unexplored. Here we compared the splenic
transcriptomes of disease-prone female BWF1 mice to disease resistant male BWF1 mice
and healthy control BALB/c mice. We found that a significant cluster of genes was
similarly regulated in the male BWF1 and female BALB/c mice in comparison to the
disease-prone female BWF1 mice. The fact that a subset of genes varied not by sex or
stain, but by disease susceptibility suggested that the lower lupus susceptibility of male
BWF1 mice could be related to differences in splenic immune processes. Subsequent
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functional analysis of genes upregulated in male BWF1 and female BALB/c compared to
female BWF1 found similarities in what functional processes were enriched in the two
disease-resistant groups compared to the disease-prone group. Of particular note was an
enrichment in the positive regulation of phagocytosis in both the male BWF1 and female
BALB/c. This was significant because a deficiency in the clearance of apoptotic cells by
phagocytosis is associated with increased lupus susceptibility [371,491,492].
The process by which phagocytes engulf apoptotic and necrotic cells is called
efferocytosis [370]. This process allows the removal apoptotic debris in a manner that
promotes anti-inflammatory responses. This is crucial to the maintenance of selftolerance, as stimulation of immune responses against apoptotic cells and the selfantigens they contain could result in autoimmunity [371]. Rapid ingestion of apoptotic
cells prevents the potentially autoimmune stimulating antigens from being exposed to
other immune cells and potentially driving immune responses. At the same time, the antiinflammatory cytokines produced by the phagocytes suppress nearby immune cells that
may have been exposed to the apoptotic debris [370-372]. Macrophages are the cells
primarily responsible for efferocytosis, and defects in macrophage efferocytosis are
strongly associated with the development of SLE. Macrophages from SLE patients
exhibit reduced ability to phagocytose apoptotic cells, and accumulation of apoptotic
cells is seen in SLE patient tissues [370,371,380,493,523]. This defect is also present in
murine models of lupus, as peritoneal macrophages from female BWF1 mice are
deficient at efferocytosis compared to healthy control female BALB/c mice [391]. Our
findings from the RNA-seq suggested that the sex bias of lupus in BWF1 mice might be
partially due to deficient efferocytic activity in female BWF1 mice. If male BWF1
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splenic macrophages are like those of healthy control mice and are intrinsically more
efficient at efferocytosis, we would expect them to express higher levels of genes directly
involved in the efferocytic process. We examined the pro-phagocytosis genes upregulated
in male BWF1 compared to the disease-prone female BWF1 mice and we identified one
gene, LRP1, which is expressed in macrophages and is responsible for binding apoptotic
cells and promoting their ingestion [405,506]. The other phagocytosis promoting genes
are either not expressed in macrophages (SFTPA1) or not directly involved in
phagocytosis (IL2RB, RAC2, and IL1B) [534-538]. Measuring expression in sorted male
and female BWF1 splenic macrophages showed that male splenic macrophages do
express higher levels of LRP1. Also, macrophages from androgen depleted lupus-prone
male BWF1 mice expressed lower levels of LRP1 compared to intact male BWF1 mice.
Together, these findings support the theory that there could be a sex-based difference in
splenic macrophage efferocytic efficiency.
Based on these findings, we compared the ability of female and male BWF1
splenic macrophages to phagocytose apoptotic cells, and found male BWF1 splenic
macrophages are more efficient at efferocytosis. Furthermore, this difference was
androgen dependent, as male BWF1 mice that had undergone androgen depletion by
castration had splenic macrophage with deficient efferocytosis compared to macrophages
from intact male BWF1 mice. This finding that male BWF1 mice exhibit increased
splenic macrophage efferocytosis in an androgen dependent manner sheds new light on
the causes of sex bias in the lupus BWF1 mouse model. An early study on lupus in the
BWF1 mouse strain found that while removal of the spleen had no effect on the
progression of disease in female mice, in the male mice splenectomy resulted in
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accelerated anti-nuclear antibody development and decreased survival [539]. Our
findings suggest a possible explanation for this sex-based difference in the effect of
spleen removal. The spleen is a major site of apoptotic cell clearance [379,387,504,505],
and reductions in the body’s ability to clear apoptotic cells promote lupus progression
[371,391,491,492]. The increased disease in splenectomized male mice could, therefore,
be driven by an increase in the accumulation of apoptotic debris. Since, as our findings
show, splenic macrophages in male BWF1 mice are more efficient at efferocytosis than
those from female BWF1 mice, the removal of the spleen would have a bigger impact on
the overall apoptotic cell clearing ability of the male mice.
While we had identified a defect in splenic macrophage efferocytosis in female
and androgen-depleted male BWF1 mice, the source of the defect was not clear. The
defect was linked to lower levels of androgen signaling (i.e., due to depletion of
androgens by castration), which raised the question of whether macrophages, which are
known to express androgen receptors, could be directly affected by androgens to increase
phagocytosis of apoptotic cells. However, an examination of the literature shows that this
is unlikely. Multiple studies have found either that treatment with androgens actually
suppressed macrophage phagocytic activity [508,540-543], or that androgen treatment
had no effect on macrophage phagocytosis [544,545]. Estrogen, conversely, generally has
a pro-phagocytic effect [546,547]. These opposite effects of sex hormones may be why
macrophages from healthy female rats and mice have been shown to have higher
phagocytic activity than those from male rats and mice [74,75]. However, it has also been
shown that castration of male mice decreases peritoneal macrophage phagocytic activity
[548]. Taken together, this suggests that androgens are important for macrophage

174

phagocytosis, but that this effect is not mediated by a direct androgen-macrophage
interaction.
One way that androgens can indirectly influence the immune system is by altering
intestinal metabolite profiles. Androgens can affect both host and microbial metabolic
activities, and alterations in metabolite production can have a major on the immune
system [218,324,436,501,502]. In our studies described in the Metabolite section of this
dissertation, we explored the functional differences between intact male and female
BWF1 microbiota by comparing their fecal metabolite levels. We found that in all three
experiments, male mice had higher levels of phytol (Fig. 30), a metabolite which is
derived from chlorophyll and exhibits RXR and PPARγ agonist activity [420]. We also
found phytol abundance was greater in intact than castrated male BWF1 mice (Fig. 31A).
Once phytol is absorbed from the intestine it is converted to phytanic acid, which readily
travels in the bloodstream and is an even more potent agonist activity than phytol and
activates the PPARγ/RXR, PPARδ/RXR, and LXR/RXR heterodimeric signaling
complexes [393-399,503]. When BWF1 fecal phytanic acid levels were tested, only the
male feces had detectable levels; it was completely absent from the female and castrated
male feces (Fig. 31B).
LXR/RXR and PPARγ/RXR signaling are known to promote efferocytosis via
many different mechanisms [381,393,397,404,409,410,414,549-560]. Also, our RNA-seq
data showed that male BWF1 splenic macrophages expressed higher levels of LXR and
PPARγ-stimulated genes. This made the phytanic acid an obvious candidate for
investigation as a source of the sex and sex-hormone-based differences in macrophage
efferocytosis. We investigated the effect of phytanic acid treatment on female BWF1
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splenic macrophages, and found that it increased their efferocytic activity. We also
performed these experiments with splenic macrophages from androgen-depleted male
BWF1 mice, and found similar results. This suggests that treatment with phytanic acid
might be able to correct the deficiency in efferocytosis that correlates with lower
androgen signaling. The naturally higher levels of phytanic acid and its precursor, phytol,
in male BWF1 mice may contribute to the higher level of efferocytosis in male BWF1
splenic macrophages. This hypothesis was strengthened by the fact that female BWF1
mice treated with phytanic acid had macrophages with higher efferocytic activity.
While mammals can convert phytol into phytanic acid, they lack the genes to
produce phytol [460-462]. Therefore, the intestinal microbiota is the most likely source of
the increased levels of phytol and phytanic acid seen in intact male BWF1 mice. This fits
with the findings of recent studies in the literature, which have suggested that the gut
microbiota could be a source of the sex bias seen in lupus. Studies have found that
patients with systemic lupus erythematosus and other autoimmune diseases have been
found to have dysbiotic (disrupted) microbiomes [184,256,257,276-280,282,283].
Multiple mechanisms by which the microbiota can influence the immune system have
been identified, including molecular mimicry of self-antigens, direct interactions with
intestinal immune cells that induce differentiation, and the production of
immunomodulatory metabolites [218,436]. Furthermore, sex hormones can significantly
affect the microbiota, suggesting that BWF1 mouse androgens levels could affect lupus
progression by influencing the composition and functions of the microbiota [276280,282,283,300-302]. This possibility was supported by the findings of two recent
studies, which showed that the sex bias in the NOD model of Type 1 diabetes was linked
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to differences in microbiota composition between male and female mice. They found that
male mice contained a higher abundance of microbes that could protect them against
developing diabetes, and that in the absence of the microbiota, the sex bias was absent
[323,324]. One of the studies found that disease was suppressed in female NOD mice that
received a microbiota transfer from male NOD mice. However, this protective microbiota
phenotype was dependent on androgen, showing that the immune system, sex hormones,
and the microbiota are closely interconnected [324]. Also, a recently published paper on
the SWRxNZB F1 (SNF1) mouse model found differences in microbiota composition
between intact male, androgen-depleted male, and female mice, but failed to find that
these alterations significantly affected disease progression. However, the fact that they
also found androgen depletion didn’t significantly alter disease progression suggests that
their model may not have been well suited to studying the relationship between sex
hormones, the microbiota, and lupus [26]. We have also found differences in microbiota
composition in feces between female and male, and intact and castrated male BWF1
mice. To investigate whether these differences were connected to the differences in
efferocytosis, we transferred male microbiota into female BWF1 mice and found it
improved splenic macrophage efferocytosis. This suggested that the sex differences in
BWF1 splenic macrophage efferocytosis may be mediated in part by the microbiota.
These findings have obvious implications for potential SLE therapeutics.
Increasing macrophage efferocytosis could potentially suppress lupus progression. In
fact, there is some evidence that glucocorticoid therapy acts in part by increasing
efferocytosis, but long-term use of glucocorticoid-based therapy is associated with
irreversible side effects and in some cases can lead to a Th17/Th1 imbalance that
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promotes inflammation [178,561,562]. However, the agonist activity of phytanic acid is
too nonspecific for it to be a viable therapy, since it can activate any permissive RXRcontaining heterodimer. For our findings to inform future research, it was crucial to
understand what pathways are involved in the pro-efferocytic effect of phytanic acid.
Phytanic acid can stimulate signaling through the PPARδ/RXR, LXR/RXR, and
PPARγ/RXR complexes [449-453,463], and all of these pathways can stimulate
macrophage phagocytosis [381,393-400]. However, we conclusively showed that the proefferocytosis effect of phytanic acid is dependent on LXR/RXR and PPARγ/RXR
signaling but not on PPARδ/RXR signaling.
This leaves open the question of what LXR and/or PPARγ stimulated genes is
phytanic acid upregulating to promote phagocytosis. We compared female and male
BWF1 splenic macrophage expression of canonical efferocytic mediators that are
stimulated by PPARγ and/or LXR agonists. AXL, MFGE8, and C1QA fit these criteria,
and defects in their expression are associated with lupus [375,382,393,400,405,522-533],
but we found no differences in splenic macrophage transcript levels between male and
female BWF1 mice. We also tested CD36, MERTK, and TIMD4 protein levels, since
they are well established important mediators of efferocytosis [372,384,393,396,404,408410,412,413,513-521]. Of these three, only the pro-efferocytic receptor CD36 exhibited a
sex-based difference in expression. CD36, a cell surface receptor that binds apoptotic
cells and facilitates their phagocytosis [408], was expressed at higher levels in male
BWF1 than female BWF1 splenic macrophages. Macrophages from castrated male
BWF1 mice also had decreased CD36 expression compared to intact male BWF1 mice.
CD36 expression can be enhanced by LXR and/or PPARγ signaling, and its expression

178

was highest in male BWF1 mice, which have been found to have higher levels of
intestinal metabolites, phytol and phytanic acid, which can activate these receptors [420].
We found treating splenic macrophages with phytanic acid increased their levels of CD36
expression, and feeding female BWF1 mice phytanic acid-containing microspheres
increased splenic macrophage CD36 expression. This suggests that the higher levels of
CD36 expression in male BWF1 splenic macrophages could be due to higher production
of phytanic acid and its precursor phytol in the intestine. Furthermore, functional CD36 is
required for phytanic acid’s enhancement of macrophage efferocytosis, which suggests
there could be a link between phytanic acid’s ability to upregulate CD36 and its ability to
improve macrophage efferocytosis.
In conclusion, we have shown that disease-resistant male BWF1 mice have
splenic macrophages that are more efficient at efferocytosis than macrophages from
disease-prone female or androgen depleted castrated male BWF1 mice. This deficiency
can be ameliorated by treatment with the metabolite phytanic acid, which is more
abundant in males and activates the efferocytosis-promoting LXR and PPARγ pathways.
This effect of phytanic acid may be mediated in part by upregulating CD36 expression.
Transferring microbiota from male BWF1 to female BWF1 mice also increases
macrophage phagocytosis, which supports the hypothesis that differences in microbiota
metabolite production between male and female BWF1 mice result in differences in
macrophage phagocytosis of apoptotic cells. This sex-based difference in efferocytosis
could contribute to lupus progression, which sheds new light on the source of the sex bias
in the BWF1 mouse model of lupus and suggests possible avenues of research into new
treatments for lupus.
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Splenocyte RNA-seq

Figure 32. Splenocyte transcriptome and macrophage gene expression analyses
indicate that male BWF1 macrophages may have greater efferocytic activity.
Splenocytes from 16-week-old female and male BWF1, and female BALB/c mice were
collected and gene expression was analyzed by RNA-seq. (A) Heat map of hierarchically
clustered differentially expressed genes in splenocytes from female BALB/c, and female
and male BWF1 mice (n=3). (B) Selected GO:BP pathways enriched in male BWF1 and
female BALB/c compared to female BWF1 splenocytes. (C) Lrp1 normalized read levels
in female and male BWF1 splenocytes. (D) F4/80+CD11b+ splenic macrophages from 16week-old female and male BWF1 mice were sorted and Lrp1 transcript levels were
measured by qPCR (n=6). (E) Expression of LRP1 16-week-old female and male BWF1
CD11b+F4/80+ +splenic macrophages measured by flow cytometry as mean fluorescence
intensity (MFI) fold difference (n=5). (F) CD11b+F4/80+splenic macrophages from 16week-old intact and castrated male BWF1 mice were sorted and Lrp1 transcript levels
were measured by qPCR (n=6). (G) Expression of LRP1 16-week-old intact and castrated
male BWF1 CD11b+F4/80+ splenic macrophages measured by flow cytometry as mean
fluorescence intensity (MFI) fold difference (n=5). *p<0.05, **p<0.01, ***p<0.001
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Figure 33. Representative histograms of LRP1 and CD36 labeling of female vs male
CD11b+F4/80+ cells. Splenocytes from 16-week-old female or male BWF1 mice were
collected and labeled with CD11b, F4/80 and LRP1 or CD36 antibodies and analyzed by
flow cytometry. Expression of LRP1 or CD36 by CD11b+F4/80+ cells was evaluated.
Fluorescence-minus-one controls (FMO Ctl) were used.
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Figure 34. Representative gating of CD11b+F4/80+ cells among adherent cells that
were positive for the apoptotic thymocyte marker CellTraceTM Violet (CTV).
Splenocytes from 16-week-old female and male BWF1 mice were collected and
macrophages enriched by selecting for adherent cells. Phagocytosis of apoptotic cells by
macrophages was assayed by culture with CellTraceTM Violet (CTV)-labeled apoptotic
thymocytes for one hour followed by analysis of percentages of CD11b+F4/80+ cells that
were CTV+.
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Figure 35. Splenic macrophages from disease-prone female or castrated male BWF1
mice are deficient in their ability to phagocytose apoptotic cells compared to diseaseresistant intact male BWF1 mice. Splenocytes from 16-week-old BWF1 mice were
collected and macrophages either enriched by selecting for adherent cells or sorted for
CD11b+F4/80+ cells by FACS. Phagocytosis of apoptotic cells by macrophages was
assayed by culture with CellTraceTM Violet (CTV)-labeled apoptotic thymocytes for one
hour followed by analysis of percentages of CD11b+F4/80+ cells that were CTV+. (A)
Adherent splenocytes from female or male BWF1 mice were labeled with CD11b and
F4/80 antibodies, and CD11b+F4/80+ cells evaluated for %CTV+ n=6). (B) Sorted
CD11b+F4/80+macrophages from female or male BWF1 mice were evaluated for %CTV+
cells (n=9). (C) Adherent splenocytes from intact male or castrated male BWF1 mice
were labeled with CD11b and F4/80 antibodies, and CD11b+F4/80+ cells evaluated for
%CTV+ (n=6-7). (D) Sorted CD11b+F4/80+macrophages from intact male or castrated
male BWF1 mice were evaluated for %CTV+ cells (n=6). (E) Adherent splenocytes from
male BWF1 mice implanted with time-release pellets containing vehicle or androgen
receptor inhibitor, flutamide, were labeled with CD11b and F4/80 antibodies, and
CD11b+F4/80+ macrophages were evaluated for %CTV+ cells (n=8). Data are reported as
fold change (FC) in %CTV+ cells. *p<0.05, **p<0.01, ***p<0.001
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Figure 36. A male microbiota associated metabolite, phytanic acid, increases the
ability of adult BWF1 splenic macrophages to phagocytose apoptotic cells. (A) Gene
expression in female and male splenocytes from 16-week-old BWF1 mice was
determined by RNA-seq. Metacore Transcription Factor Enrichment analysis shows the
fold-enrichment of upregulated genes in male vs female splenocytes that are controlled
by the transcriptional regulators PPARγ and LXRβ (n=3). Splenocytes from 16-week-old
female (B, C) or castrated male (D) BWF1 mice were collected and macrophages either
enriched by selecting for adherent cells and labeling with CD11b and F4/80 antibodies
(B) or sorted for CD11b+F4/80+ cells by FACS (C, D). Cells were pre-treated with 50 μM
phytanic acid (PA) or ethanol (Vehicle) for 48 hours then phagocytosis of apoptotic cells
by macrophages was assayed by culture with CellTraceTM Violet (CTV)-labeled
apoptotic thymocytes for one hour followed by analysis of percentages of CD11b+F4/80+
cells that were CTV+ (B, C, D; n=6-7). (E) Female BWF1 mice were treated with PBS
(Vehicle) or phytanic acid (PA) encapsulated in microspheres 3x per week for 4 weeks
beginning at 12 weeks of age then splenocytes were collected and sorted for
CD11b+F4/80+ cells by FACS. Phagocytosis of apoptotic cells by macrophages was
assayed by culture with CTV-labeled apoptotic thymocytes for one hour followed by
analysis of percentages of CD11b+F4/80+ cells that were CTV+ (n=8). (F) Twenty-fourday-old (shortly after weaning) female BWF1 mice were fed cecal contents from adult
female (negative control) or male (experimental) BWF1 mice, or 24-day-old male BWF1
mice were fed cecal contents from adult male BWF1 mice (positive control). Mice were
then fed cecal contents monthly until 16 weeks of age when splenocytes were collected
and sorted for CD11b+F4/80+ cells by FACS. Phagocytosis of apoptotic cells by
macrophages was assayed by culture with CTV-labeled apoptotic thymocytes for one
hour followed by analysis of percentages of CD11b+F4/80+ cells that were CTV+ (n=6).
Data are reported as fold change (FC) in %CTV+ cells (B-F). *p<0.05, **p<0.01,
***p<0.001, ****p<0.0001
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Figure 37. Phytanic acid increases macrophage phagocytosis in an LXR/RXR and
PPARγ/RXR dependent, and PPARδ/RXR independent manner. Splenocytes from
adult female BWF1 mice were collected and sorted for CD11b+F4/80+cells by FACS.
Cells were pre-treated with 50 μM phytanic acid (PA), ethanol (Vehicle) and/or nuclear
receptor (RXR, PPARγ, LXR, PPARδ) inhibitors for 48 hours then phagocytosis of
apoptotic cells by macrophages was assayed by culture with CellTraceTM Violet (CTV)labeled apoptotic thymocytes for one hour followed by analysis of percentages of
CD11b+F4/80+ cells that were CTV+. (A) 10 μM of RXR inhibitor HX531 (n=10). (B) 10
μM of PPARγ inhibitor GW9662 (n=10). (C) 5 μM of LXR inhibitor GSK2033 (n=10).
(D) 10 μM of PPARδ inhibitor GSK0660 (n=10). Data are reported as fold change (FC)
in %CTV+ cells. **p<0.01, ***p<0.001, ****p<0.0001
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Figure 38. Male splenic macrophages express higher levels of CD36, and phytanic
acid increases CD36 expression. Splenocytes from 16-week-old female, male, or
castrated male BWF1 mice were collected and labeled with CD11b, F4/80, and proefferocytic receptor (CD36, MERTK, or TIMD4) antibodies and analyzed by flow
cytometry. Expression is shown as mean fluorescence intensity (MFI) fold difference and
comparisons were done with Student’s t-tests. (A) CD36, MERTK, and TIMD4
expression in female and male CD11b+F4/80+ cells (n=5). (B) CD36 expression in intact
and castrated male CD11b+F4/80+ cells (n=5). (C) CD36 expression in female
CD11b+F4/80+ cells treated with 50 μM phytanic acid (PA) or ethanol (Vehicle), for 24
hours (n=5). (D) CD36 expression in castrated male CD11b+F4/80+ cells treated with 50
μM phytanic acid (PA) or ethanol (Vehicle), for 24 hours (n=5). (E) Female BWF1 mice
were treated with PBS (Vehicle) or phytanic acid (PA) encapsulated in microspheres 3x
per week for 2 weeks then splenocytes were collected. CD36 expression in
CD11b+F4/80+ cells was analyzed (n=3). (F) Splenocytes from 16-week-old female
BWF1 mice were collected and sorted for CD11b+F4/80+ cells by FACS. Sorted cells
were pre-treated for 48 hours with 50 μM phytanic acid (PA) or ethanol (Vehicle). Then
they were treated with or without blocking anti-CD36 antibody for 30 mins and
phagocytosis of apoptotic cells was assayed by culture with CellTraceTM Violet (CTV)labeled apoptotic thymocytes for one hour followed by analysis of percentages of
CD11b+F4/80+ cells that were CTV+. Data are reported as fold change (FC) in %CTV+
cells (n=7). *p<0.05, **p<0.01, ****p<0.0001
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Figure 39. Expression of pro-efferocytic genes in female and male BWF1 splenic
macrophages. Splenocytes from 16-week-old female and male BWF1 mice were
collected and sorted for CD11b+F4/80+cells by FACS. AXL, C1QA, and MFGE8
transcript levels were measured by qPCR (n=6).
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Figure 40. Raw Mean Fluorescence Intensity (MFI) data for pro-efferocytic
expression analysis by flow cytometry. Splenocytes from 16-week-old female, male, or
castrated male BWF1 mice were collected and labeled with CD11b, F4/80, and proefferocytic receptor (LRP1, CD36, MERTK, or TIMD4) antibodies and analyzed by flow
cytometry. Comparisons were done using Student’s t-tests. (A) Expression (MFI) of
LRP1 in female and male CD11b+F4/80+ cells (n=5). (B) Expression of LRP1 in intact
and castrated male CD11b+F4/80+ cells (n=5). (C) Expression of CD36 in female and
male CD11b+F4/80+ cells (n=5). (D) Expression of MERTK in female and male
CD11b+F4/80+ cells (n=5). (E) Expression of TIMD4 in female and male CD11b+F4/80+
cells (n=5). (F) Expression of CD36 in intact and castrated male CD11b+F4/80+ cells
(n=5). (G) Expression of CD36 in female CD11b+F4/80+ cells treated with 50 μM
phytanic acid (PA) or ethanol (Vehicle) for 24 hours (n=5). (H) Expression of CD36 in
castrated male CD11b+F4/80+ cells treated with 50 μM phytanic acid (PA) or ethanol
(Vehicle) for 24 hours (n=5). (I) Female BWF1 mice were treated with vehicle (control)
or phytanic acid encapsulated in microspheres 3x per week for 2 weeks then splenocytes
were collected. Expression of CD36 in CD11b+F4/80+ cells was analyzed (n=3). *p<0.05,
**p<0.01, ***p<0.001
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Figure 41. Proposed mechanism of phytanic acid enhancement of macrophage
efferocytosis. Phytanic acid binds PPARγ and RXR and activates signaling through the
LXR/RXR and PPARγ/RXR heterodimers. This leads to increased expression of CD36
and other pro-efferocytic genes, which in turn leads to enhanced clearance of apoptotic
cells. Created with Biorender.com.
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Figure 42. There are many immune cells involved in lupus progression. Defective
macrophage clearance of apoptotic cells leads to a buildup of inflammatory nuclear
antigen-containing debris. Myeloid dendritic cells (mDC) activate T cells and B cells, and
T cells activate B cells. The apoptotic debris further stimulates anti-nuclear antigen
responses CD103+ dendritic cells (CD103+ DC) induce regulatory T cells (Treg) that
produce anti-inflammatory cytokines and suppress the activation/function of T cells.
Plasmacytoid dendritic cells produce IFNα that promote B cell maturation and antibody
production.
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Table 9. Pro-phagocytosis genes upregulated in splenocytes from male compared to
female BWF1 mice.
Gene Symbol

Gene Name

SFTPA1

Pulmonary Surfactant Protein A1

LRP1

LDL Receptor-Related Protein 1

IL1B

Interleukin 1 Beta

IL2RB

Interleukin 2 Receptor, Beta Chain

RAC2

Rac Family Small GTPase 2

HSPA8

Heat Shock Protein 8
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Table 10. PPARγ-regulated genes upregulated in male compared to female BWF1
splenocytes
Gene
Symbol
RPLP1

Gene Name
Gene Function
Ribosomal Protein Lateral Ribosomal phosphoprotein 60S subunit
Stalk Subunit P1
component

SLC3A2

Solute Carrier Family 3
Member 2

Activator of dibasic and neutral amino acid
transport, regulates intracellular calcium levels

ELOVL5

ELOVL Fatty Acid
Elongase 5

Fatty acid elongase 1, involved in the
elongation of long-chain polyunsaturated fatty
acids
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Table 11. LXR-regulated genes upregulated in male compared to female BWF1
splenocytes
Gene
Symbol
CTSB

Gene Name
Cathepsin B

Gene Function
Lysosomal cysteine protease with both
endopeptidase and exopeptidase activity
that may play a role in protein turnover

TCF7

Transcription Factor 7

T-cell/lymphocyte high mobility group
box transcription activator, plays role in
NK cell and ILC development

CD3E

CD3-Epsilon

Critical part of the TCR-CD3 complex
involved in antigen recognition

S1PR1

Sphingosine-1-Phosphate
Receptor 1

FOS

FBJ Osteosarcoma Oncogene

Binds sphingosine-1 phosphate with
high affinity and induces cell-cell
adhesion
Regulator of cell proliferation,
differentiation, and transformation

ACP5

Acid Phosphatase 5, Tartrate
Resistant

LRP1

LDL Receptor Related Protein 1
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Catalyzes the conversion of
orthophosphoric monoester to alcohol
and orthophosphate
Apoptotic cell clearance, amyloid
precursor protein clearance, lipid
homeostasis, intracellular signaling

DISCUSSION
A change in animal facilities coincided with a loss of the previously discovered
ability of male microbiota to protect against lupus when transferred into female BWF1
mice, but the protective ability has since been restored (Fig. 23). We compared the
microbiota from periods when the male microbiota was protective originally (A Tower),
when it was not protective (CTRB Early), and when the protective ability was restored
(CTRB Recent). We found that while the female and male microbiota profiles were
significantly different for all three periods, the degree of significance was higher during
the A Tower and CTRB Recent periods compared to the CTRB Early period. Analysis of
specific taxa abundance showed that in the A Tower, Bacteroides was higher in male
than female BWF1, Clostridium abundance was ~10-20%, and Alistipes was detectable.
In contrast in the CTRB Early experiments, Bacteroides was almost undetectable or was
higher in female than male BWF1 mice, Clostridium was considerably higher at 30-40%
abundance, and Alistipes was completely absent. For experiments in the CTRB Recent
period, the taxa had returned to abundances more similar to that seen in the A Tower.
Bacteroides was present and higher in male than female BWF1 mice, Clostridium
abundance was ~5-15%, and Alistipes was present. Additionally, the same species in
those genera were predominant as in the A Tower and CTRB Early: B. acidifaciens, C.
leptum, A. putredinis, and A. timonensis. Bacteroides was the taxon most obviously
associated with the periods when male microbiota was protective, but for CTRB Early
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Experiment 4, female BWF1 mice had high Bacteroides but were not protected against
disease. This could potentially be due to the fact that Clostridium was also high and
Alistipes were absent in CTRB Early Experiment 4. High Clostridium could potentially
promote lupus susceptibility or block the actions of beneficial microbiota. It is also
possible that Alistipes and Bacteroides act cooperatively to suppress lupus. These
hypotheses were supported by the comparison of cecal transfer experiments from the
CTRB Early and CTRB recent periods. While high Bacteroides did not correlate with
protection in the CTRB Early cecal transfer experiment, a high ratio of Bacteroides to
Clostridium abundances did (Fig. 22B); recipients of male microbiota with a high
Bacteroides/Clostridium ratio had significantly suppressed disease whereas recipients of
male microbiota with a low Bacteroides/Clostridium ratio did not, suggesting a possible
explanation for why high Bacteroides in female mice in CTRB Early Experiment 4 did
not correlate with protection against disease. C. leptum has been found to be enriched in
SLE patient gut microbiota compared to healthy controls, and reduction of disease
activity via standard treatments correlated with reduction of C. leptum abundance [439].
Another study found that intestinal retinoic acid synthesis was suppressed by bacteria
from the class Clostridia, which includes Clostridium [440]. Retinoic acid is important
for the induction of tolerance-promoting T regulatory cells (Tregs) [441], and SLE is
associated with lower levels of Tregs [442]. Our lab has also found defects in Treg
induction due to deficient retinoic acid production (manuscript in preparation). This
suggests that an overabundance of Clostridia could potentially increase susceptibility to
lupus by suppressing retinoic acid-dependent Treg induction, resulting in an environment
that is too pro-inflammatory for the beneficial actions of Bacteroides to have any effect
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on disease progression. In other words, the beneficial actions of the male microbiota may
depend on a certain level of Treg induction. This could explain why in the CTRB Early
cecal transfer experiment, the female recipients of female microbiota were not protected
from disease despite having high Bacteroides. Further study of the effect of Clostridium
on retinoic acid production in BWF1 mice will be required. The fact that males during the
CTRB Early period did not develop disease despite having almost no Bacteroides and
high Clostridium seems to argue against Clostridium promoting disease progression.
However, despite having suboptimal microbiota compositions, the CTRB Early male
mice still were naturally producing androgens. Treating lupus-prone female BWF1 mice
with testosterone suppresses disease [133], and this effect is likely the reason that the
CTRB Early male mice did not develop lupus.
We also found that not only the microbiota compositions but also the
metabolomic profiles of female, intact male, and castrated male BWF1 mice differed.
Together with our findings that male microbiota could suppress disease in female BWF1
mice, this suggested that the taxa that were higher in male than female BWF1 mice might
produce metabolites that could suppress lupus. We subsequently identified metabolites
that were consistently higher in male than female BWF1 feces and investigated them for
whether they had the potential to influence lupus progression. Our results suggested that
histamine production by the gut microbiota is upregulated in intact male BWF1 mice
compared to female and castrated male mice. Histamine can have anti-inflammatory
effects on the intestine, which could prevent the “leaky gut” phenomenon that has been
linked to increased lupus susceptibility [297,357]. Determining what bacterial species are
responsible for the increased histamine production could be informative. Lactobacillus
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reuteri and Lactobacillus gasseri have been shown to produce histamine, but both of
those were elevated in female mice and so are unlikely to be the cause of elevated
histamine in male mice [563]. It is unknown whether Bacteroides can produce histamine,
but a recent study offered some evidence that hints it might. Higher microbiota
production of histamine has been found to promote other allergic diseases [564], and a
recent study of children with Immunoglobulin E-mediated cow’s milk allergy (IgE CMA)
found that Bacteroides was highly elevated in the gut microbiota of children with IgE
CMA compared to healthy controls [565]. This could potentially indicate that
Bacteroides is promoting IgE CMA disease by producing histamine, though additional
studies would be needed to confirm it. If Bacteroides did produce histamine, it would fit
with our findings that Bacteroides abundance and histamine levels both are higher in
male than female BWF1 mice. Unfortunately, we do not have metabolite data for the
CTRB Early cecal transfer experiment where Bacteroides was higher in female recipients
of female than male microbiota. Analysis of the metabolite profiles from this experiment
and the CTRB recent experiment could shed additional light on what metabolites are
associated with disease suppression, higher abundances of Bacteroides, and lower levels
of Clostridium. There is another possible interpretation of both our data and the IgE
CMA study, though. It is possible that higher levels of histamine favor higher
Bacteroides abundance, so the higher levels of histamine in our mice affect lupus
indirectly by promoting growth of beneficial Bacteroides.
Another interesting finding was that in every experiment where high Bacteroides
abundance correlated with disease protection, Alistipes was present. This suggests that
the successful suppression of lupus in female recipients might require both species to be
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present in the male microbiota. However, this does not necessarily imply that both
Alistipes and Bacteroides directly influence lupus. In fact, since Alistipes abundance is
not higher in CTRB Recent male to female recipients than female to female recipients, it
is unlikely that it directly suppresses lupus. It could potentially produce a precursor to a
beneficial metabolite produced by Bacteroides. For example, Alistipes could produce
histidine, and Bacteroides could convert it into histamine. Alternatively, Alistipes could
enhance engraftment of Bacteroides in female recipients of male microbiota. It is still
largely unknown what factors determine whether a microbiota transplant results in a
temporary change followed by a return to the norm or in a stable engraftment of the
donor bacteria. However, it is known that the compositions of both the donor and the
recipient matter, though the effects of specific taxa are still being studied. Several studies
have found that Alistipes species are among the most likely to stably engraft in the donor;
these included Alistipes putredinis, which was one of the predominant species of Alistipes
in our mice [566-568]. It is not clear, though, whether Alistipes higher engraftment ability
also benefits other taxa in the donor microbiota. To determine whether Bacteroides is
more successfully engrafted when Alistipes is present or absent as well as the effects of
Bacteroides and Alistipes on lupus progression, we could transfer monocultures of
Alistipes and/or Bacteroides into female BWF1 mice and compare both the effect on
disease and the abundance of the donated strains at different time points. There is also
some evidence in the literature that higher Bacteroides abundance promotes engraftment
of donor microbiota. A recent study of the long-term microbiota of patients who had
received fecal microbiota transfers to treat Clostridium difficile found that the higher the
abundance of Bacteroides in the donor, the more the microbiota composition of the
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recipient resembled the original donor composition at one year post transfer [569]. This
suggests that Bacteroides in BWF1 mice might not be affecting microbiota directly but
instead promoting the engraftment of other beneficial microbes. However, no other taxa
besides Bacteroides correlated with suppression of lupus in recipients of male microbiota,
so this is less likely than Alistipes promoting Bacteroides engraftment.
We also found that the metabolite, phytol, was consistently higher in male than
female BWF1 mice for all three metabolomic experiments. This metabolite and its
product, phytanic acid, can activate the RXR and PPARγ receptors, which means that
they could potentially suppress lupus progression via several mechanisms. RXR agonists
are known to increase retinoic acid production [490], so phytol and phytanic acid might
increase intestinal CD103+ dendritic cell (DC) retinoic acid-dependent induction of
immunosuppressive Tregs by enhancing CD103+ DC retinoic acid production (Fig. 42).
This is supported by our lab’s findings that gut CD103+ DCs from female BWF1 mice
are less effective at inducing Tregs than male-derived gut CD103+ DCs, and have a
defect in retinoic acid synthesis that can be restored by treatment with phytanic acid
(manuscript in preparation). RXR and PPARγ agonists are also known to upregulate
genes promoting macrophage efferocytosis [393,394]. This could improve clearance of
the apoptotic cell debris that is known to promote lupus progression. We focused our
efforts on investigating macrophage efferocytosis and found, through transcriptomic and
protein expression analysis, that the expression of the pro-efferocytosis receptor LRP1 is
higher in male than female BWF1 splenic macrophages. We then tested the ability of
splenic macrophages to phagocytose apoptotic cells in vitro and found more efficient
efferocytic activity in intact male than either female or castrated male BWF1 splenic
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macrophages. The fact that the intact male BWF1 mice had higher splenic macrophage
efferocytic activity as well as higher abundance of phytol and phytanic acid suggested
that there could be a connection between the two. To test this, we treated female BWF1
splenic macrophages with phytanic acid, and found that this improved their ability to
phagocytose apoptotic cells in a PPARγ and LXR-dependent manner (Fig. 41). Further
investigations showed that feeding female BWF1 mice either phytanic acid or male
BWF1 microbiota improved splenic macrophage efferocytosis, which strengthens the
connection between the differing male and female microbiota profiles, the higher levels
of phytol/phytanic acid male compared to female BWF1 mice, and the greater efferocytic
activity of male splenic macrophages. We also determined that phytanic acid treatment
upregulated the pro-efferocytic receptor CD36, and that CD36 activity was required for
the enhancement of efferocytosis by phytanic acid, suggesting a possible mechanism
(Fig. 41). It is worth noting that when LRP1 binds apoptotic cells, it can enhance PPARγ
signaling. Since male BWF1 splenic macrophages express higher levels of LRP1, this
suggests that phytanic acid might be more effective at promoting macrophage
efferocytosis in male than female macrophages.
As described in Figure 41, our data indicate that phytanic acid can increase the
ability of macrophages to phagocytose apoptotic cells by activating PPARγ. However, in
addition to increasing macrophage ability to sequester self-antigen-containing debris
away from other immune cells, PPARγ stimulation also promotes macrophage production
of anti-inflammatory cytokines, including TGFβ and IL-10 [394], and causes the
macrophages to adopt a more M2-like phenotype [570]. These cytokines can suppress the
inflammatory responses that drive lupus [394], providing another mechanism by which
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phytanic acid-activated macrophages can suppress disease. This is not limited to
macrophages in the spleen, either. Because phytanic acid is readily transported through
circulation, it may also affect kidney-infiltrating macrophages. M2 macrophages have
been found to suppress inflammation in chronic kidney disease and promote wound
healing and tissue remodeling, which can help prevent kidney damage [571]. Phytanic
acid, therefore, could potentially suppress disease not only by improving clearance of
apoptotic cells, but also by influencing kidney infiltrating macrophages into an antiinflammatory phenotype. The ability of phytanic acid to induce an anti-inflammatory
phenotype in macrophages could be tested by treating macrophages with phytanic acid or
vehicle, and then challenging them with LPS and measuring their cytokine production.
The relevance of these effects on macrophages to lupus progression could be tested by
feeding female BWF1 mice phytanic acid or vehicle and then isolating kidney infiltrating
macrophages and comparing production of pro- and anti-inflammatory cytokines.
Additionally, macrophages are far from the only type of immune cell that is
affected by PPARγ signaling, and there are many immune cells involved in lupus
progression (Fig. 42). In dendritic cells, PPARγ stimulation downregulates the
costimulatory molecules CD80, CD83, and CD40 and upregulates the coinhibitory
molecule B7H1. This makes the dendritic cells less effective at activating T-cells which
in turn reduces the activation of B cells by activated T-cells [572]. T cells can also be
directly affected by PPARγ agonists, as PPARγ stimulation suppresses T follicular helper
responses, which are important for the maturation of antibody-producing B cells [573].
Phytanic acid is unlikely to suppress lupus via interaction with B cells, though, as PPARγ
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activation has been shown to increase B cell antibody production [574]. Clearly, there are
many possible mechanisms by which phytanic acid could be affecting lupus progression.
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CONCLUSION
Our microbiota composition, metabolomic, and macrophage data strongly suggest
that the microbiota from male BWF1 mice is distinctly different both in composition and
metabolic activity from the female BWF1 mice. These differences likely play a role in
the ability of the male microbiota to suppress lupus when transferred into female BWF1
mice. However, as we found when we compared data from the A Tower, CTRB Early,
and CTRB Recent periods, when the Bacteroides/Clostridium ratio is low and Alistipes is
absent like they were in the CTRB Early period, female recipients of male microbiota are
not protected (Fig. 23). These data illustrate how environmental factors have a major
impact on microbiota composition. Microbiota function was altered as well, resulting in a
loss of the ability of the male BWF1 microbiota to suppress disease. These experiments,
therefore, simultaneously demonstrate the tremendous potential of therapeutic microbiota
transfers and the inherent challenges of developing a large-scale stable and effective
treatment based on the entire microbiota profile of a healthy person. Even if a donor
whose microbiota has the desired effect can be identified, any number of things can cause
the microbiota profile of the donor to change, and the environment of a human donor is
much less controlled than that of a laboratory mouse. Ideally, specific beneficial bacterial
strains can be identified, but here too our results highlight potential pitfalls. Our data
suggest that high Clostridium may block the therapeutic effect of other bacterial strains,
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meaning that even a therapy that works in some patients may not work in others if they
have high levels of a strain that counters the effect of the probiotic bacteria.
If the therapeutic effect is mediated via the production of an immunomodulatory
metabolite, it may be possible to bypass the bacteria entirely and design a treatment based
on that metabolite. In our model we showed the disease suppressing effect of male BWF1
microbiota may be partially due to higher abundance of the microbial metabolite phytol
and its derivative, phytanic acid, in male BWF1 mice. By activating PPARγ and LXR
signaling, phytanic acid can upregulate the pro-efferocytic receptor CD36 and promote
splenic macrophage efferocytosis. Defective efferocytosis contributes to lupus
progression, so enhancement of efferocytic activity in macrophages could potentially
suppress disease. This higher production of an efferocytosis-enhancing metabolite could
potentially contribute to the lower incidence of lupus in male BWF1 mice. The BWF1
mouse model mimics the sex-bias seen in SLE patients, raising the possibility that sexbased differences in the microbiota might also indicate that the microbiota could also
play a part in women being more susceptible to SLE.
Looking at the bigger picture, these findings show that treatments that alter the
microbiota could be useful for managing SLE. This will require greater understanding of
the complex and numerous mechanisms connecting the immune system and the
microbiota, and our findings represent a significant step in that direction. Probiotics,
prebiotics, or other therapeutic modalities designed to encourage the growth of beneficial
bacteria and/or reduce the prevalence of harmful bacteria may become a standard part of
the treatment a lupus patient receives.
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